PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30143940-0	2018	Expression of prolactin receptors in the duodenum, kidneys and skeletal system during physiological and sulpiride-induced hyperprolactinaemia.	Sulpiride	104-113	prolactin	Rattus norvegicus	14-23
30612641-4	2019	While, the impurity and other cations were eluted to the 2nd D column (RP2) for separation and identification by connected IT-TOF MS. Methods were programmed and applied to identify impurities in two generic drugs, sulpiride (hydrophilic drug with logP 0.57) and dobutamine (hydrophobic drug with logP 3.6).	Sulpiride	215-224	RP2 activator of ARL3 GTPase	Homo sapiens	71-74
31089367-3	2019	The current study aimed to examine the effect of intra-hippocampal CA1 administration of SCH23390 and Sulpiride as D1- and D2-like receptor antagonists on the acquisition of orexin-induced conditioned place preference (CPP), respectively.	Sulpiride	102-111	hypocretin neuropeptide precursor	Rattus norvegicus	174-180
30703109-9	2019	On the other hand, the dopamine D2 receptor antagonist sulpiride and GABAA receptor antagonist bicuculline only attenuated the ameliorative effect of KSS on repetitive self-grooming behaviors.	Sulpiride	55-64	dopamine receptor D2	Mus musculus	23-43
29289668-10	2018	In addition, SfL antidepressant-like effect was inhibited by the pretreatment of mice with SCH 23390, a dopamine D1 receptor antagonist, and by sulpiride, a dopamine D2 receptor antagonist.	Sulpiride	144-153	dopamine receptor D2	Mus musculus	157-177
31256886-0	2018	Effects of Various Methods of Sulpiride Administration on Prolactin Release in Horses.	Sulpiride	30-39	prolactin	Equus caballus	58-67
31256886-1	2018	Four experiments assessed factors affecting prolactin responses to sulpiride administration in horses.	Sulpiride	67-76	prolactin	Equus caballus	44-53
31256886-6	2018	Prolactin responses in groups receiving sulpiride were robust but similar in magnitude with minor differences in timing.	Sulpiride	40-49	prolactin	Equus caballus	0-9
31256886-8	2018	Prolactin responses to sulpiride lasted a minimum of 96 hours.	Sulpiride	23-32	prolactin	Equus caballus	0-9
31256886-9	2018	In experiment 4, prolactin responses to 3 g of racemic sulpiride in vegetable shortening were compared to similar injections (3 g) in 5 mL of sucrose acetate isobutyrate (SAIB; SucroMate) or just SAIB (control) in ECP-primed geldings.	Sulpiride	55-64	prolactin	Equus caballus	17-26
31256886-11	2018	It is concluded that prolactin responses to sulpiride in horses can be greatly extended by using hydrophobic vehicles like vegetable shortening or SAIB.	Sulpiride	44-53	prolactin	Equus caballus	21-30
29476749-9	2018	Pretreatment with subcutaneous injection of either naloxone hydrochloride or sulpiride, a dopamine D2 receptor antagonist, significantly blocked ghrelin-induced visceral antinociception; furthermore, neither subcutaneous injection of naloxone methiodide, a peripheral selective opioid antagonist, SCH23390, a dopamine D1 receptor antagonist, nor DPCPX, an adenosine A1 receptor antagonist, blocked antinociception.	Sulpiride	77-86	ghrelin and obestatin prepropeptide	Rattus norvegicus	145-152
28818747-10	2018	Sulpiride (50mg/kg, i.p., a D2 receptor antagonist) or haloperidol (0.2mg/kg, i.p., a dopamine receptor antagonist) reversed the anti-immobility effect of MJ.	Sulpiride	0-9	dopamine receptor D2	Mus musculus	28-39
29551354-0	2018	The antipsychotics sulpiride induces fatty liver in rats via phosphorylation of insulin receptor substrate-1 at Serine 307-mediated adipose tissue insulin resistance.	Sulpiride	19-28	insulin receptor substrate 1	Rattus norvegicus	80-108
29551354-8	2018	Adipose gene expression profile revealed that sulpiride decreased mRNA and protein expression of insulin receptor substrate (IRS)-1, but not IRS-2.	Sulpiride	46-55	insulin receptor substrate 1	Rattus norvegicus	97-131
29551354-9	2018	Furthermore, sulpiride increased phosphorylation of both Ser307 in IRS-1 and Ser473 in Akt at baseline.	Sulpiride	13-22	insulin receptor substrate 1	Rattus norvegicus	67-72
29551354-11	2018	Therefore, the present results suggest that sulpiride induces fatty liver in rats via phosphorylation of IRS-1 at Ser307-mediated adipose tissue insulin resistance, in which dopamine D2 receptor is possibly not involved.	Sulpiride	44-53	insulin receptor substrate 1	Rattus norvegicus	105-110
28597291-6	2017	Our results revealed that sulpiride was a substrate of human organic cation transporter (hOCT) 3, human multidrug resistance protein (hMDR) 1 and human breast cancer resistance protein (hBCRP) using transfected cells expressing respective transporters.	Sulpiride	26-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	152-184
29137945-4	2018	Opposite, the microinjection into the DRN of the DA D1 and D2 receptor antagonists SCH23390 and sulpiride, respectively, significantly augmented REMS and the number of REM periods.	Sulpiride	96-105	defender against cell death 1	Rattus norvegicus	49-54
29019791-2	2018	For this purpose, the study included two experimental approaches: first, we investigated the effect of infusion of sulpiride, a dopaminergic D2 receptor antagonist (D2R), on GnRH and GnRH receptor (GnRHR) biosynthesis in the hypothalamus and on GnRHR in the anterior pituitary using an immunoassay.	Sulpiride	115-124	Progonadoliberin-1	Ovis aries	174-178
29019791-2	2018	For this purpose, the study included two experimental approaches: first, we investigated the effect of infusion of sulpiride, a dopaminergic D2 receptor antagonist (D2R), on GnRH and GnRH receptor (GnRHR) biosynthesis in the hypothalamus and on GnRHR in the anterior pituitary using an immunoassay.	Sulpiride	115-124	gonadotropin-releasing hormone receptor	Ovis aries	183-196
29019791-2	2018	For this purpose, the study included two experimental approaches: first, we investigated the effect of infusion of sulpiride, a dopaminergic D2 receptor antagonist (D2R), on GnRH and GnRH receptor (GnRHR) biosynthesis in the hypothalamus and on GnRHR in the anterior pituitary using an immunoassay.	Sulpiride	115-124	gonadotropin-releasing hormone receptor	Ovis aries	198-203
29019791-4	2018	Second, we used real-time polymerase chain reaction to analyse the influence of sulpiride on the levels of kisspeptin (Kiss1) mRNA in the preoptic area and ventromedial hypothalamus including arcuate nucleus (VMH/ARC), and RFamide-related peptide-3 (RFRP-3) mRNA in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus.	Sulpiride	80-89	metastasis-suppressor KiSS-1	Ovis aries	107-117
29019791-4	2018	Second, we used real-time polymerase chain reaction to analyse the influence of sulpiride on the levels of kisspeptin (Kiss1) mRNA in the preoptic area and ventromedial hypothalamus including arcuate nucleus (VMH/ARC), and RFamide-related peptide-3 (RFRP-3) mRNA in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus.	Sulpiride	80-89	metastasis-suppressor KiSS-1	Ovis aries	119-124
29019791-5	2018	Sulpiride significantly increased plasma LH concentration and the levels of GnRH and GnRHR in the hypothalamic-pituitary unit.	Sulpiride	0-9	Progonadoliberin-1	Ovis aries	76-80
29019791-5	2018	Sulpiride significantly increased plasma LH concentration and the levels of GnRH and GnRHR in the hypothalamic-pituitary unit.	Sulpiride	0-9	gonadotropin-releasing hormone receptor	Ovis aries	85-90
28597291-6	2017	Our results revealed that sulpiride was a substrate of human organic cation transporter (hOCT) 3, human multidrug resistance protein (hMDR) 1 and human breast cancer resistance protein (hBCRP) using transfected cells expressing respective transporters.	Sulpiride	26-35	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	186-191
28597291-7	2017	In addition, the accumulation of sulpiride in BeWo cells (a human choriocarcinoma cell line) was obviously affected by inhibitors of carnitine/organic cation transporter (OCTN) 2, MDR1 and BCRP.	Sulpiride	33-42	solute carrier family 22 member 5	Homo sapiens	133-178
28597291-7	2017	In addition, the accumulation of sulpiride in BeWo cells (a human choriocarcinoma cell line) was obviously affected by inhibitors of carnitine/organic cation transporter (OCTN) 2, MDR1 and BCRP.	Sulpiride	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	180-184
28597291-7	2017	In addition, the accumulation of sulpiride in BeWo cells (a human choriocarcinoma cell line) was obviously affected by inhibitors of carnitine/organic cation transporter (OCTN) 2, MDR1 and BCRP.	Sulpiride	33-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	189-193
28597291-8	2017	The accumulation of sulpiride in primary human trophoblast cells was obviously affected by inhibitors of OCT3, OCTN1 and OCTN2.	Sulpiride	20-29	solute carrier family 22 member 3	Homo sapiens	105-109
28597291-8	2017	The accumulation of sulpiride in primary human trophoblast cells was obviously affected by inhibitors of OCT3, OCTN1 and OCTN2.	Sulpiride	20-29	solute carrier family 22 member 4	Homo sapiens	111-116
28597291-8	2017	The accumulation of sulpiride in primary human trophoblast cells was obviously affected by inhibitors of OCT3, OCTN1 and OCTN2.	Sulpiride	20-29	solute carrier family 22 member 5	Homo sapiens	121-126
28597291-9	2017	The above results indicate that hOCTN1 and hOCTN2 likely contribute to the sulpiride uptake from maternal circulation to trophoblast cells, while hMDR1 and hBCRP mediate the efflux from trophoblast cells to maternal circulation, and hOCT3 probably is involved in the bidirectional transport of sulpiride between the placenta and fetal blood.	Sulpiride	75-84	solute carrier family 22 member 4	Homo sapiens	32-38
28597291-9	2017	The above results indicate that hOCTN1 and hOCTN2 likely contribute to the sulpiride uptake from maternal circulation to trophoblast cells, while hMDR1 and hBCRP mediate the efflux from trophoblast cells to maternal circulation, and hOCT3 probably is involved in the bidirectional transport of sulpiride between the placenta and fetal blood.	Sulpiride	75-84	solute carrier family 22 member 5	Homo sapiens	43-49
28585780-10	2017	l-DOPA inhibited and sulpiride stimulated PRL release during both periods.	Sulpiride	21-30	prolactin	Bos taurus	42-45
28649130-0	2017	Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer.	Sulpiride	32-41	dopamine receptor D2	Homo sapiens	0-20
28926871-5	2017	Sulpiride accumulation from the basolateral (BL) to the apical (AP) side in MDCK-hOCT2/pcDNA3.1 cell monolayers was much greater than that in MDCK-hOCT2/hMATE1 cells, and cimetidine dramatically reduced the intracellular accumulation of sulpiride from BL to AP.	Sulpiride	0-9	solute carrier family 22 member 2	Homo sapiens	81-86
28926871-5	2017	Sulpiride accumulation from the basolateral (BL) to the apical (AP) side in MDCK-hOCT2/pcDNA3.1 cell monolayers was much greater than that in MDCK-hOCT2/hMATE1 cells, and cimetidine dramatically reduced the intracellular accumulation of sulpiride from BL to AP.	Sulpiride	0-9	solute carrier family 47 member 1	Homo sapiens	153-159
28926871-6	2017	In addition, the accumulation of sulpiride in mouse primary renal tubular cells (mPRTCs) was markedly reduced by inhibitors of Oct2 and Octns.	Sulpiride	33-42	POU domain, class 2, transcription factor 2	Mus musculus	127-131
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	109-118	solute carrier family 22 member 4	Homo sapiens	25-30
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	109-118	solute carrier family 22 member 5	Homo sapiens	32-37
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	109-118	solute carrier family 22 member 2	Homo sapiens	39-43
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	109-118	solute carrier family 47 member 1	Homo sapiens	45-50
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	109-118	solute carrier family 47 member 2	Homo sapiens	55-62
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	109-118	solute carrier family 22 member 2	Homo sapiens	129-133
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	157-166	solute carrier family 22 member 2	Homo sapiens	129-133
28926871-7	2017	The results implied that OCTN1, OCTN2, OCT2, MATE1 and MATE2-K probably contributed to the renal transfer of sulpiride, in which OCT2 mediated the uptake of sulpiride from the bloodstream to the proximal tubular cells, while MATEs contributed to the sulpiride efflux from the proximal tubular cells to the renal lumen, and OCTNs participated in both renal secretion and reabsorption.	Sulpiride	157-166	solute carrier family 22 member 2	Homo sapiens	129-133
28744563-7	2017	Sulpiride (0-30 mg/kg) dose-dependently reduced elevated FAR in MAM-E17 rats whereas low-dose modafinil (8 mg/kg) only improved d" in sham controls.	Sulpiride	0-9	alpha-2-macroglobulin	Rattus norvegicus	64-67
28926871-4	2017	The results demonstrated that sulpiride was a substrate of human carnitine/organic cation transporter 1 (hOCTN1) and 2 (hOCTN2), human organic cation transporter 2 (hOCT2), human multidrug and toxin efflux extrusion protein 1 (hMATE1) and 2-K (hMATE2-K).	Sulpiride	30-39	solute carrier family 22 member 1	Homo sapiens	75-103
28926871-4	2017	The results demonstrated that sulpiride was a substrate of human carnitine/organic cation transporter 1 (hOCTN1) and 2 (hOCTN2), human organic cation transporter 2 (hOCT2), human multidrug and toxin efflux extrusion protein 1 (hMATE1) and 2-K (hMATE2-K).	Sulpiride	30-39	solute carrier family 22 member 4	Homo sapiens	105-111
28926871-4	2017	The results demonstrated that sulpiride was a substrate of human carnitine/organic cation transporter 1 (hOCTN1) and 2 (hOCTN2), human organic cation transporter 2 (hOCT2), human multidrug and toxin efflux extrusion protein 1 (hMATE1) and 2-K (hMATE2-K).	Sulpiride	30-39	solute carrier family 22 member 5	Homo sapiens	120-126
28926871-4	2017	The results demonstrated that sulpiride was a substrate of human carnitine/organic cation transporter 1 (hOCTN1) and 2 (hOCTN2), human organic cation transporter 2 (hOCT2), human multidrug and toxin efflux extrusion protein 1 (hMATE1) and 2-K (hMATE2-K).	Sulpiride	30-39	solute carrier family 22 member 2	Homo sapiens	135-163
28926871-4	2017	The results demonstrated that sulpiride was a substrate of human carnitine/organic cation transporter 1 (hOCTN1) and 2 (hOCTN2), human organic cation transporter 2 (hOCT2), human multidrug and toxin efflux extrusion protein 1 (hMATE1) and 2-K (hMATE2-K).	Sulpiride	30-39	solute carrier family 22 member 2	Homo sapiens	165-170
28926871-4	2017	The results demonstrated that sulpiride was a substrate of human carnitine/organic cation transporter 1 (hOCTN1) and 2 (hOCTN2), human organic cation transporter 2 (hOCT2), human multidrug and toxin efflux extrusion protein 1 (hMATE1) and 2-K (hMATE2-K).	Sulpiride	30-39	solute carrier family 47 member 1	Homo sapiens	227-233
28926871-4	2017	The results demonstrated that sulpiride was a substrate of human carnitine/organic cation transporter 1 (hOCTN1) and 2 (hOCTN2), human organic cation transporter 2 (hOCT2), human multidrug and toxin efflux extrusion protein 1 (hMATE1) and 2-K (hMATE2-K).	Sulpiride	30-39	solute carrier family 47 member 2	Homo sapiens	244-250
28623711-6	2017	The antinociceptive effect of PSAP (1mg/kg) was abolished when the animals were pre-treated with prazosin (alpha1-adrenergic antagonist receptor, 0.15mg/kg, intraperitoneally, ip), yohimbine (alpha2-adrenergic antagonist receptor, 1mg/kg, ip) and sulpiride (D2/D3 dopamine antagonist, 5mg/kg, ip).	Sulpiride	247-256	prosaposin	Mus musculus	30-34
28956481-0	2017	Influence of sulpiride treatment on the level of prolactin and immunoglobulins in the peripheral blood of mares during the postpartum period.	Sulpiride	13-22	prolactin	Equus caballus	49-58
27260326-4	2016	EtOH (50 or 150 mg%) or the D2/3 receptor antagonist sulpiride (100 or 200 muM) was microinjected into the pVTA while DA was sampled with microdialysis in the NAC shell (NACsh).	Sulpiride	53-62	latexin	Homo sapiens	75-78
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	solute carrier family 22 member 1	Homo sapiens	69-74
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	latexin	Homo sapiens	83-86
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	POU class 2 homeobox 2	Homo sapiens	89-94
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	latexin	Homo sapiens	102-105
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	solute carrier family 47 member 1	Homo sapiens	108-114
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	latexin	Homo sapiens	102-105
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	solute carrier family 47 member 2	Homo sapiens	132-140
28499878-5	2017	From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 muM), hOCT2 (Km 68 muM), hMATE1 (Km 40 muM), and hMATE2-K (Km 60 muM).	Sulpiride	41-50	latexin	Homo sapiens	102-105
28499878-6	2017	Moreover, the uptake of sulpiride by human hepatocytes was diminished by tetraethylammonium, and saturable with Km of 18 muM.	Sulpiride	24-33	latexin	Homo sapiens	121-124
28499878-7	2017	Oct1/2 double knockout mice and wild-type mice received Mate1 inhibitors (pyrimethamine/cimetidine) manifested reduced renal clearance of sulpiride, accompanied with its accumulation in the plasma.	Sulpiride	138-147	solute carrier family 22 (organic cation transporter), member 1	Mus musculus	0-6
28499878-7	2017	Oct1/2 double knockout mice and wild-type mice received Mate1 inhibitors (pyrimethamine/cimetidine) manifested reduced renal clearance of sulpiride, accompanied with its accumulation in the plasma.	Sulpiride	138-147	solute carrier family 47, member 1	Mus musculus	56-61
28499878-8	2017	In conclusion, we found that sulpiride is a substrate of OCT1, OCT2, MATE1, and MATE2-K, and this suggests that [11C]sulpiride would be a useful radioligand to investigate the organic cation transporters in humans.	Sulpiride	29-38	solute carrier family 22 member 1	Homo sapiens	57-61
28499878-8	2017	In conclusion, we found that sulpiride is a substrate of OCT1, OCT2, MATE1, and MATE2-K, and this suggests that [11C]sulpiride would be a useful radioligand to investigate the organic cation transporters in humans.	Sulpiride	29-38	POU class 2 homeobox 2	Homo sapiens	63-67
28499878-8	2017	In conclusion, we found that sulpiride is a substrate of OCT1, OCT2, MATE1, and MATE2-K, and this suggests that [11C]sulpiride would be a useful radioligand to investigate the organic cation transporters in humans.	Sulpiride	29-38	solute carrier family 47 member 1	Homo sapiens	69-74
28499878-8	2017	In conclusion, we found that sulpiride is a substrate of OCT1, OCT2, MATE1, and MATE2-K, and this suggests that [11C]sulpiride would be a useful radioligand to investigate the organic cation transporters in humans.	Sulpiride	29-38	solute carrier family 47 member 2	Homo sapiens	80-87
28473645-7	2017	Interestingly, 1 mum sulpiride, a D2 receptor antagonist, restored tLTP.	Sulpiride	21-30	dopamine receptor D2	Mus musculus	34-45
28233634-3	2017	The administration of CTS (1.0 g/kg, for 3 days) decreased the immobility time in the forced-swim test, and this decrease was prevented by the prior administration of sulpiride (an antagonist of D2/3 receptors) and WAY100635 (an antagonist of 5-HT1A receptors).	Sulpiride	167-176	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	243-249
28740751-12	2017	By using connectivity mapping of these co-regulated genes, we have identified amcinonide and sulpiride as potential small molecules that could potentially reverse DAPK1/PCOLCE/ZBTB16/SLC16A3 expression.	Sulpiride	93-102	death associated protein kinase 1	Homo sapiens	163-168
28740751-12	2017	By using connectivity mapping of these co-regulated genes, we have identified amcinonide and sulpiride as potential small molecules that could potentially reverse DAPK1/PCOLCE/ZBTB16/SLC16A3 expression.	Sulpiride	93-102	procollagen C-endopeptidase enhancer	Homo sapiens	169-175
28740751-12	2017	By using connectivity mapping of these co-regulated genes, we have identified amcinonide and sulpiride as potential small molecules that could potentially reverse DAPK1/PCOLCE/ZBTB16/SLC16A3 expression.	Sulpiride	93-102	zinc finger and BTB domain containing 16	Homo sapiens	176-182
28740751-12	2017	By using connectivity mapping of these co-regulated genes, we have identified amcinonide and sulpiride as potential small molecules that could potentially reverse DAPK1/PCOLCE/ZBTB16/SLC16A3 expression.	Sulpiride	93-102	solute carrier family 16 member 3	Homo sapiens	183-190
28214542-5	2017	For this, we selected the common orally administered drugs sulpiride, bestatin, valacyclovir, ampicillin and oseltamivir, that are all transported by hPepT1.	Sulpiride	59-68	solute carrier family 15 member 1	Homo sapiens	150-156
27260326-7	2016	In contrast, sulpiride increased DA release in the NACsh more in the "Water" than "EtOH" groups (e.g., 200 muM sulpiride: to ~ 190-240 vs 150-160% of baseline).	Sulpiride	13-22	latexin	Homo sapiens	107-110
27260326-7	2016	In contrast, sulpiride increased DA release in the NACsh more in the "Water" than "EtOH" groups (e.g., 200 muM sulpiride: to ~ 190-240 vs 150-160% of baseline).	Sulpiride	111-120	latexin	Homo sapiens	107-110
26742031-1	2016	The aim of this work was to study the interaction of sulpiride with human serum albumin (HSA) and bovine serum albumin (BSA) through the fluorescence quenching technique.	Sulpiride	53-62	albumin	Homo sapiens	74-87
26178146-1	2016	Sulpiride and ethylene glycol monomethyl ether (EGME) are known ovarian toxicants that stimulate prolactin (PRL) secretion, resulting in hypertrophy of the corpora lutea and increased progesterone (P4) production.	Sulpiride	0-9	prolactin	Rattus norvegicus	97-106
26178146-1	2016	Sulpiride and ethylene glycol monomethyl ether (EGME) are known ovarian toxicants that stimulate prolactin (PRL) secretion, resulting in hypertrophy of the corpora lutea and increased progesterone (P4) production.	Sulpiride	0-9	prolactin	Rattus norvegicus	108-111
26178146-6	2016	Moreover, sulpiride-treated animals showed high PRL and P4 serum levels without changes in the levels of estradiol-17beta, low uterine weights and histological luteal cell hypertrophy.	Sulpiride	10-19	prolactin	Rattus norvegicus	48-51
26178146-8	2016	These results suggest that the prolonged low estradiol-17beta to P4 ratio accompanied by persistent estrous cycle abnormalities secondary to the luteal stimulatory effects of PRL may explain the inhibitory effects of sulpiride on uterine carcinogenesis in rats.	Sulpiride	217-226	prolactin	Rattus norvegicus	175-178
27047394-4	2016	Twenty-four young, healthy volunteers ingested a single dose of placebo or 400 mg oral sulpiride, a dopamine D2-receptor antagonist, just before starting the recognition memory task in a randomized, double-blind, and placebo-controlled trial.	Sulpiride	87-96	dopamine receptor D2	Homo sapiens	100-120
26742031-1	2016	The aim of this work was to study the interaction of sulpiride with human serum albumin (HSA) and bovine serum albumin (BSA) through the fluorescence quenching technique.	Sulpiride	53-62	albumin	Homo sapiens	105-118
26466350-3	2015	Inhibition of dopamine D2-receptors with sulpiride (SULP) significantly repressed the constitutive and benzo[a]pyrene (B[a]P)-induced CYP1A1, CYP1A2 and CYP1B expression in the rat liver.	Sulpiride	41-50	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	134-140
27303599-12	2016	Sulpiride (selective D2-receptor antagonist), p-CPA (tryptophan hydroxylase inhibitor), and baclofen (GABAB agonist) significantly attenuated the oil-induced antidepressant-like effect, when assessed during TST.	Sulpiride	0-9	dopamine receptor D2	Mus musculus	21-32
26466350-3	2015	Inhibition of dopamine D2-receptors with sulpiride (SULP) significantly repressed the constitutive and benzo[a]pyrene (B[a]P)-induced CYP1A1, CYP1A2 and CYP1B expression in the rat liver.	Sulpiride	41-50	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	142-148
26466350-3	2015	Inhibition of dopamine D2-receptors with sulpiride (SULP) significantly repressed the constitutive and benzo[a]pyrene (B[a]P)-induced CYP1A1, CYP1A2 and CYP1B expression in the rat liver.	Sulpiride	52-56	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	134-140
26466350-3	2015	Inhibition of dopamine D2-receptors with sulpiride (SULP) significantly repressed the constitutive and benzo[a]pyrene (B[a]P)-induced CYP1A1, CYP1A2 and CYP1B expression in the rat liver.	Sulpiride	52-56	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	142-148
26275349-6	2015	Pretreatment with either the D1 or D2 dopamine receptor antagonist (SCH23390 or sulpiride, respectively) potently blocked the centrally injected orexin-A-induced antinociceptive action against colonic distension.	Sulpiride	80-89	dopamine receptor D2	Rattus norvegicus	35-55
26275349-6	2015	Pretreatment with either the D1 or D2 dopamine receptor antagonist (SCH23390 or sulpiride, respectively) potently blocked the centrally injected orexin-A-induced antinociceptive action against colonic distension.	Sulpiride	80-89	hypocretin neuropeptide precursor	Rattus norvegicus	145-153
23867765-7	2013	Moreover, the proline-induced increase on AChE activity was completely reverted by acute administration of antipsychotic drugs (haloperidol and sulpiride), as well as the changes induced in ache expression.	Sulpiride	144-153	acetylcholinesterase	Danio rerio	42-46
25155823-5	2014	We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied.	Sulpiride	46-55	solute carrier family 22 member 4	Homo sapiens	129-134
25155823-6	2014	In contrast, sulpiride was only transported by OCT1 and OCT2.	Sulpiride	13-22	solute carrier family 22 member 1	Homo sapiens	47-51
25155823-6	2014	In contrast, sulpiride was only transported by OCT1 and OCT2.	Sulpiride	13-22	solute carrier family 22 member 2	Homo sapiens	56-60
25155823-7	2014	OCT1 showed the highest transport ability both for amisulpride (CLint = 1.9 ml/min/mg protein) and sulpiride (CLint = 4.2 ml/min/mg protein) and polymorphisms in OCT1 significantly reduced the uptake of both drugs.	Sulpiride	99-108	solute carrier family 22 member 1	Homo sapiens	0-4
24773408-1	2014	Consistent with dopamine accounts of internal and external feedback processing, prior work showed that the dopamine D2 receptor antagonist sulpiride modulates the relationship between the dopaminergic COMT Val158Met polymorphism and the error-related negativity (ERN).	Sulpiride	139-148	dopamine receptor D2	Homo sapiens	107-127
24773408-1	2014	Consistent with dopamine accounts of internal and external feedback processing, prior work showed that the dopamine D2 receptor antagonist sulpiride modulates the relationship between the dopaminergic COMT Val158Met polymorphism and the error-related negativity (ERN).	Sulpiride	139-148	catechol-O-methyltransferase	Homo sapiens	201-205
24773408-3	2014	N = 83 female participants genotyped for COMT Val158Met received 200 mg sulpiride versus placebo and performed a virtual ball-catching task.	Sulpiride	72-81	catechol-O-methyltransferase	Homo sapiens	41-45
24323704-5	2014	To probe the involvement of dopamine, participants received either placebo or the selective dopamine D2 receptor antagonist sulpiride (200 mg).	Sulpiride	124-133	dopamine receptor D2	Homo sapiens	92-112
23236209-5	2014	Moreover, we show that administration of the D2-receptor-blocking antipsychotic drug sulpiride either systemically or directly into the mPFC reverses the alterations in the MAM rat.	Sulpiride	85-94	alpha-2-macroglobulin	Rattus norvegicus	173-176
26092311-5	2015	METHODS: Here, we assess the hypothesis that pathological gambling is accompanied by dopamine-related problems with learning from reward and punishment by investigating effects of the dopamine D2-receptor antagonist sulpiride (400 mg) on reward- and punishment-based reversal learning in 18 pathological gamblers and 22 healthy controls, using a placebo-controlled, double-blind, counter-balanced design.	Sulpiride	216-225	dopamine receptor D2	Homo sapiens	184-204
25083185-14	2014	CONCLUSION: The present findings suggest that SPD-induced disturbances depend on PRL level.	Sulpiride	46-49	prolactin	Rattus norvegicus	81-84
24035947-4	2013	The different reaction conditions influencing the condensation reaction were carefully optimized and a linear range of 0.1-3.5 microg mL-1 with good correlation coefficient between flourescent intensity and concentration of sulpiride was found at optimum parameters.	Sulpiride	224-233	L1 cell adhesion molecule	Mus musculus	134-138
23872092-9	2013	Thus, quinpirole and sulpiride seem to compensate the effects of the intra-CA1 injection of exogenous histamine, and tend to exert anxiolytic effects in the presence of histamine.	Sulpiride	21-30	carbonic anhydrase 1	Mus musculus	75-78
23453939-11	2013	was prevented by the pretreatment of mice with SCH23390 (0.05 mg/kg, i.g., a dopamine D1 receptor antagonist) or sulpiride (50 mg/kg, i.g., a dopamine D2 receptor antagonist).	Sulpiride	113-122	dopamine receptor D2	Mus musculus	142-162
23541636-6	2013	VGF expression was altered in the IL of rats receivingthe dopamine D2 receptor agonist bromocriptine or the antagonist sulpiride.	Sulpiride	119-128	VGF nerve growth factor inducible	Rattus norvegicus	0-3
23708948-1	2013	The aim of this study was to explore effects on anxiety-like behavior of the D2 dopamine receptor agonist, quinpirole and of the D2 dopamine receptor antagonist, sulpiride given alone or in combination with a low dose of 17beta-estradiol (17beta-E2) to ovariectomized (OVX) rats.	Sulpiride	162-171	dopamine receptor D2	Rattus norvegicus	129-149
25610268-4	2013	We report a case of a 43-year-old woman with an extremely high prolactin level in medication-induced hyperprolactinemia caused by a combination of an antipsychotic (sulpirid) and an antidepressant (paroxetine).	Sulpiride	165-173	prolactin	Homo sapiens	63-72
23747494-5	2013	RESULTS: The anti-immobility effect elicited by AE in the TST was prevented by the pre-treatment of mice with the antagonists, NAN-190 (5-HT(1A) receptor), ketanserin (5-HT(2A/2C) receptor), prazosin (alpha1-adrenoceptor), yohimbine (alpha2-adrenoceptor), SCH23390 (dopamine D1 receptor), or sulpiride (dopamine D2 receptor).	Sulpiride	292-301	thiosulfate sulfurtransferase, mitochondrial	Mus musculus	58-61
22910534-0	2012	Sulpiride, but not SCH23390, modifies cocaine-induced conditioned place preference and expression of tyrosine hydroxylase and elongation factor 1alpha in zebrafish.	Sulpiride	0-9	tyrosine hydroxylase	Danio rerio	101-121
23571008-12	2013	The greater MSH responses to sulpiride and TRH in insulin-insensitive mares were similar to, but not as exaggerated as, those observed by others for PPID horses.	Sulpiride	29-38	INS	Equus caballus	50-57
23590508-6	2013	SAL as well as TRH and sulpiride stimulated the release of PRL promptly after each injection in both the saline- and MEL-treated groups (P < 0.05).	Sulpiride	23-32	prolactin	Capra hircus	59-62
22910534-9	2012	The cocaine-induced change in TH/EF1alpha was blocked by co-treatment with sulpiride, but not SCH23390, correlating closely with the action of these drugs on the CPP behavioral response.	Sulpiride	75-84	tyrosine hydroxylase	Danio rerio	30-32
22910534-9	2012	The cocaine-induced change in TH/EF1alpha was blocked by co-treatment with sulpiride, but not SCH23390, correlating closely with the action of these drugs on the CPP behavioral response.	Sulpiride	75-84	eukaryotic translation elongation factor 1 alpha 1, like 1	Danio rerio	33-41
22940588-10	2012	in the TST was prevented by the pretreatment of mice with SCH23390 (0.05mg/kg, s.c., a dopamine D(1) receptor antagonist) and sulpiride (50mg/kg, i.p., a dopamine D(2) receptor antagonist).	Sulpiride	126-135	dopamine receptor D2	Mus musculus	154-176
22426507-2	2012	The current study assessed the ability of the selective D1 receptor antagonist SCH 23390 and D2 receptor antagonist sulpiride administrated into the CA1 region of hippocampus (dorsal hippocampus) to alter the rewarding effects of intra-VTA administration of morphine using the conditioned place preference (CPP).	Sulpiride	116-125	carbonic anhydrase 1	Rattus norvegicus	149-152
22981453-6	2012	When slices were preperfused with 100muM sulpiride, a selective dopamine D(2) receptor antagonist, the CCK-8 (0.01muM) effect on electrically stimulated ACh release was increased nearly 2-fold.	Sulpiride	41-50	cholecystokinin	Rattus norvegicus	103-106
22885281-9	2012	Furthermore, intra-CA1 administration of different doses of sulpiride (0.12, 0.5 and 0.75 mug/rat), 5 min before the injection of an effective dose of MK801 (2 mug/rat), decreased %OAT and %OAE, however did not alter other exploratory behaviors induced by MK801.	Sulpiride	60-69	carbonic anhydrase 1	Rattus norvegicus	19-22
22819281-1	2012	The effects of a PRL-stimulating substance (sulpiride) on PRL and PGF2alpha secretion and on luteal and ovarian follicular dynamics were studied during the estrous cycle in mares.	Sulpiride	44-53	prolactin	Equus caballus	58-61
22819281-8	2012	The PRL pulses were more prominent (P < 0.008) in the sulpiride group (peak, 19.4 +- 1.9 ng/mL; mean +- SEM) than in the controls (11.5 +- 1.8 ng/mL).	Sulpiride	57-66	prolactin	Equus caballus	4-7
22819281-10	2012	A novel observation was that the peak of a PRL pulse occurred at the same hour or 1 h later than the peak of a PGFM pulse in 8 of 8 PGFM pulses in the controls and in 6 of 10 pulses in the Sp group (P < 0.04), indicating that sulpiride interfered with the synchrony between PGFM and PRL pulses.	Sulpiride	229-238	prolactin	Equus caballus	43-46
22819281-11	2012	The hypothesis that sulpiride treatment during the equine estrous cycle increases concentrations of PRL and the prominence of PRL pulses was supported.	Sulpiride	20-29	prolactin	Equus caballus	100-103
22651101-4	2012	The MPTP-mediated transient AMPAr-fEPSP facilitation was antagonized by the dopamine D2-like receptor antagonists, eticlopride (1 muM) and sulpiride (1 and 40 muM).	Sulpiride	139-148	latexin	Homo sapiens	159-162
23038740-5	2012	Finally, intracerebroventricular infusion of a kisspeptin receptor antagonist completely blocked the increase in LH pulse frequency induced by systemic administration of sulpiride to anestrous ewes.	Sulpiride	170-179	kisspeptin	Ovis aries	47-57
22266218-8	2012	Sulpiride inhibited KNT-127-induced reduction of GABA release in NAc.	Sulpiride	0-9	kinectin 1	Homo sapiens	20-23
22131382-6	2012	Injections of the D2LR antagonist sulpiride resulted in effects opposite to those of quinpirole in GPe and GPi.	Sulpiride	34-43	glucose-6-phosphate isomerase	Homo sapiens	107-110
22574794-4	2012	SAL, as well as TRH or sulpiride, stimulated the release of PRL promptly after each injection in both 8- and 16-h daily photoperiods at 20 C (P<0.05).	Sulpiride	23-32	prolactin	Capra hircus	60-63
22574794-5	2012	The area under the response curve (AUC) of PRL for the 60-min period after injections of saline (controls), SAL, TRH and sulpiride in the 16-h daily photoperiod group was greater than each corresponding value in the 8-h daily photoperiod group (P<0.05).	Sulpiride	121-130	prolactin	Capra hircus	43-46
22574794-7	2012	The PRL-releasing responses to SAL, TRH and sulpiride under a short and long photoperiod condition at 5 C resembled those at 20 C. These results show that a long photoperiod highly enhances the PRL-releasing response to SAL as well as TRH or sulpiride in either medium or low ambient temperature in goats.	Sulpiride	44-53	prolactin	Capra hircus	4-7
22574794-7	2012	The PRL-releasing responses to SAL, TRH and sulpiride under a short and long photoperiod condition at 5 C resembled those at 20 C. These results show that a long photoperiod highly enhances the PRL-releasing response to SAL as well as TRH or sulpiride in either medium or low ambient temperature in goats.	Sulpiride	44-53	prolactin	Capra hircus	194-197
22574794-7	2012	The PRL-releasing responses to SAL, TRH and sulpiride under a short and long photoperiod condition at 5 C resembled those at 20 C. These results show that a long photoperiod highly enhances the PRL-releasing response to SAL as well as TRH or sulpiride in either medium or low ambient temperature in goats.	Sulpiride	242-251	prolactin	Capra hircus	4-7
22574794-7	2012	The PRL-releasing responses to SAL, TRH and sulpiride under a short and long photoperiod condition at 5 C resembled those at 20 C. These results show that a long photoperiod highly enhances the PRL-releasing response to SAL as well as TRH or sulpiride in either medium or low ambient temperature in goats.	Sulpiride	242-251	prolactin	Capra hircus	194-197
22472310-2	2012	Higher levels of prolactin result from longer exposure to higher doses, especially with older antipsychotics or with risperidone, sulpiride or amisulpride.	Sulpiride	130-139	prolactin	Homo sapiens	17-26
22033896-3	2012	The cocaine-induced place preference was dose-dependently inhibited by intracerebroventricular pretreatment with IP(3) R antagonists, 2-aminophenoxyethane-borate (2-APB), and xestospongin C. The levels of IP(3) R-1 in the frontal cortex and nucleus accumbens of cocaine-conditioned mice significantly increased, which was completely abolished by SCH23390 and sulpiride, selective dopamine D1 and D2 receptor antagonists, respectively.	Sulpiride	359-368	inositol 1,4,5-trisphosphate receptor 1	Mus musculus	113-120
23051896-10	2012	The dopamine-induced IL-6 secretion was partially reduced by sulpiride and abrogated by propranolol.	Sulpiride	61-70	interleukin 6	Homo sapiens	21-25
22250741-12	2012	They also suggest that in terms of the regulatory process for the secretion of PRL, SAL resembles sulpiride but differs from TRH.	Sulpiride	98-107	prolactin	Capra hircus	79-82
23051896-12	2012	The cabergoline-induced IL-6 release was reduced by sulpiride.	Sulpiride	52-61	interleukin 6	Homo sapiens	24-28
22049425-8	2011	Importantly, all, IC-ERN, delta/theta power, and PES were modulated by COMT x Substance interactions such that the Val allele predicted elevated IC-ERN, delta/theta power, and PES after placebo; this association was reversed under sulpiride.	Sulpiride	231-240	catechol-O-methyltransferase	Homo sapiens	71-75
21839753-4	2011	DLL was inhibited in slices treated with the group 1 metabotropic glutamate receptor (mGluR) antagonists MPEP (40 muM) and CPCCOEt (40 muM), the dopamine D2 receptor antagonist sulpiride (5 muM), the L-type calcium channel blocker nifedipine (20 muM), the nicotinic receptor antagonist mecamylamine (10 muM), the muscarinic agonist oxotremorine sesquifumarate (10 muM), and strychnine (0.1 muM).	Sulpiride	177-186	dopamine receptor D2	Homo sapiens	145-165
21611724-9	2011	This beneficial effect of bromocriptine on cognitive flexibility was blocked by pretreatment with the selective dopamine D2 receptor antagonist sulpiride (n = 14).	Sulpiride	144-153	dopamine receptor D2	Homo sapiens	112-132
21925239-8	2011	The administration of SCH23390 (0.01-0.2 mug/rat) or sulpiride (0.1-1 mug/rat) into the CA1 region, immediately after training, had no effect on memory retrieval.	Sulpiride	53-62	carbonic anhydrase 1	Rattus norvegicus	88-91
21925239-9	2011	Furthermore, the amnesic effect of intra-VTA administration of muscimol was significantly decreased by intra-CA1 administration of sulpiride (0.5 and 1 mug/rat, intra-CA1), but not SCH23390.	Sulpiride	131-140	carbonic anhydrase 1	Rattus norvegicus	109-112
21925239-9	2011	Furthermore, the amnesic effect of intra-VTA administration of muscimol was significantly decreased by intra-CA1 administration of sulpiride (0.5 and 1 mug/rat, intra-CA1), but not SCH23390.	Sulpiride	131-140	carbonic anhydrase 1	Rattus norvegicus	167-170
22049425-9	2011	Because low doses of sulpiride presumably increase PFC DA levels, the COMT x Substance interaction supports the hypothesis that low (Val, placebo) and high (Met, sulpiride) versus medium (Val, sulpiride; Met, placebo) DA levels elevate reactivity to errors.	Sulpiride	21-30	catechol-O-methyltransferase	Homo sapiens	70-74
21521749-9	2011	Dopamine regulation of pituitary TGF-beta1 activation process was inferred by the inhibition of active cytokine by in vivo sulpiride treatment.	Sulpiride	123-132	transforming growth factor, beta 1	Mus musculus	33-42
21584865-7	2011	In this experiment, either the dopamine D1 antagonist, SCH23390, or the dopamine D2 receptor antagonist, sulpiride, was intrastriatally infused during a binge mAMPH regimen.	Sulpiride	105-114	dopamine receptor D2	Homo sapiens	72-92
20875051-6	2011	Furthermore, the D(2)R antagonist sulpiride inhibited the dopamine-induced migration of DAT from cytosol to cell membrane.	Sulpiride	34-43	solute carrier family 6 member 3	Rattus norvegicus	88-91
21427058-5	2011	Treatment with all chemicals significantly increased serum P4 levels, and EGME as well as sulpiride induced increases in prolactin (PRL) levels.	Sulpiride	90-99	prolactin	Rattus norvegicus	121-130
21593319-4	2011	This study examined region- and receptor-specific modulation of SSRT in the rat using direct infusions of the dopamine D1 receptor (DRD1) antagonist SCH 23390 or dopamine D2 receptor (DRD2) antagonist sulpiride into the dorsomedial striatum (DMStr) or nucleus accumbens core (NAcbC).	Sulpiride	201-210	dopamine receptor D2	Rattus norvegicus	184-188
21720142-1	2011	A facile fluorometric assay using D-kynurenine as a substrate was utilized for evaluating the inhibition of D-amino acid oxidase (DAAO), which is one of the products of a susceptibility gene for schizophrenia, by commercial antipsychotic drugs, namely, chlorpromazine (CPZ), carbamazepine, sulpiride, quetiapine, and imipramine.	Sulpiride	290-299	D-amino acid oxidase	Homo sapiens	108-128
21894759-4	2011	The inhibition of D1 and D2 dopamine receptors in the amygdala with SCH23390 (1 microg) or sulpiride (1 microg) respectively, also reduced self-stimulation but to a lower degree.	Sulpiride	91-100	dopamine receptor D2	Rattus norvegicus	18-46
21145945-5	2011	The inhibitory effect of 0.5 mug/rat of WIN (intra-CA1) on memory formation was significantly decreased by the D1 dopamine receptor antagonist SCH23390 (0.1-0.5 mug/rat, intra-BLA) or the D2 dopamine receptor antagonist sulpiride (0.02-0.5 mug/rat, intra-BLA) given 5 min before post-training intra-CA1 microinjection of WIN.	Sulpiride	220-229	carbonic anhydrase 1	Rattus norvegicus	51-54
21897053-6	2011	Although the up-regulation of RyRs was not affected by blockade of L-type voltage-gated calcium channels, the increase of RyR-1 and -2 in the limbic forebrain and frontal cortex was completely abolished by SCH23390, a selective antagonist of dopamine D(1) receptors, but not by sulpiride, a selective antagonist of dopamine D(2) receptors.	Sulpiride	278-287	ryanodine receptor 1, skeletal muscle	Mus musculus	122-134
20854431-6	2010	Both the dopamine D(1) receptor antagonist SCH23390 and the dopamine D(2) receptor antagonist sulpiride inhibited the development of METH-induced place conditioning.	Sulpiride	94-103	dopamine receptor D2	Mus musculus	60-82
21720142-1	2011	A facile fluorometric assay using D-kynurenine as a substrate was utilized for evaluating the inhibition of D-amino acid oxidase (DAAO), which is one of the products of a susceptibility gene for schizophrenia, by commercial antipsychotic drugs, namely, chlorpromazine (CPZ), carbamazepine, sulpiride, quetiapine, and imipramine.	Sulpiride	290-299	D-amino acid oxidase	Homo sapiens	130-134
20172684-4	2010	injection of SAL (5mg/kg body weight [BW]) or sulpiride (a DA receptor antagonist, 0.1mg/kg BW) significantly stimulated the release of PRL in male and female calves (P<0.05), though the response to SAL was smaller than that to sulpiride.	Sulpiride	46-55	prolactin	Bos taurus	136-139
21165329-0	2010	Response of i(kr) and HERG currents to the antipsychotics tiapride and sulpiride.	Sulpiride	71-80	potassium voltage-gated channel subfamily H member 2	Homo sapiens	22-26
21165329-2	2010	We studied the effects of two antipsychotics, tiapride and sulpiride, on hERG channels expressed in Xenopus oocytes and also on delayed rectifier K(+) currents in guinea pig cardiomyocytes.	Sulpiride	59-68	ETS transcription factor ERG	Homo sapiens	73-77
20172684-5	2010	The secretory pattern of PRL in response to SAL or sulpiride in female calves resembled that in male calves.	Sulpiride	51-60	prolactin	Bos taurus	25-28
20172684-7	2010	injection of SAL or sulpiride significantly stimulated the release of PRL in cows (P<0.05).	Sulpiride	20-29	prolactin	Bos taurus	70-73
19795811-1	2009	This study was aimed to determine the effect of D2/D3 receptor antagonist sulpiride on the expression of immobility reflex ("pinch-test") and pinch-induced catalepsy ("bar-test") of CBA/Lac male mice depending on their social status ("aggressors" with repeated experience of victories or a "losers" with repeated experience of social defeats).	Sulpiride	74-83	lactase	Mus musculus	186-189
20361897-10	2010	Dopamine D2receptor occupancies of sulpiride were markedly different between the pituitary and temporal cortex, and the B/P ratio for sulpiride (0.34) was significantly lower than for olanzapine (P = .007) and risperidone (P = .015).	Sulpiride	35-44	dopamine receptor D2	Homo sapiens	0-19
20304506-4	2010	Here, we seek to determine whether Homer1a and Yotiao might be implicated in post-synaptic response to antipsychotics with affinity to different dopamine D(2) receptors: haloperidol (0.8mg kg(-1)), risperidone (3mg kg(-1)), olanzapine (2.5mg kg(-1)) and (-)-sulpiride (50mg kg(-1)).	Sulpiride	254-267	homer scaffold protein 1	Homo sapiens	35-42
20304506-4	2010	Here, we seek to determine whether Homer1a and Yotiao might be implicated in post-synaptic response to antipsychotics with affinity to different dopamine D(2) receptors: haloperidol (0.8mg kg(-1)), risperidone (3mg kg(-1)), olanzapine (2.5mg kg(-1)) and (-)-sulpiride (50mg kg(-1)).	Sulpiride	254-267	A-kinase anchoring protein 9	Homo sapiens	47-53
20304506-7	2010	All antipsychotics, with the exclusion of sulpiride, elicited a dorsolateral-to-ventromedial distribution pattern of Homer1a expression.	Sulpiride	42-51	homer scaffold protein 1	Homo sapiens	117-124
20012492-2	2010	Learning was degraded only after administration of the D(2) receptor antagonist sulpiride and was independent of the initial functional state of the mice.	Sulpiride	80-89	dopamine receptor D2	Mus musculus	55-68
19672580-0	2009	The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory.	Sulpiride	36-45	dopamine receptor D2	Homo sapiens	4-24
19444963-6	2009	Therefore, we have evaluated the in vitro and in vivo effects of sulpiride, olanzapine, and haloperidol on acetylcholinesterase activity and ache expression pattern in zebrafish brain.	Sulpiride	65-74	acetylcholinesterase	Danio rerio	107-127
19444963-6	2009	Therefore, we have evaluated the in vitro and in vivo effects of sulpiride, olanzapine, and haloperidol on acetylcholinesterase activity and ache expression pattern in zebrafish brain.	Sulpiride	65-74	acetylcholinesterase	Danio rerio	141-145
19795811-1	2009	This study was aimed to determine the effect of D2/D3 receptor antagonist sulpiride on the expression of immobility reflex ("pinch-test") and pinch-induced catalepsy ("bar-test") of CBA/Lac male mice depending on their social status ("aggressors" with repeated experience of victories or a "losers" with repeated experience of social defeats).	Sulpiride	74-83	dopamine receptor D2	Mus musculus	48-62
19770639-6	2009	In contrast, pretest intra-CA1 administration of either D1 receptor antagonist SCH23390 (0.01-1 microg/mouse) or D2 receptor antagonist sulpiride (5-10 microg/mouse) inhibited the improvement of memory retrieval by lithium (4 microg/mouse, intra-CA1).	Sulpiride	136-145	carbonic anhydrase 1	Mus musculus	27-30
19770639-6	2009	In contrast, pretest intra-CA1 administration of either D1 receptor antagonist SCH23390 (0.01-1 microg/mouse) or D2 receptor antagonist sulpiride (5-10 microg/mouse) inhibited the improvement of memory retrieval by lithium (4 microg/mouse, intra-CA1).	Sulpiride	136-145	dopamine receptor D2	Mus musculus	113-124
19770639-6	2009	In contrast, pretest intra-CA1 administration of either D1 receptor antagonist SCH23390 (0.01-1 microg/mouse) or D2 receptor antagonist sulpiride (5-10 microg/mouse) inhibited the improvement of memory retrieval by lithium (4 microg/mouse, intra-CA1).	Sulpiride	136-145	carbonic anhydrase 1	Mus musculus	246-249
18978642-2	2009	Sulpiride, an inductor of hyperprolactinemia, increased mRNA levels of 5alpha-reductase (5alpha-R), the key enzyme in the biosynthesis of these neurosteroids, indicating a possible interrelationship between prolactin levels and 5alpha-R, although the effects of sulpiride per se cannot be ruled out.	Sulpiride	0-9	prolactin	Rattus norvegicus	31-40
19332443-8	2009	Furthermore, we demonstrated that dopamine D2-like receptor antagonists, such as sulpiride and nemonapride, induced a significant DC-mediated T(h)2 differentiation, using mixed lymphocyte reaction between human Mo-DCs and allogeneic naive CD4(+) T cells.	Sulpiride	81-90	CD4 molecule	Homo sapiens	239-242
19546258-4	2009	Sulpiride dose-dependently decreased the hERG tail current.	Sulpiride	0-9	ETS transcription factor ERG	Homo sapiens	41-45
19546258-5	2009	It is considered that the prolonged action potential duration by sulpiride was mainly the result of inhibition of the hERG channel.	Sulpiride	65-74	ETS transcription factor ERG	Homo sapiens	118-122
18958626-6	2009	The dopamine D2 receptor antagonist RS +/- sulpiride significantly reversed the Meth-induced upregulation of CCR5, demonstrating that the Meth-induced effect is mediated via the D2 receptor.	Sulpiride	43-52	dopamine receptor D2	Homo sapiens	4-24
18958626-6	2009	The dopamine D2 receptor antagonist RS +/- sulpiride significantly reversed the Meth-induced upregulation of CCR5, demonstrating that the Meth-induced effect is mediated via the D2 receptor.	Sulpiride	43-52	C-C motif chemokine receptor 5	Homo sapiens	109-113
19244540-8	2009	Sulpiride abolished iPAS-induced inhibition, but not ePAS-generated facilitation, underlining the importance of D(1)-receptor activity for focal facilitatory neuroplasticity.	Sulpiride	0-9	hypoxia inducible factor 3 subunit alpha	Homo sapiens	20-24
19244540-9	2009	Combining sulpiride with L-dopa reestablished iPAS-induced inhibition, but did not affect ePAS-induced plasticity.	Sulpiride	10-19	hypoxia inducible factor 3 subunit alpha	Homo sapiens	46-50
22408528-4	2009	The electrode showed a fast, stable and Nernstian response over a sulpiride concentration range (1 x 10(-4) - 1 x 10(-2) M) with a mean slope of 58.4 +- 0.9 mV dec(-1) of concentration, a mean detection limit of 4.2 x 10(-5) +- 1.2 x 10(-5) M, a wide working pH range (2 - 8) and a fast response time (< 15 s).	Sulpiride	66-75	deleted in esophageal cancer 1	Homo sapiens	160-166
17976947-13	2008	The AUC of PRL during 120min was 2.12 and 1.78 times greater after the injection of sulpiride plus TRH than either sulpiride alone or sulpiride plus SAL, respectively (P<0.05).	Sulpiride	84-93	prolactin	Capra hircus	11-14
18354386-7	2008	BLA-LTP in Ntsr1-KO mice was impaired by sulpiride, a DA D(2)-like receptor antagonist.	Sulpiride	41-50	neurotensin receptor 1	Mus musculus	11-16
18536982-8	2008	Sulpiride, an antagonist of DA D(2), reversed the effect of dopamine on 10% ethanol induced ALDH activity in hepatocytes.	Sulpiride	0-9	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	92-96
18528813-1	2008	We examined by Real-time PCR how prolonged inhibition of dopaminergic D-2 receptors (DA-2) in the hypothalamus of anestrous ewes by infusion of sulpiride into the third cerebral ventricle affected GnRH and GnRH-R gene expression in discrete parts of this structure and GnRH-R gene expression in the anterior pituitary.	Sulpiride	144-153	gonadotropin releasing hormone 1	Homo sapiens	197-201
18528813-4	2008	An infusion of sulpiride into the III-rd ventricle increased GnRH mRNA levels in the anterior pituitary gland and LH secretion.	Sulpiride	15-24	gonadotropin releasing hormone 1	Homo sapiens	61-65
18528813-5	2008	It is suggested that the increase of GnRH gene expression in the anterior pituitary gland and LH secretion in sulpiride-treated ewes are related with an increase of biosynthesis GnRH with concomitant decreased biosynthesis of GnRH-R protein in the ventromedial hypothalamus/stalk median eminence allowing to an increase of GnRH release.	Sulpiride	110-119	gonadotropin releasing hormone 1	Homo sapiens	178-182
18528813-5	2008	It is suggested that the increase of GnRH gene expression in the anterior pituitary gland and LH secretion in sulpiride-treated ewes are related with an increase of biosynthesis GnRH with concomitant decreased biosynthesis of GnRH-R protein in the ventromedial hypothalamus/stalk median eminence allowing to an increase of GnRH release.	Sulpiride	110-119	gonadotropin releasing hormone receptor	Homo sapiens	226-232
18528813-5	2008	It is suggested that the increase of GnRH gene expression in the anterior pituitary gland and LH secretion in sulpiride-treated ewes are related with an increase of biosynthesis GnRH with concomitant decreased biosynthesis of GnRH-R protein in the ventromedial hypothalamus/stalk median eminence allowing to an increase of GnRH release.	Sulpiride	110-119	gonadotropin releasing hormone 1	Homo sapiens	178-182
18777019-6	2008	RESULTS AND DISCUSSION: Olanzapine (5 mg/kg), sulpiride (5, or 10 mg/kg), and amisulpride (10 mg/kg) treatments significantly increased the level of Golf protein, but there was no increase with administration of higher doses of these three antipsychotics.	Sulpiride	46-55	G protein subunit alpha L	Rattus norvegicus	149-153
19004320-2	2008	Training was impaired only by administration of D2 receptor antagonist sulpiride and did not depend on the initial functional condition of mice.	Sulpiride	71-80	dopamine receptor D2	Mus musculus	48-59
17976947-13	2008	The AUC of PRL during 120min was 2.12 and 1.78 times greater after the injection of sulpiride plus TRH than either sulpiride alone or sulpiride plus SAL, respectively (P<0.05).	Sulpiride	115-124	prolactin	Capra hircus	11-14
17976947-13	2008	The AUC of PRL during 120min was 2.12 and 1.78 times greater after the injection of sulpiride plus TRH than either sulpiride alone or sulpiride plus SAL, respectively (P<0.05).	Sulpiride	115-124	prolactin	Capra hircus	11-14
17620102-7	2007	Treatment of lactating female rats with the dopamine D(2) receptor antagonist sulpiride (40 microg/kg) produced a significant increase (P < 0.05) in PRL granule exocytosis from type I and type III lactotrophs and a significant increase (P < 0.05) in the proportion of type I and II cells undergoing exocytosis of PRL.	Sulpiride	78-87	prolactin	Rattus norvegicus	152-155
18162529-8	2008	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.	Sulpiride	156-165	prolactin receptor	Rattus norvegicus	20-62
18162529-8	2008	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.	Sulpiride	156-165	suppressor of cytokine signaling 1	Rattus norvegicus	64-77
18162529-9	2008	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.	Sulpiride	0-9	suppressor of cytokine signaling 1	Rattus norvegicus	23-29
18162529-9	2008	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.	Sulpiride	0-9	prolactin receptor	Rattus norvegicus	140-145
18162529-9	2008	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.	Sulpiride	0-9	suppressor of cytokine signaling 3	Rattus norvegicus	147-153
18216231-7	2008	These effects were reversed by the D2 receptor antagonist sulpiride.	Sulpiride	58-67	dopamine receptor D2	Mus musculus	35-46
17561380-3	2008	In the current study, we investigated the influence of chronic treatment with clozapine and other antipsychotics (thioridazine,sulpiride and risperidone) on TSPO binding in cell cultures and rat tissues.	Sulpiride	127-136	translocator protein	Rattus norvegicus	157-161
17912501-0	2008	Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers.	Sulpiride	47-56	dopamine receptor D2	Homo sapiens	0-20
17632222-6	2007	In sulpiride group, body mass index and triglyceride, insulin, and IRI levels of women increased higher than those of men.	Sulpiride	3-12	insulin	Homo sapiens	54-61
18336307-5	2008	These two CAs are catalytically efficient with almost identical activity to that of the human isoform CA I for the CO(2) hydration reaction, and highly inhibited by many sulfonamides/sulfamates, including acetazolamide, ethoxzolamide, topiramate and sulpiride, all clinically used drugs.	Sulpiride	250-259	carbonic anhydrase 1	Homo sapiens	102-106
17620102-7	2007	Treatment of lactating female rats with the dopamine D(2) receptor antagonist sulpiride (40 microg/kg) produced a significant increase (P < 0.05) in PRL granule exocytosis from type I and type III lactotrophs and a significant increase (P < 0.05) in the proportion of type I and II cells undergoing exocytosis of PRL.	Sulpiride	78-87	prolactin	Rattus norvegicus	319-322
17325183-4	2007	Some mice were treated with melatonin or sulpiride, a D2 dopamine receptor antagonist.	Sulpiride	41-50	dopamine receptor D2	Mus musculus	54-74
17133263-8	2007	These improving effects of galantamine were blocked by the treatment with mecamylamine, SCH-23390, a dopamine-D1 receptor antagonist, and sulpiride, a dopamine-D2 receptor antagonist, but not by scopolamine, a muscarinic acetylcholine receptor antagonist.	Sulpiride	138-147	dopamine receptor D2	Mus musculus	151-171
16723261-4	2006	administration of the dopamine D1 receptor agonist (SKF38393), dopamine D2 receptor agonist (quinpirole) and dopamine D2 receptor antagonist (sulpiride) not only reversed the effect of pre-training morphine treatment, but also increased this action of the drug.	Sulpiride	142-151	dopamine receptor D2	Mus musculus	109-129
16288681-4	2006	In this study, we measured dopamine D2 receptor occupancy of two conventional benzamide antipsychotics, sulpiride and sultopride, using positron emission tomography, to investigate the rationale of their clinical dose.	Sulpiride	104-113	dopamine receptor D2	Homo sapiens	27-47
16844308-9	2006	Microinfusion of the D2/3 dopamine receptor antagonist sulpiride ((S)-5-aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide) (1.0 microg) into the nucleus accumbens shell 10 minutes prior to SKF-81297 (1.0 microg) blocked the ability of this D1-like dopamine receptor agonist to reinstate cocaine seeking.	Sulpiride	55-64	dopamine receptor D2	Rattus norvegicus	21-43
16288681-6	2006	In terms of dose, sultopride has about 50 times greater potency than sulpiride based on dopamine D2 receptor occupancy.	Sulpiride	69-78	dopamine receptor D2	Homo sapiens	88-108
16205775-0	2006	Administration of the D2 dopamine receptor antagonist sulpiride into the shell, but not the core, of the nucleus accumbens attenuates cocaine priming-induced reinstatement of drug seeking.	Sulpiride	54-63	dopamine receptor D2	Rattus norvegicus	22-42
17141847-7	2006	The D2 receptor antagonist, sulpiride, which induced hyperalgesia of the substance P-induced behaviors in naive mice, did not have any effects on L-DOPA-induced hyperalgesia.	Sulpiride	28-37	dopamine receptor D2	Mus musculus	4-15
17141847-7	2006	The D2 receptor antagonist, sulpiride, which induced hyperalgesia of the substance P-induced behaviors in naive mice, did not have any effects on L-DOPA-induced hyperalgesia.	Sulpiride	28-37	tachykinin 1	Mus musculus	73-84
16463121-7	2006	Moreover, the beneficial effect of lisuride could be completely inhibited by the D2/D3 receptor antagonist sulpiride when co-treated in cultures.	Sulpiride	107-116	dopamine receptor D2	Mus musculus	81-95
15671126-0	2005	Sulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteers.	Sulpiride	0-9	dopamine receptor D2	Homo sapiens	46-66
16914952-3	2006	Intraperitoneal administration of the D2 dopamine receptor antagonist, sulpiride (25 and 50 mg/kg) reduced swim stress-induced antinociception in the second phase of the formalin test.	Sulpiride	71-80	dopamine receptor D2	Homo sapiens	38-58
16242731-9	2006	Pretreatment with dopamine D2 receptor antagonist (sulpiride, 20 mg/kg) prior to drug administration showed decreased mu receptor binding on P1 and P7.	Sulpiride	51-60	perforin 1	Rattus norvegicus	141-150
15621023-1	2005	The dopamine D2-receptor antagonist sulpiride decreases spontaneous locomotor velocity of planarians (pLMV) in an enantiomeric-selective and dose-dependent manner and is significantly attenuated by UV light (254 and 366 nm).	Sulpiride	36-45	dopamine receptor D2	Homo sapiens	4-24
16766383-4	2006	Stimulatory and inhibitory effect of dopamine on glucose-induced insulin secretion was reverted by the addition of dopamine D2 receptor antagonists such as butaclamol and sulpiride.	Sulpiride	171-180	dopamine receptor D2	Homo sapiens	115-135
16302824-7	2005	Three compounds showed better activity against hCA VB over hCA II, among which were sulpiride and ethoxzolamide, which were 2 times more effective inhibitors of the mitochondrial over the cytosolic isozyme.	Sulpiride	84-93	carbonic anhydrase 5B	Homo sapiens	47-53
16302824-7	2005	Three compounds showed better activity against hCA VB over hCA II, among which were sulpiride and ethoxzolamide, which were 2 times more effective inhibitors of the mitochondrial over the cytosolic isozyme.	Sulpiride	84-93	HCA1	Homo sapiens	47-50
16272707-6	2005	We examined the effects of cetraxate, ecabet and sulpiride on the plasma levels of ACTH and cortisol under stress conditions by repetitive blood sampling.	Sulpiride	49-58	proopiomelanocortin	Homo sapiens	83-87
16153700-7	2005	in the FST was prevented by pre-treatment of mice with methysergide (2 mg/kg, i.p., a non-selective serotonin receptor antagonist), sulpiride (32 mg/kg, i.p., a D2 receptor antagonist) or yohimbine (1 mg/kg, i.p., an alpha2-adrenoceptor antagonist).	Sulpiride	132-141	dopamine receptor D2	Mus musculus	161-172
15819972-12	2005	PrRP failed to stimulate PRL release; however, plasma PRL increased immediately following the injection of bPP extract, TRH and sulpiride.	Sulpiride	128-137	prolactin	Bos taurus	54-57
15578005-9	2005	In all subcortical areas examined, the Fos expression induced by SPD was mimicked by the D2 antagonist sulpiride and reversed by the D2 agonist quinpirole, suggesting that the effect is due to blockade of D2-like receptors by SPD.	Sulpiride	103-112	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	39-42
15383832-12	2005	These findings suggest that the combination of prefrontal DA-D2/3 receptor blockade and 5-HT1A receptor activation in regions other than the cortex plays an important role in sulpiride and fluvoxamine-induced increase in prefrontal DA release.	Sulpiride	175-184	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
15584931-6	2004	Sulpiride increased prolactin secretion rates in hypothyroid (P < 0.0001) and control (P = 0.007) mares, but did not alter TRH or thyrotrophin secretion rates.	Sulpiride	0-9	prolactin	Equus caballus	20-29
15635191-1	2005	The effects of sulpiride, an antipsychotic drug, on cytochrome P450 (CYP) activities in human liver microsomes were investigated.	Sulpiride	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	52-67
15635191-1	2005	The effects of sulpiride, an antipsychotic drug, on cytochrome P450 (CYP) activities in human liver microsomes were investigated.	Sulpiride	15-24	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72
15541423-4	2004	Anti-immobility effects of bupropion and nomifensine were inhibited by the dopamine D1 receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-HCl (SCH 23390) and the dopamine D2 receptor antagonist sulpiride.	Sulpiride	242-251	dopamine receptor D1	Mus musculus	75-95
15265766-2	2004	The dopamine D(3) receptor agonist 7-OH-DPAT decreased NHE3 activity, which was prevented by the D(2)-like receptor antagonist S-sulpiride, pertussis toxin (PTX; overnight treatment), and the PKC inhibitor chelerythrine, but not by cholera toxin (overnight treatment), the MAPK inhibitor PD-098059, or the p38 inhibitor SB-203580.	Sulpiride	127-138	dopamine receptor D3	Rattus norvegicus	4-26
15265766-2	2004	The dopamine D(3) receptor agonist 7-OH-DPAT decreased NHE3 activity, which was prevented by the D(2)-like receptor antagonist S-sulpiride, pertussis toxin (PTX; overnight treatment), and the PKC inhibitor chelerythrine, but not by cholera toxin (overnight treatment), the MAPK inhibitor PD-098059, or the p38 inhibitor SB-203580.	Sulpiride	127-138	solute carrier family 9 member A3	Rattus norvegicus	55-59
15519677-12	2004	The D2R blockade by sulpiride increased POMC mRNA levels in the hypothalamus, indicating that D2R exerts a tonic inhibitory effect on hypothalamic POMC gene expression.	Sulpiride	20-29	proopiomelanocortin	Rattus norvegicus	40-44
15519677-12	2004	The D2R blockade by sulpiride increased POMC mRNA levels in the hypothalamus, indicating that D2R exerts a tonic inhibitory effect on hypothalamic POMC gene expression.	Sulpiride	20-29	proopiomelanocortin	Rattus norvegicus	147-151
15114435-0	2004	Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers.	Sulpiride	127-136	dopamine receptor D2	Homo sapiens	95-115
15584931-12	2004	In hypothyroid mares, sulpiride increased (P = 0.02) the synchrony between TRH and prolactin patterns.	Sulpiride	22-31	thyrotropin releasing hormone	Equus caballus	75-78
15584931-12	2004	In hypothyroid mares, sulpiride increased (P = 0.02) the synchrony between TRH and prolactin patterns.	Sulpiride	22-31	prolactin	Equus caballus	83-92
15305869-6	2004	The D1 antagonist, SCH23390, and the D2 antagonist, sulpiride, both attenuated expression of Fos in the medial parvocellular hypothalamic paraventricular nucleus (mpPVN) corticotropin-releasing factor cells at the apex of the HPA axis, as well as in most extra-hypothalamic brain regions examined in response to interleukin-1 beta.	Sulpiride	52-61	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	93-96
15305869-6	2004	The D1 antagonist, SCH23390, and the D2 antagonist, sulpiride, both attenuated expression of Fos in the medial parvocellular hypothalamic paraventricular nucleus (mpPVN) corticotropin-releasing factor cells at the apex of the HPA axis, as well as in most extra-hypothalamic brain regions examined in response to interleukin-1 beta.	Sulpiride	52-61	interleukin 1 beta	Rattus norvegicus	312-330
14709903-2	2004	The absorption of sulpiride from rat intestine was decreased by the substrates or inhibitors of PEPT1, OCTN1, and OCTN2.	Sulpiride	18-27	solute carrier family 22 member 4	Rattus norvegicus	103-108
15033340-3	2004	This inhibition was due to a membrane hyperpolarisation that was blocked by the D2 dopamine receptor antagonist sulpiride and was not potentiated by the dopamine-uptake blocker, cocaine.	Sulpiride	112-121	dopamine receptor D2	Rattus norvegicus	80-100
15468991-1	2004	L-sulpiride is the levorotatory enantiomer of sulpiride, a neuroleptic of the family of benzamide derivatives; it has a characteristic antagonist effect on central DA2 dopaminergic receptors and dopamine DA1 "autoreceptors".	Sulpiride	2-11	immunoglobulin heavy diversity 4-11 (non-functional)	Homo sapiens	204-207
15107193-6	2004	Sulpiride caused an increase in prolactin (643 U/ml) [confidence interval (CI) 549-737).	Sulpiride	0-9	prolactin	Homo sapiens	32-41
14698154-3	2004	Sulpiride shows CA inhibitory properties of the same magnitude as dichlorophenamide, a clinically used antiglaucoma sulfonamide, or valdecoxib, a COX-2 selective inhibitor recently shown to inhibit CA.	Sulpiride	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	146-151
14698154-4	2004	The binding of sulpiride to the hCA II active site is similar to that of other sulfonamide inhibitors, considering the interactions of the sulfonamide zinc anchoring group, but differs considerably when the organic scaffold of the molecule is analyzed.	Sulpiride	15-24	carbonic anhydrase 2	Homo sapiens	32-38
14709903-2	2004	The absorption of sulpiride from rat intestine was decreased by the substrates or inhibitors of PEPT1, OCTN1, and OCTN2.	Sulpiride	18-27	solute carrier family 15 member 1	Rattus norvegicus	96-101
14657189-3	2004	Confocal laser imaging of 300-microm-thick slices of neonatal mouse olfactory epithelium loaded with the Ca(2+)-indicator dye fluo-4 AM revealed that dopaminergic suppression of odor responses could be blocked by the D2 dopamine receptor antagonist sulpiride (<500 microM).	Sulpiride	249-258	dopamine receptor D2	Mus musculus	217-237
14657189-6	2004	As with the suppression of odor responses, the effects of dopamine on ORN excitability were blocked by the D2 dopamine receptor antagonist sulpiride (<500 microM).	Sulpiride	139-148	dopamine receptor D2	Mus musculus	107-127
14751417-6	2004	These results suggest that morphine disrupts the learning of CAR and that the classical neuroleptic haloperidol profoundly impairs acquisition and performance of CAR to a greater degree than atypical neuroleptics such as sulpiride and risperidone.	Sulpiride	221-230	nuclear receptor subfamily 1, group I, member 3	Mus musculus	162-165
14709903-1	2004	The aim of this study was to investigate whether the concomitant administration of the substrates or inhibitors of PEPT1, OCTN1, OCTN2, and P-glycoprotein affects the intestinal absorption of sulpiride in rats.	Sulpiride	192-201	solute carrier family 15 member 1	Rattus norvegicus	115-120
14709903-1	2004	The aim of this study was to investigate whether the concomitant administration of the substrates or inhibitors of PEPT1, OCTN1, OCTN2, and P-glycoprotein affects the intestinal absorption of sulpiride in rats.	Sulpiride	192-201	solute carrier family 22 member 4	Rattus norvegicus	122-127
14709903-1	2004	The aim of this study was to investigate whether the concomitant administration of the substrates or inhibitors of PEPT1, OCTN1, OCTN2, and P-glycoprotein affects the intestinal absorption of sulpiride in rats.	Sulpiride	192-201	solute carrier family 22 member 5	Rattus norvegicus	129-134
14709903-1	2004	The aim of this study was to investigate whether the concomitant administration of the substrates or inhibitors of PEPT1, OCTN1, OCTN2, and P-glycoprotein affects the intestinal absorption of sulpiride in rats.	Sulpiride	192-201	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	140-154
14709903-2	2004	The absorption of sulpiride from rat intestine was decreased by the substrates or inhibitors of PEPT1, OCTN1, and OCTN2.	Sulpiride	18-27	solute carrier family 22 member 5	Rattus norvegicus	114-119
14709903-5	2004	Peak concentration (C(max)) and area under the plasma concentration-time curve (AUC(0-8 h)) of sulpiride were decreased by the concomitant administration of the substrates or inhibitors of PEPT1, OCTN1, and OCTN2.	Sulpiride	95-104	solute carrier family 15 member 1	Rattus norvegicus	189-194
14709903-5	2004	Peak concentration (C(max)) and area under the plasma concentration-time curve (AUC(0-8 h)) of sulpiride were decreased by the concomitant administration of the substrates or inhibitors of PEPT1, OCTN1, and OCTN2.	Sulpiride	95-104	solute carrier family 22 member 4	Rattus norvegicus	196-201
14709903-5	2004	Peak concentration (C(max)) and area under the plasma concentration-time curve (AUC(0-8 h)) of sulpiride were decreased by the concomitant administration of the substrates or inhibitors of PEPT1, OCTN1, and OCTN2.	Sulpiride	95-104	solute carrier family 22 member 5	Rattus norvegicus	207-212
13679252-6	2003	Local infusion of sulpiride, 10 microM, D(2) receptor antagonist, potentiated (about 100%) the SOM (1 microM)-induced release of ACh.	Sulpiride	18-27	somatostatin	Rattus norvegicus	95-98
14683704-1	2003	The dopamine D2 receptor antagonist sulpiride can produce a range of cognitive deficits in normal volunteers, consistent with those seen in Parkinson"s disease (PD).	Sulpiride	36-45	dopamine receptor D2	Homo sapiens	4-24
14683704-7	2003	Sulpiride increased striatal rCBF bilaterally and the working memory and planning tasks activated discrete frontoparietal networks in keeping with previous studies.	Sulpiride	0-9	CCAAT/enhancer binding protein zeta	Rattus norvegicus	29-33
14683704-11	2003	These findings suggest that (1) sulpiride produces clear increases in striatal rCBF, (2) in contrast to previous studies no effects of sulpiride on performance of the working memory tasks or the associated neural networks were observed, and (3) sulpiride may modulate performance of more complex cognitive tasks via alterations in striatal neural activity.	Sulpiride	32-41	CCAAT/enhancer binding protein zeta	Rattus norvegicus	79-83
14730115-0	2003	Opposite effects of clozapine and sulpiride on the lipopolysaccharide-induced inhibition of the GR-mediated gene transcription in fibroblast cells.	Sulpiride	34-43	nuclear receptor subfamily 3 group C member 1	Homo sapiens	96-98
14730115-9	2003	Opposite effect of clozapine and sulpiride on LPS action may result from their distinct effect on activity of some kinases involved in regulation of GR transcriptional function and may determine their utility in the treatment of schizophrenia with or without immune system activation.	Sulpiride	33-42	nuclear receptor subfamily 3 group C member 1	Homo sapiens	149-151
12950692-1	2003	The aim of this study was to compare the effects of treatment with repeated injections of sulpiride (a dopamine D2 antagonist) on prolactin secretion and induced lactation in ovariectomized and intact adult mares and to verify if this induction was possible at the beginning and at the end of the birth season.	Sulpiride	90-99	prolactin	Homo sapiens	130-139
12950692-10	2003	Prolactin increase after sulpiride treatment was not so great in the ovariectomized-treated mares as in the intact-treated mares.	Sulpiride	25-34	prolactin	Homo sapiens	0-9
12716422-9	2003	Conversely, in homozygous VMAT2 mutant mice, it was attenuated by (-)sulpiride but not GBR12935.	Sulpiride	66-78	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	26-31
12826582-5	2003	Sulpiride (0.6 mg/kg twice daily; 22-30 wk of long days) induced a marginal increase in blood PRL concentrations, but again, it had no effect on the long-term PRL cycle (PRL minimum, 37.9 +/- 0.4 and 37.6 +/- 0.9 wk for sulpiride and control groups, respectively; not significant).	Sulpiride	0-9	prolactin	Ovis aries	94-97
11846864-7	2002	From the marked increase in PRL level and the slight decrease in T/E2 ratio observed during sulpiride therapy, it is proposed that sulpiride may induce gynecomastia by inhibiting hypothalamic-pituitary function directly, and/or indirectly through hyperPRLemia.	Sulpiride	131-140	prolactin	Homo sapiens	28-31
12574225-6	2003	LIF (5 nM) treatment reduced PRL secretion in primary human prolactinoma cultures by up to 42% (P < 0.0005), an effect that was surprisingly blocked by sulpiride, a D2-like dopamine receptor antagonist.	Sulpiride	155-164	LIF interleukin 6 family cytokine	Homo sapiens	0-3
12574225-6	2003	LIF (5 nM) treatment reduced PRL secretion in primary human prolactinoma cultures by up to 42% (P < 0.0005), an effect that was surprisingly blocked by sulpiride, a D2-like dopamine receptor antagonist.	Sulpiride	155-164	prolactin	Homo sapiens	29-32
12574225-7	2003	LIF (5 nM) also suppressed PRL levels in primary rat pituitary cultures by 70% (P < 0.005), and in rat MMQ pituitary tumor cells, and this effect was also reversed by sulpiride (200 micro M).	Sulpiride	170-179	LIF, interleukin 6 family cytokine	Rattus norvegicus	0-3
12392092-6	2002	The results obtained from these examinations indicated that the apical-to-basolateral transport of sulpiride is mediated by the peptide transporter PEPT1, organic cation transporters OCTN1 and OCTN2 on the apical membrane, and the basolateral peptide transporter on the basolateral membrane.	Sulpiride	99-108	solute carrier family 15 member 1	Homo sapiens	148-153
12392092-6	2002	The results obtained from these examinations indicated that the apical-to-basolateral transport of sulpiride is mediated by the peptide transporter PEPT1, organic cation transporters OCTN1 and OCTN2 on the apical membrane, and the basolateral peptide transporter on the basolateral membrane.	Sulpiride	99-108	solute carrier family 22 member 4	Homo sapiens	183-188
12392092-6	2002	The results obtained from these examinations indicated that the apical-to-basolateral transport of sulpiride is mediated by the peptide transporter PEPT1, organic cation transporters OCTN1 and OCTN2 on the apical membrane, and the basolateral peptide transporter on the basolateral membrane.	Sulpiride	99-108	solute carrier family 22 member 5	Homo sapiens	193-198
12392092-8	2002	A decrease in the absorption of sulpiride may occur in coadministration protocols involving PEPT1-, OCTN1-, and OCTN2-transported drugs.	Sulpiride	32-41	solute carrier family 15 member 1	Homo sapiens	92-97
12392092-8	2002	A decrease in the absorption of sulpiride may occur in coadministration protocols involving PEPT1-, OCTN1-, and OCTN2-transported drugs.	Sulpiride	32-41	solute carrier family 22 member 4	Homo sapiens	100-105
12392092-8	2002	A decrease in the absorption of sulpiride may occur in coadministration protocols involving PEPT1-, OCTN1-, and OCTN2-transported drugs.	Sulpiride	32-41	solute carrier family 22 member 5	Homo sapiens	112-117
12392092-9	2002	Coadministration using the P-glycoprotein-transported drugs, in contrast, may enhance the absorption of sulpiride.	Sulpiride	104-113	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
12695877-3	2003	Using cultured ventral tegmental area (VTA) dopaminergic neurons as a model, we report that nanomolar concentrations of haloperidol cause a time-dependent increase in Fos expression in dopaminergic neurons.Surprisingly, this induction was not mimicked by sulpiride, a selective D2 receptor antagonist, and was not blocked by Rp-cAMPS, an antagonist of protein kinase A (PKA), thus suggesting that D2 receptors and the cAMP cascade are not required.	Sulpiride	255-264	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-170
12573525-4	2003	Both these plasticity related phenomena were NMDA-receptor-dependent; LTD was blocked by sulpiride, a dopamine D2-receptor antagonist.	Sulpiride	89-98	dopamine receptor D2	Mus musculus	102-122
12568792-4	2003	We carried out a biological validation of the prolactin assay by administering three different doses each of sulpiride and cabergoline to adult male meerkats.	Sulpiride	109-118	prolactin	Homo sapiens	46-55
12568792-5	2003	Increasing doses of sulpiride and cabergoline caused substantial increases and decreases, respectively, in the plasma prolactin of the study animals as expected.	Sulpiride	20-29	prolactin	Homo sapiens	118-127
12242090-6	2002	The effect of apomorphine on jumping was reduced by the dopamine D2 receptor antagonist, sulpiride.	Sulpiride	89-98	dopamine receptor D2	Mus musculus	56-76
12132663-13	2002	P-glycoprotein may also contribute to the efflux of sulpiride.	Sulpiride	52-61	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
11903811-7	2002	Propranolol (beta antagonist) had no effect on PRL secretion, while sulpiride (DA D-2 antagonist) induced a marked increase in blood PRL concentrations in control rams (> 4 h), and a transient effect in HPD rams (15 min).	Sulpiride	68-77	prolactin	Ovis aries	133-136
15018806-9	2002	Interestingly, the D2 receptor antagonist sulpiride also blocked the SKF-38393-triggered rise of pCREB.	Sulpiride	42-51	dopamine receptor D2	Mus musculus	19-30
11771945-8	2002	Quinpirole (0.1 and 1 mg/kg) further reduced bladder capacity in both types of rats, an effect blocked by sulpiride (20 mg/kg), a D2 dopamine receptor antagonist.	Sulpiride	106-115	dopamine receptor D2	Rattus norvegicus	130-150
12207161-4	2002	decreased serum prolactin levels after 1 or 3 h. Sulpiride, a dopaminergic antagonist, increased serum prolactin and blocked the inhibitory effect of LPS.	Sulpiride	49-58	prolactin	Rattus norvegicus	16-25
12207161-4	2002	decreased serum prolactin levels after 1 or 3 h. Sulpiride, a dopaminergic antagonist, increased serum prolactin and blocked the inhibitory effect of LPS.	Sulpiride	49-58	prolactin	Rattus norvegicus	103-112
11998830-0	2002	Administration of sulpiride to anovulatory mares in winter: effects on prolactin and gonadotropin concentrations, ovarian activity, ovulation and hair shedding.	Sulpiride	18-27	prolactin	Homo sapiens	71-80
11998830-2	2002	Sulpiride administration increased daily plasma prolactin concentrations (P < 0.05), although the prolactin response during the 6 h following sulpiride injections decreased markedly from the 1st to the 6th day of treatment (treatment by day, P < 0.0001).	Sulpiride	0-9	prolactin	Homo sapiens	48-57
11998830-2	2002	Sulpiride administration increased daily plasma prolactin concentrations (P < 0.05), although the prolactin response during the 6 h following sulpiride injections decreased markedly from the 1st to the 6th day of treatment (treatment by day, P < 0.0001).	Sulpiride	145-154	prolactin	Homo sapiens	101-110
11998830-4	2002	Injection of GnRH and TRH on 15 February showed that the response of plasma prolactin to secretagogue was increased in sulpiride-treated mares (P < 0.005), while there was no effect (P > 0.1) of sulpiride treatment on the response of LH or FSH.	Sulpiride	119-128	gonadotropin releasing hormone 1	Homo sapiens	13-17
11998830-4	2002	Injection of GnRH and TRH on 15 February showed that the response of plasma prolactin to secretagogue was increased in sulpiride-treated mares (P < 0.005), while there was no effect (P > 0.1) of sulpiride treatment on the response of LH or FSH.	Sulpiride	119-128	prolactin	Homo sapiens	76-85
11998830-4	2002	Injection of GnRH and TRH on 15 February showed that the response of plasma prolactin to secretagogue was increased in sulpiride-treated mares (P < 0.005), while there was no effect (P > 0.1) of sulpiride treatment on the response of LH or FSH.	Sulpiride	201-210	prolactin	Homo sapiens	76-85
11998830-9	2002	It was concluded that sulpiride administration to seasonally anovulatory mares under the conditions of our experiment increased daily plasma prolactin levels but did not stimulate gonadotropin secretion or ovarian activity.	Sulpiride	22-31	prolactin	Homo sapiens	141-150
11722701-8	2001	The third experiment tested if the effect of vmPOA oestradiol during anoestrus could be overcome by an injection of the dopamine-D2 receptor antagonist (-)-sulpiride.	Sulpiride	152-165	dopamine receptor D2	Homo sapiens	120-140
11711040-4	2001	The dopamine D(1) receptor antagonist 7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390) antagonized p-chloroamphetamine-induced hyperthermia, although the dopamine D(2) receptor antagonist sulpiride was without effect.	Sulpiride	224-233	dopamine receptor D1	Mus musculus	4-26
11418281-6	2001	Significantly higher prolactin levels after sulpiride challenge were however found in depressed patients than controls at all time points after sulpiride administration.	Sulpiride	44-53	prolactin	Homo sapiens	21-30
11418281-0	2001	The prolactin response to sulpiride in major depression: the role of the D2 receptor in depression.	Sulpiride	26-35	prolactin	Homo sapiens	4-13
11418281-2	2001	The aim of the study was to characterise the Dopamine D2 receptor sensitivity status in depressed patients versus controls by means of a novel neuro-endocrine challenge test, the prolactin response to sulpiride.	Sulpiride	201-210	dopamine receptor D2	Homo sapiens	45-65
11418281-2	2001	The aim of the study was to characterise the Dopamine D2 receptor sensitivity status in depressed patients versus controls by means of a novel neuro-endocrine challenge test, the prolactin response to sulpiride.	Sulpiride	201-210	prolactin	Homo sapiens	179-188
11899856-2	2001	It is noted that sulpiride clearly increases the evolution of prolactin in both sexes.	Sulpiride	17-26	prolactin	Homo sapiens	62-71
11899856-7	2001	In the article the analysis has been carried out how wider and wider used neuroleptic-sulpiride--influences upon endocrine system and particularly upon the evaluation of prolactin.	Sulpiride	86-95	prolactin	Homo sapiens	170-179
11353673-4	2001	Pretreatment with another DA D(2) receptor antagonist, sulpiride [50 mg/kg (154 micromol/kg) ip], similarly reduced amylin"s satiety effect, whereas pretreatment with the DA D(1)-receptor antagonist SCH-23390 [10 microg/kg (0.03 micromol/kg) ip] did not influence amylin"s effect.	Sulpiride	55-64	islet amyloid polypeptide	Rattus norvegicus	116-122
11418281-6	2001	Significantly higher prolactin levels after sulpiride challenge were however found in depressed patients than controls at all time points after sulpiride administration.	Sulpiride	144-153	prolactin	Homo sapiens	21-30
11418281-7	2001	This neuroendocrine challenge paradigm suggests that the prolactin response to sulpiride, a D2 receptor antagonist, is enhanced in depression, which suggests that this receptor might be supersensitive in depression compared to controls.	Sulpiride	79-88	prolactin	Homo sapiens	57-66
11238736-4	2001	M100907 (0.1 mg/kg), a 5-HT(2A) antagonist, significantly increased the ability of both S:(-)-sulpiride (10 mg/kg), a D(2) antagonist devoid of 5-HT(1A) affinity, and R:(+)-8-OH-DPAT (0.05 mg/kg), a 5-HT(1A) agonist, to increase mPFC dopamine release.	Sulpiride	90-103	5-hydroxytryptamine receptor 2A	Rattus norvegicus	23-30
11325806-7	2001	The 15 mM K(+)-induced release of [(3)H]-GABA in the presence of sulpiride was inhibited by 100 microM histamine (mean inhibition 78+/-3%) and by the histamine H(3) receptor-selective agonist, immepip, 1 microM (mean inhibition 81+/-5%).	Sulpiride	65-74	histamine receptor H3	Rattus norvegicus	150-173
11303060-6	2001	This inhibition was blocked by the D(2) dopamine receptor antagonist, sulpiride (2 microM).	Sulpiride	70-79	dopamine receptor D2	Rattus norvegicus	35-57
10940355-1	2000	We previously reported that following acute administration of haloperidol or (-)-sulpiride, both dopamine D(2)-receptor antagonists, to mice induced nerve growth factor (NGF) gene expression, mediated by the interaction of c-fos with the AP-1 binding site present in the first intron on the NGF gene.	Sulpiride	77-90	dopamine receptor D2	Mus musculus	97-119
11672604-4	2001	To determine whether the ability of the D2 receptor antagonist, sulpiride, to induce Fos in rat pallidal neurons is mediated by D2-like receptors in striatum or globus pallidus, intrastriatal or intrapallidal sulpiride infusions were conducted.	Sulpiride	64-73	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-88
11672604-7	2001	Intrastriatal infusions of (-)-sulpiride (10-200 ng) dose-dependently increased the number of striatal cells expressing Fos; and the Fos-immunoreactive striatal cells were D2 receptor mRNA-expressing, the same population in which systemic D2 receptor antagonists induce Fos.	Sulpiride	27-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	120-123
11672604-7	2001	Intrastriatal infusions of (-)-sulpiride (10-200 ng) dose-dependently increased the number of striatal cells expressing Fos; and the Fos-immunoreactive striatal cells were D2 receptor mRNA-expressing, the same population in which systemic D2 receptor antagonists induce Fos.	Sulpiride	27-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	133-136
11672604-7	2001	Intrastriatal infusions of (-)-sulpiride (10-200 ng) dose-dependently increased the number of striatal cells expressing Fos; and the Fos-immunoreactive striatal cells were D2 receptor mRNA-expressing, the same population in which systemic D2 receptor antagonists induce Fos.	Sulpiride	27-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	133-136
11672604-8	2001	Intrastriatal infusions of high (5 microg), but not low (10-200 ng), (-)-sulpiride doses also induced Fos in globus pallidus cells but the sulpiride appeared to spread to the globus pallidus.	Sulpiride	69-82	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	102-105
11672604-8	2001	Intrastriatal infusions of high (5 microg), but not low (10-200 ng), (-)-sulpiride doses also induced Fos in globus pallidus cells but the sulpiride appeared to spread to the globus pallidus.	Sulpiride	73-82	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	102-105
11672604-9	2001	Direct intrapallidal infusions of (-)-sulpiride (50-100 ng) dose-dependently induced Fos in globus pallidus with minimal influence on striatum or other basal ganglia structures.	Sulpiride	34-47	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	85-88
11160501-12	2001	In WT mice, activation of D2 family receptors with quinpirole decreased spontaneous excitatory events and conversely sulpiride, a D2 receptor antagonist, increased activity.	Sulpiride	117-126	dopamine receptor D2	Mus musculus	130-141
11166414-7	2001	It is speculated that the poor oral bioavailability of SP was caused by brush border P-gp efflux.	Sulpiride	55-57	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	85-89
11166414-8	2001	Synchronous release delivery systems of SP containing also the P-gp inhibitor Qn were able to increase SP bioavailability after intestinal administration in the rat.	Sulpiride	40-42	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	63-67
11166414-8	2001	Synchronous release delivery systems of SP containing also the P-gp inhibitor Qn were able to increase SP bioavailability after intestinal administration in the rat.	Sulpiride	103-105	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	63-67
11040357-1	2000	The dopamine D2 receptor antagonist sulpiride decreases the spontaneous locomotor activity of Planaria in an enantiomeric-selective and dose-dependent manner.	Sulpiride	36-45	dopamine receptor D2	Homo sapiens	4-24
12545830-1	2000	This study examined the effects of sulpiride, a dopamine D2 receptor antagonist, on morphine rewarding properties and its relation to cyclic AMP levels in brain.	Sulpiride	35-44	dopamine receptor D2	Mus musculus	48-68
10940355-1	2000	We previously reported that following acute administration of haloperidol or (-)-sulpiride, both dopamine D(2)-receptor antagonists, to mice induced nerve growth factor (NGF) gene expression, mediated by the interaction of c-fos with the AP-1 binding site present in the first intron on the NGF gene.	Sulpiride	77-90	FBJ osteosarcoma oncogene	Mus musculus	223-228
10940355-1	2000	We previously reported that following acute administration of haloperidol or (-)-sulpiride, both dopamine D(2)-receptor antagonists, to mice induced nerve growth factor (NGF) gene expression, mediated by the interaction of c-fos with the AP-1 binding site present in the first intron on the NGF gene.	Sulpiride	77-90	nerve growth factor	Mus musculus	291-294
10940355-6	2000	Thus, our data suggest that haloperidol- and (-)-sulpiride-induced NGF expression may be associated with both beneficial and adverse effects.	Sulpiride	45-58	nerve growth factor	Mus musculus	67-70
10940355-1	2000	We previously reported that following acute administration of haloperidol or (-)-sulpiride, both dopamine D(2)-receptor antagonists, to mice induced nerve growth factor (NGF) gene expression, mediated by the interaction of c-fos with the AP-1 binding site present in the first intron on the NGF gene.	Sulpiride	77-90	nerve growth factor	Mus musculus	149-168
10940355-1	2000	We previously reported that following acute administration of haloperidol or (-)-sulpiride, both dopamine D(2)-receptor antagonists, to mice induced nerve growth factor (NGF) gene expression, mediated by the interaction of c-fos with the AP-1 binding site present in the first intron on the NGF gene.	Sulpiride	77-90	nerve growth factor	Mus musculus	170-173
10565846-0	1999	R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.	Sulpiride	63-76	5-hydroxytryptamine receptor 1A	Rattus norvegicus	18-40
10933217-6	2000	Parallels are identified in human subjects receiving drugs such as the indirect catecholamine agonists L-dopa, methylphenidate and the dopamine D2 receptor blocker sulpiride.	Sulpiride	164-173	dopamine receptor D2	Homo sapiens	135-155
10855458-10	2000	Leptin and insulin levels were significantly higher after SUL administration--leptin: 2.77+/-0.22 ng/ml.	Sulpiride	58-61	leptin	Homo sapiens	0-6
10855458-10	2000	Leptin and insulin levels were significantly higher after SUL administration--leptin: 2.77+/-0.22 ng/ml.	Sulpiride	58-61	insulin	Homo sapiens	11-18
10855458-10	2000	Leptin and insulin levels were significantly higher after SUL administration--leptin: 2.77+/-0.22 ng/ml.	Sulpiride	58-61	leptin	Homo sapiens	78-84
20681131-7	2000	Sulpiride administration increased plasma prolactin concentrations at all times of the year and was most pronounced in cyclic mares, whereas naloxone administration did not affect prolactin secretion.	Sulpiride	0-9	prolactin	Homo sapiens	42-51
10915829-4	2000	In behavioral studies, we found that orexin-A induced hyperlocomotion, stereotypy and grooming behavior when administered centrally in rats, and these effects were abolished by dopamine D(2) (haloperidol and sulpiride) or D(1) (SCH23390) antagonists.	Sulpiride	208-217	hypocretin neuropeptide precursor	Rattus norvegicus	37-45
10989281-5	2000	Our results show that two D2 receptor antagonists, butaclamol and sulpiride, enhance hypoxia-induced phosphorylation of p38gamma, but not p38.	Sulpiride	66-75	mitogen activated protein kinase 14	Rattus norvegicus	120-123
10686348-9	2000	The D(2) receptor antagonist sulpiride exerted synergistic and antagonistic effects on NMDA- and SKF 38393-triggered Fos production, in a region specific manner.	Sulpiride	29-38	dopamine receptor D2	Mus musculus	4-17
10686348-9	2000	The D(2) receptor antagonist sulpiride exerted synergistic and antagonistic effects on NMDA- and SKF 38393-triggered Fos production, in a region specific manner.	Sulpiride	29-38	FBJ osteosarcoma oncogene	Mus musculus	117-120
10746297-7	2000	On sulpiride, patients gained weight and exhibited fatigue and increased levels of prolactin.	Sulpiride	3-12	prolactin	Homo sapiens	83-92
10640628-4	2000	In this study, we investigated the mechanism of such increase by examining the effects of DA agonists (SKF38393 or bromocriptine) and DA antagonists (SCH23390 or sulpiride) on the expression of MT-III mRNA.	Sulpiride	162-171	metallothionein 3	Mus musculus	194-200
10446316-9	1999	Pre-treatment with sulpiride prevented ropinirole from enhancing striatal GSH, catalase and SOD activities and abolished the protection of dopaminergic neurons against 6-OHDA.	Sulpiride	19-28	catalase	Mus musculus	79-87
10520140-7	1999	Northern blot analysis demonstrated that the GR mRNA level was significantly increased by 14-day treatment with desipramine (+142% over control), amitriptyline (+108%), mianserin (+124%), paroxetine (+42%) and sulpiride (+92%), but not with haloperidol.	Sulpiride	210-219	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	45-47
10512033-1	1999	It was shown that intracerebral injections of D2 dopamine receptor agonist quinpirol after systemic administration of D2 antagonist sulpiride inhibited both locomotor and food-procuring activity in rats.	Sulpiride	132-141	dopamine receptor D2	Rattus norvegicus	46-66
9918563-5	1999	This effect was 1) additive with that of a pure H3-receptor antagonist, ciproxifan, 2) mimicked by a 5-HT2A receptor antagonist, ketanserin, 3) reversed by a 5-HT2A receptor agonist, DOI, 4) not shared by antipsychotics with low affinity for the 5-HT2A receptor, i.e., haloperidol, sulpiride, raclopride, or remoxipride that, on the contrary, tended to reduce tele-methylhistamine levels.	Sulpiride	282-291	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	158-173
10505482-14	1999	The laboratory parameters revealed no significant differences between the treatment groups, with the exception of prolactin which moderately exceeded the range of normal in 50% of the patients treated with sulpiride.	Sulpiride	206-215	prolactin	Homo sapiens	114-123
10204691-3	1999	Haloperidol (0.1-8 mg/kg) and (-)-sulpiride (10-100 mg/kg), induced NGF mRNA in a dose-dependent fashion in the hippocampus, piriform cortex, striatum and nucleus accumbens.	Sulpiride	30-43	nerve growth factor	Homo sapiens	68-71
10204691-4	1999	The haloperidol (1 mg/kg)- and (-)-sulpiride (20 mg/kg)-induced NGF mRNA expression attained a maximum level 120 min after injection and returned to control levels 24 h later.	Sulpiride	31-44	nerve growth factor	Homo sapiens	64-67
10204691-5	1999	Prior administration of the protein synthesis inhibitor cycloheximide blocked the haloperidol- and (-)-sulpiride-mediated induction of NGF mRNA.	Sulpiride	99-112	nerve growth factor	Homo sapiens	135-138
10204691-7	1999	Our previous studies have shown that haloperidol and (-)-sulpiride induce the expression of c-fos and c-jun mRNAs and increase their AP-1 DNA binding activities.	Sulpiride	53-66	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	92-97
10204691-7	1999	Our previous studies have shown that haloperidol and (-)-sulpiride induce the expression of c-fos and c-jun mRNAs and increase their AP-1 DNA binding activities.	Sulpiride	53-66	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-107
10204691-7	1999	Our previous studies have shown that haloperidol and (-)-sulpiride induce the expression of c-fos and c-jun mRNAs and increase their AP-1 DNA binding activities.	Sulpiride	53-66	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	133-137
10082643-1	1999	Male Sprague-Dawley rats implanted with bilateral intracerebral guide cannulae were trained in the standard hidden platform version of the Morris water maze and given immediate posttraining infusions of the D2 dopamine receptor antagonist sulpiride (10.0 or 100.0 ng/side) or saline vehicle into the posteroventral caudate-putamen.	Sulpiride	239-248	dopamine receptor D2	Rattus norvegicus	207-227
10357247-6	1999	In contrast, the D1CT mice displayed supersensitivity to cataleptic induction by the D2 receptor antagonist sulpiride.	Sulpiride	108-117	dopamine receptor D2	Mus musculus	85-96
10096770-2	1999	The serum prolactin level gradually increased during the twice-daily administration of sulpiride and reached a plateau after 4 days.	Sulpiride	87-96	prolactin	Callithrix jacchus	10-19
9918563-5	1999	This effect was 1) additive with that of a pure H3-receptor antagonist, ciproxifan, 2) mimicked by a 5-HT2A receptor antagonist, ketanserin, 3) reversed by a 5-HT2A receptor agonist, DOI, 4) not shared by antipsychotics with low affinity for the 5-HT2A receptor, i.e., haloperidol, sulpiride, raclopride, or remoxipride that, on the contrary, tended to reduce tele-methylhistamine levels.	Sulpiride	282-291	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	158-173
10368869-4	1999	At day 10, the area under the glucose curve did not differ between sulpiride and vehicle-treated rats, however, the area under the insulin curve was significantly decreased by sulpiride.	Sulpiride	176-185	insulin	Homo sapiens	131-138
9988094-9	1999	The systemic administration of the dopamine D2 receptor antagonist, sulpiride did not suppress the residual grooming activity shown by animals injected with oxytocin, prolactin or ACTH-(1-24), and did not change the behavioral expression of those injected with beta-endorphin.	Sulpiride	68-77	dopamine receptor D2	Mus musculus	35-55
10025710-5	1999	Application of the D2 DA-receptor antagonist sulpiride (50 microM) also significantly increased the time course, suggesting that DA-induced hyperpolarization enhances DAT activity.	Sulpiride	45-54	solute carrier family 6 member 3	Rattus norvegicus	167-170
10025680-13	1999	Further, chronic, but not acute, treatment of cells with either a protein kinase inhibitor H-7 or a cAMP-dependent protein kinase (PKA) inhibitor H-89 abolished this effect of sulpiride on the NMDA-induced [Ca2+]i changes.	Sulpiride	176-185	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	66-80
10210518-7	1999	Furthermore, in C57 mice pretreatment with selective D1 or D2 receptor antagonists (SCH 23390 or (-)-sulpiride) in otherwise non-effective doses (0.025 and 6 mg/kg, respectively) blocked the memory enhancing effects of oxotremorine.	Sulpiride	97-110	dopamine receptor D2	Mus musculus	59-70
10082228-0	1999	Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat.	Sulpiride	76-85	neuropeptide Y	Rattus norvegicus	89-103
10082228-2	1999	administration of chlorpromazine (2 or 10 mg/kg), haloperidol (0.5 or 2 mg/kg) or sulpiride (50 or 100 mg/kg) on the neuropeptide Y (NPY) system in the rat nucleus accumbens were studied.	Sulpiride	82-91	neuropeptide Y	Rattus norvegicus	117-131
10082228-2	1999	administration of chlorpromazine (2 or 10 mg/kg), haloperidol (0.5 or 2 mg/kg) or sulpiride (50 or 100 mg/kg) on the neuropeptide Y (NPY) system in the rat nucleus accumbens were studied.	Sulpiride	82-91	neuropeptide Y	Rattus norvegicus	133-136
10025680-13	1999	Further, chronic, but not acute, treatment of cells with either a protein kinase inhibitor H-7 or a cAMP-dependent protein kinase (PKA) inhibitor H-89 abolished this effect of sulpiride on the NMDA-induced [Ca2+]i changes.	Sulpiride	176-185	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	115-129
10025680-13	1999	Further, chronic, but not acute, treatment of cells with either a protein kinase inhibitor H-7 or a cAMP-dependent protein kinase (PKA) inhibitor H-89 abolished this effect of sulpiride on the NMDA-induced [Ca2+]i changes.	Sulpiride	176-185	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	131-134
10025680-15	1999	The results with protein kinase inhibitors indicate that the potentiation of NMDA responses by sulpiride involves intracellular biochemical events.	Sulpiride	95-104	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	17-31
9852568-6	1998	Quinpirole increased DAT activity that was blocked by sulpiride and the protein kinase A selective inhibitor H-89.	Sulpiride	54-63	solute carrier family 6 member 3	Homo sapiens	21-24
9726645-5	1998	Dopamine D2 receptor blockade with sulpiride caused a small but significant reduction in alcohol intake and preference in D1 +/+ mice and attenuated residual alcohol drinking in D1 -/- mice.	Sulpiride	35-44	dopamine receptor D2	Mus musculus	0-20
9845010-3	1998	The most pronounced changes in NPY-LI levels were found 24 h after acute chlorpromazine or haloperidol administration (a decrease) and after withdrawal of chlorpromazine, haloperidol or sulpiride (an increase).	Sulpiride	186-195	neuropeptide Y	Rattus norvegicus	31-34
9630573-7	1998	Pretreatment with sulpiride, a dopamine D2 receptor antagonist, blocked the induction of Fos protein in the prefrontal cortex and the core region of accumbens nucleus, but not in the medial striatum and the shell division of nucleus accumbens of rat brain.	Sulpiride	18-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	89-92
9578405-3	1998	The densities of Fos-, FosB-, Fra-1-, Jun- and JunD-immunoreactive nuclei induced by haloperidol and sulpiride in the hippocampus, piriform cortex and accumbens nucleus were higher than those in the control groups.	Sulpiride	101-110	jun D proto-oncogene	Mus musculus	47-51
9578405-6	1998	These results suggested that induced Fos, FosB, Fra-1, Jun and JunD proteins constitute the activator protein-1 complex after the administration of haloperidol and sulpiride.	Sulpiride	164-173	FBJ osteosarcoma oncogene	Mus musculus	37-40
9578405-6	1998	These results suggested that induced Fos, FosB, Fra-1, Jun and JunD proteins constitute the activator protein-1 complex after the administration of haloperidol and sulpiride.	Sulpiride	164-173	FBJ osteosarcoma oncogene B	Mus musculus	42-46
9578405-6	1998	These results suggested that induced Fos, FosB, Fra-1, Jun and JunD proteins constitute the activator protein-1 complex after the administration of haloperidol and sulpiride.	Sulpiride	164-173	fos-like antigen 1	Mus musculus	48-53
9578405-6	1998	These results suggested that induced Fos, FosB, Fra-1, Jun and JunD proteins constitute the activator protein-1 complex after the administration of haloperidol and sulpiride.	Sulpiride	164-173	jun D proto-oncogene	Mus musculus	63-67
9578405-6	1998	These results suggested that induced Fos, FosB, Fra-1, Jun and JunD proteins constitute the activator protein-1 complex after the administration of haloperidol and sulpiride.	Sulpiride	164-173	jun proto-oncogene	Mus musculus	92-111
9566505-8	1998	The D2 dopamine receptor antagonist sulpiride (10 microM) increased the electrical stimulation-induced [3H]GABA overflow, and this stimulation was counteracted by concomitant administration of atropine (1 microM).	Sulpiride	36-45	dopamine receptor D2	Rattus norvegicus	4-24
9551766-6	1998	However, AP5 blocked the ability of repeated sulpiride infusions to increase locomotor activity, and the ability of intra-perifornical sulpiride to support the acquisition of a conditioned place preference.	Sulpiride	45-54	adaptor related protein complex 5 subunit beta 1	Homo sapiens	9-12
9553994-4	1998	SCH 23390 (D1 dopamine receptor antagonist, 0.02-0.08 mg/kg) and sulpiride (D2 dopamine receptor antagonist, 25-100 mg/kg) decreased apomorphine-induced pecking dose-dependently.	Sulpiride	65-74	dopamine receptor D2	Homo sapiens	76-96
9535054-9	1998	In the presence of 1 microM sulpiride (selective D-2 dopaminergic antagonist), the inhibitory phase of the curve was abolished, and the subsequent increase was reduced.	Sulpiride	28-37	solute carrier family 3 member 1	Rattus norvegicus	49-52
9434203-7	1998	Sulpiride injection did not affect the parameters of the orienting response to acoustic stimulus alone, suggesting a direct effect on A10 dopaminergic neurons.	Sulpiride	0-9	immunoglobulin kappa variable 6D-21 (non-functional)	Homo sapiens	134-137
9406865-6	1997	It was also completely blocked by the D2 dopamine receptor antagonist sulpiride (10 microM).	Sulpiride	70-79	dopamine receptor D2	Rattus norvegicus	38-58
9401675-0	1997	Sulpiride-induced increases in serum prolactin levels in female rats exposed prenatally to alcohol.	Sulpiride	0-9	prolactin	Rattus norvegicus	37-46
9401675-1	1997	We examined the impact of prenatal alcohol exposure on serum prolactin levels and on the ability of the D2 dopamine antagonist sulpiride to stimulate prolactin release in Long-Evans rats.	Sulpiride	127-136	prolactin	Rattus norvegicus	150-159
9401675-6	1997	Sulpiride produced dramatic dose-dependent increases in serum prolactin levels in all prenatal treatment groups.	Sulpiride	0-9	prolactin	Rattus norvegicus	62-71
9401675-7	1997	Across all doses of sulpiride, the group given the higher dose of prenatal alcohol (5 g/kg/day) had significantly lower serum prolactin levels than all other groups.	Sulpiride	20-29	prolactin	Rattus norvegicus	126-135
9300613-4	1997	However, the reduction of CCK-LI induced by MAP (20-40%) was abolished by the pretreatment with HAL (0.025 and 0.25 mg/kg), YM (0.01 and 0.1 mg/kg), or SCH (1.0 mg/kg), without being affected by SUL (up to 250 mg/kg).	Sulpiride	195-198	cholecystokinin	Rattus norvegicus	26-29
9392783-8	1997	In the last experiment, we tested the magnitude of the increase in PRL release produced by the administration of either SKF 38393, a specific D1 agonist, or sulpiride, a specific D2 antagonist.	Sulpiride	157-166	prolactin	Rattus norvegicus	67-70
9369345-10	1997	The dopamine-induced constriction in the presence of phentolamine was further inhibited by both SCH23390 (a selective dopamine D1 receptor antagonist) and sulpiride (a selective dopamine D2 receptor antagonist), but was not affected by dopamine D3 or D4 receptor antagonists.	Sulpiride	155-164	dopamine receptor D2	Homo sapiens	178-198
9335069-7	1997	Sulpiride and pimozide increased response induced by CCK-8 agonists.	Sulpiride	0-9	cholecystokinin	Mus musculus	53-56
9300613-3	1997	A single subcutaneous administration of HAL (0.25 mg/kg), YM (0.1 mg/kg), or SUL (250 mg/kg) significantly reduced the basal CCK-LI in mPFC by 20-40%; a selective D1 antagonist, SCH (up to 1.0 mg/kg), had no effect on basal CCK-LI.	Sulpiride	77-80	cholecystokinin	Rattus norvegicus	125-128
9213076-0	1997	The comparative effects of haloperidol, (-)-sulpiride, and SCH23390 on c-fos and c-jun mRNA expressions, and AP-1 DNA binding activity.	Sulpiride	40-53	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-76
9300613-3	1997	A single subcutaneous administration of HAL (0.25 mg/kg), YM (0.1 mg/kg), or SUL (250 mg/kg) significantly reduced the basal CCK-LI in mPFC by 20-40%; a selective D1 antagonist, SCH (up to 1.0 mg/kg), had no effect on basal CCK-LI.	Sulpiride	77-80	cholecystokinin	Rattus norvegicus	224-227
9379848-3	1997	Regionally, 32 days treatment with haloperidol (3 mg/kg/day), sulpiride (100 mg/kg/day) or clozapine (10 mg/kg/day) resulted in a drop of approximately 30-40% in 5HT2C mRNA levels in both cortex and cerebellum, and decreases (or non-significant trends) of 15-40% in 5HT2A mRNA levels in hippocampus, brainstem and mid brain.	Sulpiride	62-71	5-hydroxytryptamine receptor 2C	Rattus norvegicus	162-167
9379848-3	1997	Regionally, 32 days treatment with haloperidol (3 mg/kg/day), sulpiride (100 mg/kg/day) or clozapine (10 mg/kg/day) resulted in a drop of approximately 30-40% in 5HT2C mRNA levels in both cortex and cerebellum, and decreases (or non-significant trends) of 15-40% in 5HT2A mRNA levels in hippocampus, brainstem and mid brain.	Sulpiride	62-71	5-hydroxytryptamine receptor 2A	Rattus norvegicus	266-271
9213076-7	1997	Administration of haloperidol or (-)-sulpiride increased AP-1 DNA binding activity with similar manner of dose-dependence, whereas their activities were reduced by Fos and Jun antibodies, implying that AP-1 components, transcriptional factors, forming due to Fos and Jun were actually activated by either haloperidol or (-)-sulpiride.	Sulpiride	33-46	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	57-61
26735788-6	1997	Furthermore, the induction of Fos protein in the striatum and olfactory tubercle after administration of MDMA (10 mg/kg) was blocked by pre-treatment with the dopamine D receptor antagonist SCH 23390 (1 mg/kg) or the NMDA receptor antagonist dizocilpine (1 mg/kg), but not by the dopamine D receptor antagonist (-)-sulpiride (100 mg/kg).	Sulpiride	311-324	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	30-33
9213076-0	1997	The comparative effects of haloperidol, (-)-sulpiride, and SCH23390 on c-fos and c-jun mRNA expressions, and AP-1 DNA binding activity.	Sulpiride	40-53	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	81-86
9213076-7	1997	Administration of haloperidol or (-)-sulpiride increased AP-1 DNA binding activity with similar manner of dose-dependence, whereas their activities were reduced by Fos and Jun antibodies, implying that AP-1 components, transcriptional factors, forming due to Fos and Jun were actually activated by either haloperidol or (-)-sulpiride.	Sulpiride	33-46	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	202-206
9213076-7	1997	Administration of haloperidol or (-)-sulpiride increased AP-1 DNA binding activity with similar manner of dose-dependence, whereas their activities were reduced by Fos and Jun antibodies, implying that AP-1 components, transcriptional factors, forming due to Fos and Jun were actually activated by either haloperidol or (-)-sulpiride.	Sulpiride	33-46	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	259-262
9213076-7	1997	Administration of haloperidol or (-)-sulpiride increased AP-1 DNA binding activity with similar manner of dose-dependence, whereas their activities were reduced by Fos and Jun antibodies, implying that AP-1 components, transcriptional factors, forming due to Fos and Jun were actually activated by either haloperidol or (-)-sulpiride.	Sulpiride	320-333	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	202-206
9110224-1	1997	This experiment was designed to determine 1) the efficacy of daily s.c. injections of a dopamine antagonist, sulpiride, for increasing prolactin secretion in geldings in winter and 2) whether increasing prolactin concentrations would hasten the onset of hair shedding or enhance gonadotropin secretion.	Sulpiride	109-118	prolactin	Homo sapiens	135-144
9213076-7	1997	Administration of haloperidol or (-)-sulpiride increased AP-1 DNA binding activity with similar manner of dose-dependence, whereas their activities were reduced by Fos and Jun antibodies, implying that AP-1 components, transcriptional factors, forming due to Fos and Jun were actually activated by either haloperidol or (-)-sulpiride.	Sulpiride	320-333	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	259-262
9110224-5	1997	Over the 8-wk sampling period, prolactin response to sulpiride varied in a quadratic manner (P < .002).	Sulpiride	53-62	prolactin	Homo sapiens	31-40
9051657-4	1997	The levels of NMDAR2A and R2B mRNAs decreased after the acute administration of sulpiride, whereas the levels of R2A and R2B increased following the chronic administration.	Sulpiride	80-89	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	14-21
9011126-8	1996	The results show that all of the three medicines cause elevation of prolactin level in serum, and sulpiride causes the highest elevation of prolactin level in this study.	Sulpiride	98-107	prolactin	Homo sapiens	140-149
9083779-5	1997	The blockade of dopamine D2 receptors by the dopamine D2 receptor antagonist, sulpiride, diminished the inhibitory effects of neuropeptide Y on the stimulation-evoked [3H]dopamine release.	Sulpiride	78-87	neuropeptide Y	Rattus norvegicus	126-140
9016916-7	1996	Acute sulpiride treatment reduced the level of c-fos mRNA in the olfactory tubercle, parietal cortex and cingulate cortex.	Sulpiride	6-15	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	47-52
9016916-8	1996	After chronic treatment with sulpiride the level of c-fos mRNA was reduced in the dorsal caudate-putamen only.	Sulpiride	29-38	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	52-57
9016916-12	1996	This study also demonstrated that acute blockade of dopamine receptors with haloperidol, sulpiride and clozapine induced different regionally specific patterns of c-fos expression which were altered after chronic blockade.	Sulpiride	89-98	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	163-168
9110224-10	1997	In conclusion, even though prolactin concentrations were increased by sulpiride, the effects on gonadotropin secretion and hair shedding were minor and opposite of those expected.	Sulpiride	70-79	prolactin	Homo sapiens	27-36
8955921-3	1996	Bilateral injection of haloperidol (5 micrograms/side) or the selective dopamine D2 receptor antagonist, (+/-)-sulpiride (200 ng/side) before the hippocampal AD, into the NAC selectively reduced rearings and locomotor activity, but not the number of wet-dog shakes and face washes.	Sulpiride	105-120	dopamine receptor D2	Canis lupus familiaris	72-92
8633048-8	1996	Activation of the dopamine D2 receptor subtype, which physiologically controls prolactin release, resulted in a complete inhibition of vasoactive intestinal peptide-stimulated NGF secretion in vitro, whereas the specific D2 antagonist (-)-sulpiride stimulated NGF secretion in vivo, suggesting that the anterior pituitary is a possible source of circulating NGF.	Sulpiride	235-248	dopamine receptor D2	Homo sapiens	18-38
8904716-3	1996	Prolactin concentrations in plasma were increased by sexual stimulation (P < .01) and sulpiride (P < .001) administration and were decreased (P < .01) when bromocriptine was administered before sexual stimulation.	Sulpiride	89-98	prolactin	Homo sapiens	0-9
8800626-11	1996	Sulpiride is known to induce prolactin elevation in both serum and CSF, which may be associated with impotence in men and diminished gonadal function in women; these effects appear to be dosage-dependent.	Sulpiride	0-9	colony stimulating factor 2	Homo sapiens	67-70
8949937-5	1996	The impact of endogenous dopamine on [3H]GABA was evaluated by measuring the ability of sulpiride, a D2 dopamine receptor antagonist, to increase the depolarization-induced [3H]GABA overflow.	Sulpiride	88-97	dopamine receptor D2	Rattus norvegicus	101-121
8781526-2	1996	At equipotent doses (with respect to receptor blockade and behavioural tests), the dopamine D2-receptor selective sulpiride and remoxipride gave a conspicuous down-regulation of CYP2C11 and its associated androstenedione 16 alpha-hydroxylation activity as well as of the CYP2C11-specific mRNA.	Sulpiride	114-123	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	178-185
8781526-2	1996	At equipotent doses (with respect to receptor blockade and behavioural tests), the dopamine D2-receptor selective sulpiride and remoxipride gave a conspicuous down-regulation of CYP2C11 and its associated androstenedione 16 alpha-hydroxylation activity as well as of the CYP2C11-specific mRNA.	Sulpiride	114-123	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	271-278
8781526-7	1996	In contrast, diverging effects were observed for clozapine, compared to sulpiride and remoxipride, on the immunoidentified CYP1A2, CYP2B1, and CYP3A.	Sulpiride	72-81	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	123-129
8781526-7	1996	In contrast, diverging effects were observed for clozapine, compared to sulpiride and remoxipride, on the immunoidentified CYP1A2, CYP2B1, and CYP3A.	Sulpiride	72-81	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	131-137
8781526-7	1996	In contrast, diverging effects were observed for clozapine, compared to sulpiride and remoxipride, on the immunoidentified CYP1A2, CYP2B1, and CYP3A.	Sulpiride	72-81	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	143-148
8728542-1	1996	Differences in the behavioural profiles of dopamine D2 receptor antagonists (e.g., haloperidol vs. sulpiride) in a animal models of anxiety have prompted speculation concerning the importance of their relative affinities for D2-like receptor populations.	Sulpiride	99-108	dopamine receptor D2	Mus musculus	43-63
8787211-1	1996	Classical (chlorpromazine, haloperidol) and atypical (sulpiride and clozapine) neuroleptics applied for a period of 2 weeks diminished neuropeptide Y (NPY) levels in nucleus accumbens, but not in striatum.	Sulpiride	54-63	neuropeptide Y	Homo sapiens	135-149
8739308-3	1996	Sulpiride, an antagonist of dopamine D2 receptors, decreased the LPS-induced TNF-alpha plasma levels in a dose-dependent manner and inhibited the LPS-induced NO production by peritoneal macrophages.	Sulpiride	0-9	tumor necrosis factor	Mus musculus	77-86
8787211-1	1996	Classical (chlorpromazine, haloperidol) and atypical (sulpiride and clozapine) neuroleptics applied for a period of 2 weeks diminished neuropeptide Y (NPY) levels in nucleus accumbens, but not in striatum.	Sulpiride	54-63	neuropeptide Y	Homo sapiens	151-154
8628109-8	1996	On the other hand, treatment with LY 171555 or (-)-sulpiride, but not their combination, markedly increased Met-ENK levels in all brain regions investigated, whereas, treatment with nomifensine increased Met-Enk levels in all brain regions investigated, whereas, treatment with selegiline significantly elevated Met-Enk in HYPO, HIPP and MID but not in CTX.	Sulpiride	47-60	proenkephalin	Rattus norvegicus	112-115
9029407-7	1996	Chronic administration to chicks of clozapine and sulpiride, but not raclopride, resulted in a markedly increased response of retinal NAT activity to the action of QNP.	Sulpiride	50-59	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	134-137
9029407-10	1996	These results indicate that long-term treatment with clozapine, sulpiride and L-DOPA may modify the reactivity of D4-like DA receptors regulating NAT activity of chick retina.	Sulpiride	64-73	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	146-149
22302894-4	1996	When animals were pre-treated with different doses of the D-1 dopamine receptor antagonist, SCH 23390, or the D-2 dopamine receptor antagonist, sulpiride, the PE response was decreased.	Sulpiride	144-153	dopamine receptor D2	Rattus norvegicus	110-131
8750862-8	1995	Chronic treatment with the D2/D3 dopamine receptor antagonist sulpiride resulted in a significant increase in GAD67 in the ventromedial and ventrolateral and PPE in the dorsomedial and ventrolateral striatal sectors.	Sulpiride	62-71	dopamine receptor D3	Rattus norvegicus	30-50
8750862-8	1995	Chronic treatment with the D2/D3 dopamine receptor antagonist sulpiride resulted in a significant increase in GAD67 in the ventromedial and ventrolateral and PPE in the dorsomedial and ventrolateral striatal sectors.	Sulpiride	62-71	glutamate decarboxylase 1	Rattus norvegicus	110-115
8750862-11	1995	In the present experimental conditions, stimulation of dopamine receptors with apomorphine or SKF-38393 resulted in increased GAD65 mRNA levels whereas blockade of dopamine receptors with haloperidol or sulpiride resulted in increased GAD67 mRNA levels.	Sulpiride	203-212	glutamate decarboxylase 1	Rattus norvegicus	235-240
8704738-7	1995	Sulpiride had no effect in the HPD rams on any occasion, but caused a very marked increase in the plasma concentrations of prolactin in the control rams under short days, long days, and under long days + melatonin.	Sulpiride	0-9	prolactin	Ovis aries	123-132
7589658-5	1995	MAIN OUTCOME MEASURE: Basal PRL levels and PRL increase induced by sulpiride.	Sulpiride	67-76	prolactin	Homo sapiens	43-46
7589658-6	1995	RESULTS: Basal PRL levels and the PRL response to sulpiride were increased in women with PCOS.	Sulpiride	50-59	prolactin	Homo sapiens	34-37
7589658-7	1995	In women with PCOS medical ovariectomy induced by GnRH-a administration reversed to normal both basal and sulpiride-stimulated PRL levels.	Sulpiride	106-115	prolactin	Homo sapiens	127-130
8896713-8	1996	In a second set, the D2 dopamine receptor antagonist, (-)-sulpiride, antagonized the enhancing effect of caffeine on memory.	Sulpiride	54-67	dopamine receptor D2	Mus musculus	21-41
8748117-4	1995	D2 receptor antagonist, sulpiride, on the other hand, stimulated basal IR-beta-EP release and blocked LY 141865-induced inhibition of IR-beta-EP release in a concentration dependent manner.	Sulpiride	24-33	proopiomelanocortin	Homo sapiens	74-81
8748117-4	1995	D2 receptor antagonist, sulpiride, on the other hand, stimulated basal IR-beta-EP release and blocked LY 141865-induced inhibition of IR-beta-EP release in a concentration dependent manner.	Sulpiride	24-33	proopiomelanocortin	Homo sapiens	137-144
7675859-6	1995	In contrast, treatment with 10-50 mg/kg of the dopmaine D2 receptor antagonist, sulpiride, had no effects on the development of sensitization and tolerance to cocaine-induced seizures.	Sulpiride	80-89	dopamine receptor D2	Mus musculus	56-67
7518029-2	1994	In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%).	Sulpiride	34-43	proopiomelanocortin	Rattus norvegicus	82-102
7886117-4	1994	In marked contrast to the lack of effect or nonspecific effects seen with the other ligands tested, the D2 receptor antagonist, sulpiride (2.5-20.0 mg/kg), produced an unambiguous anxiolytic-like profile under present test conditions.	Sulpiride	128-137	dopamine receptor D2	Mus musculus	104-115
7813560-6	1994	On the other hand, neurotensin-like immunoreactivity was markedly increased in striatal cell bodies and in the globus pallidus after treatment with sulpiride, indicating that this pathway is mainly regulated by dopamine D2 receptors.	Sulpiride	148-157	neurotensin	Rattus norvegicus	19-30
7871084-8	1994	For experiment 1, animals received intra-accumbens infusions of the D1 dopamine receptor antagonist SCH-23390, or the D2 dopamine receptor antagonist sulpiride over two test sessions.	Sulpiride	150-159	dopamine receptor D2	Rattus norvegicus	118-138
8082693-4	1994	The hypothermic effect of theophylline was decreased by pretreatment of animals with the dopamine D2 receptor antagonists sulpiride (15 and 30 mg/kg i.p.)	Sulpiride	122-131	dopamine receptor D2	Mus musculus	89-109
8067624-10	1994	By 4 and 9 days after the start of treatment, serum prolactin concentration was higher (P < 0.05) in domperidone-treated mares and sulpiride-treated mares, respectively, than in control mares.	Sulpiride	134-143	prolactin	Equus caballus	52-61
7518029-3	1994	In the striatum, sulpiride and haloperidol had different effects: sulpiride induced a higher increase than haloperidol of both preproenkephalin A (PPA) mRNA (+67% versus +47%) and D2 dopamine receptor (D2R) mRNAs (+72% versus +40%).	Sulpiride	66-75	dopamine receptor D2	Rattus norvegicus	180-200
7518029-3	1994	In the striatum, sulpiride and haloperidol had different effects: sulpiride induced a higher increase than haloperidol of both preproenkephalin A (PPA) mRNA (+67% versus +47%) and D2 dopamine receptor (D2R) mRNAs (+72% versus +40%).	Sulpiride	66-75	dopamine receptor D2	Rattus norvegicus	202-205
7773679-1	1995	Sulpiride in the perifornical lateral hypothalamus (pfLH) (4, 8 and 16 micrograms/0.5 microliter) increased intracranial temperature (Tic).	Sulpiride	0-9	aryl hydrocarbon receptor nuclear translocator-like	Rattus norvegicus	134-137
7737329-4	1995	The effects of apomorphine and of the coadministration of SKF 38393 and quinpirole on the conditioned fear stress were completely blocked by the dopamine D1 receptor antagonist, SCH 23390 (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H- 3-benzazepine), and by the dopamine D2 receptor antagonist, (-)-sulpiride.	Sulpiride	315-328	dopamine receptor D1	Mus musculus	145-165
22298689-4	1995	The response was inhibited by reserpine (5 mg/kg), the centrally active nicotinic receptor antagonist mecamylamine (0.1-1 mg/kg) and the D-2 dopamine receptor antagonist sulpiride (25-100 mg/kg).	Sulpiride	170-179	dopamine receptor D2	Mus musculus	137-158
7623621-4	1995	Prolactin responses to sulpiride and TRH were tested on day 12.	Sulpiride	23-32	prolactin	Rattus norvegicus	0-9
7965077-5	1994	This effect was observed in the presence of the D2 dopamine receptor antagonists sulpiride (1 microM) and eticlopride (0.1 microM).	Sulpiride	81-90	dopamine receptor D2	Homo sapiens	48-68
7981639-3	1994	Spiperone (1 microM) and sulpiride (1 microM) were used to displace [125I]LSD binding from 5-HT2A and D2 binding sites, respectively.	Sulpiride	25-34	5-hydroxytryptamine receptor 2A	Rattus norvegicus	91-97
7518029-2	1994	In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%).	Sulpiride	34-43	proopiomelanocortin	Rattus norvegicus	104-108
7518029-2	1994	In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%).	Sulpiride	34-43	prolactin	Rattus norvegicus	127-136
7518029-2	1994	In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%).	Sulpiride	34-43	gonadotropin releasing hormone receptor	Rattus norvegicus	165-179
7518029-2	1994	In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%).	Sulpiride	34-43	gonadotropin releasing hormone receptor	Rattus norvegicus	181-183
7518029-2	1994	In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%).	Sulpiride	34-43	dopamine receptor D2	Rattus norvegicus	246-249
7911301-5	1994	Pretreatment with either selective D1 or D2 dopamine (DA) receptor antagonists SCH 23390 and (-)-sulpiride administered at per se noneffective doses (0.025 and 6 mg/kg, respectively) potentiated the effects of morphine, while either selective D1 or D2 receptor agonists SKF 38393 and LY 171555 at per se noneffective doses (5 and 0.25 mg/kg, respectively) antagonized the effects of the opiate on memory consolidation.	Sulpiride	93-106	dopamine receptor D2	Mus musculus	249-260
8004444-5	1994	In these 15-day-old rats, however, sulpiride produced an increase in GAD67 but not preproenkephalin mRNA levels.	Sulpiride	35-44	glutamate decarboxylase 1	Rattus norvegicus	69-74
8004444-9	1994	In addition, the differential effect of haloperidol, sulpiride or pertussis toxin on GAD67 and preproenkephalin mRNA levels suggests that these two mRNAs are regulated through different dopamine receptor subtypes.	Sulpiride	53-62	glutamate decarboxylase 1	Rattus norvegicus	85-90
7855206-8	1994	Adulteration of the infusate with either the D1 dopamine receptor antagonist SCH-23390 or the D2 dopamine receptor antagonist sulpiride enhanced the rate of response selectively upon the drug lever.	Sulpiride	126-135	dopamine receptor D2	Homo sapiens	94-114
8004444-1	1994	The mRNA levels encoding for the enzyme glutamate decarboxylase (GAD67) and the peptide enkephalin were measured in the striatum of adult and 15 day-old rats by in situ hybridization histochemistry and radioautography after neonatal injections of 6-hydroxydopamine or after acute pharmacological blockade of dopamine receptors with haloperidol or sulpiride.	Sulpiride	347-356	glutamate-ammonia ligase	Rattus norvegicus	40-63
8004444-1	1994	The mRNA levels encoding for the enzyme glutamate decarboxylase (GAD67) and the peptide enkephalin were measured in the striatum of adult and 15 day-old rats by in situ hybridization histochemistry and radioautography after neonatal injections of 6-hydroxydopamine or after acute pharmacological blockade of dopamine receptors with haloperidol or sulpiride.	Sulpiride	347-356	glutamate decarboxylase 1	Rattus norvegicus	65-70
8004444-3	1994	The D2 dopamine receptor antagonist, sulpiride, did not change the mRNA levels of either GAD67 or PPE in the striatum.	Sulpiride	37-46	dopamine receptor D2	Rattus norvegicus	4-24
7920056-1	1994	The ovulation rate at 14 hours after human chorionic gonadotropin (hCG) injection in female rabbits was significantly reduced and the postovulatory increase in progesterone levels in peripheral and ovarian veins were suppressed by four days sulpiride-induced hyperprolactinemia, as compared to the control group.	Sulpiride	241-250	chorionic gonadotropin subunit beta 5	Homo sapiens	67-70
7920056-3	1994	When progesterone was added to hCG to induce ovulation in sulpiride-primed animals, the ovulation rate was restored as compared to the control group.	Sulpiride	58-67	chorionic gonadotropin subunit beta 5	Homo sapiens	31-34
8119306-4	1993	The inactivity of the highly selective dopamine D2 receptor antagonist (-)-sulpiride indicates that both (+)-pentazocine and haloperidol are acting through sigma receptors.	Sulpiride	71-84	dopamine receptor D2	Homo sapiens	39-59
22298628-3	1994	Pre-treatment of animals with the opioid receptor antagonist naloxone (1, 1.5 and 3 mg/kg), the D-2 receptor antagonists sulpiride (25 and 50 mg/kg), pimozide (0.0625, 0.125 and 0.25 mg/kg) and the adenosine receptor antagonist theophylline (25 and 50 mg/kg) decreased the morphine-induced hypothermia.	Sulpiride	121-130	dopamine receptor D2	Mus musculus	96-108
8025535-8	1994	Moreover, although sulpiride effectively prevented the quinpirole-induced decline in the nighttime NAT activity of the chick retina, there was no marked stereoselectivity in its action.	Sulpiride	19-28	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	99-102
8301582-2	1994	Only limited binding selectivity was observed for known dopamine D2 receptor antagonists from a variety of chemical classes, which included haloperidol, chlorpromazine, sulpiride, pimozide and cis flupenthixol.	Sulpiride	169-178	dopamine receptor D2	Homo sapiens	56-76
8492125-1	1993	Aromatic L-amino acid decarboxylase (AAAD) activity is enhanced in the striatum of control and MPTP-treated mice after administration of a single dose of the dopamine receptor antagonists haloperidol, sulpiride, and SCH 23390.	Sulpiride	201-210	dopa decarboxylase	Mus musculus	0-35
7906871-4	1993	Furthermore, the increases in the TRH release from the striatal slices, induced by 10(-5) M of amphetamine, apomorphine or quinpirole, were completely blocked by the selective D2 receptor antagonist sulpiride (10(-5) M), but not by the selective D1 receptors antagonist SCH-23390 (10(-5) M).	Sulpiride	199-208	thyrotropin releasing hormone	Rattus norvegicus	34-37
8230103-4	1993	These findings are consistent with earlier studies of chlorpromazine and sulpiride analogues and provide further evidence that dopamine antagonists bind in their charged molecular forms to anionic sites on the D2 receptor.	Sulpiride	73-82	dopamine receptor D2	Mus musculus	210-221
8492125-1	1993	Aromatic L-amino acid decarboxylase (AAAD) activity is enhanced in the striatum of control and MPTP-treated mice after administration of a single dose of the dopamine receptor antagonists haloperidol, sulpiride, and SCH 23390.	Sulpiride	201-210	dopa decarboxylase	Mus musculus	37-41
8101133-5	1993	Sulpiride, 0.1 mM, induced a 2-fold increase in the NT- and electrically-induced release of ACh.	Sulpiride	0-9	neurotensin	Rattus norvegicus	52-54
8487949-5	1993	The decrease in methionine enkephalin neuronal content induced by dopamine or bromocriptine was reversed by the simultaneous application of sulpiride (10(-6) M), a selective D2 antagonist.	Sulpiride	140-149	proenkephalin	Rattus norvegicus	27-37
8329499-0	1993	Prolactin response to sulpiride before and after sleep deprivation in depression.	Sulpiride	22-31	prolactin	Homo sapiens	0-9
8097720-2	1993	GBR 12909 (10 and 20 mg/kg) impaired latent learning, and this effect was counteracted by the dopamine D2 receptor antagonist, (-)-sulpiride (20 and 40 mg/kg), but not by the dopamine D1 receptor antagonist, SCH 23390 (0.025 and 0.05 mg/kg).	Sulpiride	127-140	dopamine receptor D2	Mus musculus	94-114
7901792-0	1993	Clozapine and sulpiride up-regulate dopamine D3 receptor mRNA levels.	Sulpiride	14-23	dopamine receptor D3	Rattus norvegicus	36-56
7901792-1	1993	Chronic treatment (32 days) with sulpiride (100 mg/kg/day) up-regulated rat brain dopamine D3 receptor mRNA levels by 4-fold but had no effect on the mRNA levels encoding the dopamine D1A, D1B or D2 receptors or the enzymes tyrosine hydroxylase and aromatic amino acid decarboxylase as measured by multiprobe oligonucleotide solution hybridisation.	Sulpiride	33-42	dopamine receptor D3	Rattus norvegicus	82-102
8094754-7	1993	However, the D2 dopamine receptor antagonist, sulpiride, blocked pergolide-induced rotations at concentrations about 4-fold lower than those needed to inhibit apomorphine-induced rotational behavior.	Sulpiride	46-55	dopamine receptor D2	Mus musculus	13-33
1362660-1	1992	The effects of administration of antipsychotic drugs (haloperidol, loxapine, sulpiride; 1-32 day time course) on the rat brain mRNA levels of the dopamine D5 receptor has been assessed using solution hybridisation with oligonucleotides.	Sulpiride	77-86	dopamine receptor D5	Rattus norvegicus	146-166
8096819-8	1993	Sulpiride increased the levels of NPY in the striatum and brainstem.	Sulpiride	0-9	neuropeptide Y	Rattus norvegicus	34-37
1361666-6	1992	In these protected rats, the amphetamine-induced change in activity of PKC was attenuated by sulpiride.	Sulpiride	93-102	protein kinase C, alpha	Rattus norvegicus	71-74
1482216-6	1992	The effect of PRL was mimicked by injection of a single dose of the dopamine antagonist sulpiride, which provoked a ninefold increase in serum PRL levels.	Sulpiride	88-97	prolactin	Rattus norvegicus	14-17
1482216-6	1992	The effect of PRL was mimicked by injection of a single dose of the dopamine antagonist sulpiride, which provoked a ninefold increase in serum PRL levels.	Sulpiride	88-97	prolactin	Rattus norvegicus	143-146
1360868-5	1992	When administered alone, the alpha 1-adrenergic antagonist, prazosin, the sigma antagonist, BMY 14802, and the dopamine D2 antagonist, sulpiride decreased striatal NPY levels; however, only prazosin and the dopamine D1 antagonist, SCH 23390, significantly attenuated PCP-induced changes.	Sulpiride	135-144	neuropeptide Y	Rattus norvegicus	164-167
1362452-4	1992	Infusion of the D-2 specific receptor antagonist (--)-sulpiride into the nigra induced an increase in the release of dopamine in the nigra (after 1 mumol/l) as well as in the ipsilateral striatum (10 mumol/l).	Sulpiride	49-63	immunoglobulin heavy diversity 2-15	Homo sapiens	16-19
1356602-2	1992	A single injection IP of haloperidol (2 mg/kg) or sulpiride (100 mg/kg) produced a rapid and transient increase in c-jun, zif-268 and c-fos mRNA.	Sulpiride	50-59	early growth response 1	Rattus norvegicus	122-129
1356602-2	1992	A single injection IP of haloperidol (2 mg/kg) or sulpiride (100 mg/kg) produced a rapid and transient increase in c-jun, zif-268 and c-fos mRNA.	Sulpiride	50-59	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	134-139
1358747-10	1992	The D-2 dopamine antagonist sulpiride (i.p.)	Sulpiride	28-37	solute carrier family 3 member 1	Rattus norvegicus	4-7
1358747-21	1992	Single administration of D-2 dopamine agonist bromocriptine also showed a slight but significant purposeless chewing, which was decreased by sulpiride pretreatment.	Sulpiride	141-150	solute carrier family 3 member 1	Rattus norvegicus	25-28
1331654-4	1992	The decrease in transcription may be mediated via blockade of D2-receptor, since S(-)-sulpiride but not the inactive enantiomer R(+)-sulpiride produced the inhibition.	Sulpiride	82-95	dopamine receptor D2	Rattus norvegicus	62-73
1361442-4	1992	The behavioral effects of methamphetamine (1.0 mg/kg s.c.) were almost completely antagonized by pretreatment with the dopamine D2 receptor antagonist, S(-)-sulpiride (3.0 and/or 10.0 mg/kg i.p.	Sulpiride	153-166	dopamine receptor D2	Mus musculus	119-139
1402534-2	1992	Administration of both oestrogen and sulpiride resulted in a significant increase in prolactin secretion and in the lactotroph population.	Sulpiride	37-46	prolactin	Rattus norvegicus	85-94
1402534-10	1992	The highest levels of serum prolactin were seen in sulpiride-treated rats (467.2 +/- 28.7 micrograms/l).	Sulpiride	51-60	prolactin	Rattus norvegicus	28-37
1356874-8	1992	In animals pretreated with D-1 antagonist SCH 23390, high doses of apomorphine showed higher PE response, while D-2 antagonist sulpiride pretreatment decreased the response of the low doses of the drug.	Sulpiride	127-136	solute carrier family 3 member 1	Rattus norvegicus	112-115
1625208-7	1992	Concomitant administration of SCH 23390 and sulpiride attenuated the neurotensin increases observed after treatment with sulpiride.	Sulpiride	44-53	neurotensin	Rattus norvegicus	69-80
1625208-7	1992	Concomitant administration of SCH 23390 and sulpiride attenuated the neurotensin increases observed after treatment with sulpiride.	Sulpiride	121-130	neurotensin	Rattus norvegicus	69-80
1331654-4	1992	The decrease in transcription may be mediated via blockade of D2-receptor, since S(-)-sulpiride but not the inactive enantiomer R(+)-sulpiride produced the inhibition.	Sulpiride	129-142	dopamine receptor D2	Rattus norvegicus	62-73
1352252-7	1992	The augmented response to (+)-3-PPP was reversed by the combined administration of 100 mg/kg (+/-)-sulpiride, a D2 dopamine receptor antagonist, and 30 mg/kg BMY 14802, a sigma receptor antagonist.	Sulpiride	93-108	dopamine receptor D2	Rattus norvegicus	112-132
1624729-7	1992	On the other hand the PRL response with TRH after sulpiride was not significantly different as between the controls (less than 175%) and the patients (less than 91%).	Sulpiride	50-59	thyrotropin releasing hormone	Homo sapiens	40-43
1938655-8	1991	Sulpiride treatment resulted in (P less than .05) a six- to eightfold increase in daily PRL secretion.	Sulpiride	0-9	prolactin	Homo sapiens	88-91
1835974-4	1991	Dopamine treatment caused a 40-50% decrease in endogenous prolactin mRNA that was specifically blocked by addition of (-)-sulpiride.	Sulpiride	118-131	prolactin	Rattus norvegicus	58-67
1839620-7	1991	A similar reduction of activity was found in mice pretreated with sulpiride (10 mg/kg), a dopamine D2 receptor antagonist, but not with Sch23390 (0.25 mg/kg), a dopamine D1 receptor antagonist.	Sulpiride	66-75	dopamine receptor D2	Mus musculus	90-110
1784404-1	1991	The Authors examine serum levels of HPRL in basal conditions and after TRH and sulpiride test in 15 patients with endometrial lesions (hyperplasia) and in 15 patients with endometrial adenocarcinoma included in a age range between 44 and 62 years, in which 7 patients present obesity, 10 patients present hypertension and 2 patients are hyperglycemic.	Sulpiride	79-88	prolactin receptor	Homo sapiens	36-40
1365637-3	1992	The effect of 1.0 microgram neurotensin on struggling was completely antagonized by 0.5 microgram (-)-sulpiride administered in the posterior nucleus accumbens.	Sulpiride	98-111	neurotensin	Rattus norvegicus	28-39
1938655-9	1991	The PRL response to TRH increased (P less than .05) fourfold in stallions treated with sulpiride but was unchanged in control stallions.	Sulpiride	87-96	prolactin	Homo sapiens	4-7
1938655-9	1991	The PRL response to TRH increased (P less than .05) fourfold in stallions treated with sulpiride but was unchanged in control stallions.	Sulpiride	87-96	thyrotropin releasing hormone	Homo sapiens	20-23
1826198-1	1991	In summary then these data suggest that butyrophenones such as spiperone and substituted benzamides such as sulpiride interact with different groups at the active site of the D2 dopamine receptor.	Sulpiride	108-117	dopamine receptor D2	Bos taurus	175-195
1906182-6	1991	It also inhibited PRL release in sulpiride-pretreated stressed or suckled rats.	Sulpiride	33-42	prolactin	Rattus norvegicus	18-21
1832389-7	1991	In experiment II, sulpiride, which raises serum prolactin level, was injected daily in to 4 groups of immature female rats starting from 14, 21, 28, and 35 days of age till the day before vaginal opening.	Sulpiride	18-27	prolactin	Rattus norvegicus	48-57
1673340-3	1991	Quinpirole had no effect on [Met5]- and [Leu5]-enkephalin levels but sulpiride produced an increase in both [Met5]- and [Leu5]-enkephalin content.	Sulpiride	69-78	proenkephalin	Rattus norvegicus	127-137
1673340-5	1991	Quinpirole decreased [Met5]- and [Leu5]-enkephalin levels, while sulpiride decreased [Leu5]-enkephalin levels alone.	Sulpiride	65-74	proenkephalin	Rattus norvegicus	92-102
1676524-3	1991	Remoxipride and sulpiride increased the serum levels of prolactin to similar peak levels.	Sulpiride	16-25	prolactin	Homo sapiens	56-65
1648747-8	1991	In the second experiment, body weight and food intake were assessed in female rats treated with lithium alone, or in combination with insulin or sulpiride, a D2 dopamine receptor blocker.	Sulpiride	145-154	dopamine receptor D2	Rattus norvegicus	158-178
1849533-5	1991	In a separate series of experiments, prior central administration of alpha 1- and alpha 2-antagonist phentolamine, or the dopamine receptor (DA1 and DA2) antagonist RS-sulpiride, was also effective in inhibiting the hypotensive and bradycardiac effects of intracerebroventricular administration of potassium.	Sulpiride	165-177	RT1 class II, locus Da	Rattus norvegicus	141-144
1687392-8	1991	D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.	Sulpiride	110-119	deiodinase, iodothyronine, type I	Mus musculus	0-3
1679335-5	1991	Either D2 receptor blockade (sulpiride, 1 microM), or DA synthesis inhibition (alpha-methylparatyrosine, 50 microM) resulted in a marked increase in the firing rates of dopaminergic cells.	Sulpiride	29-38	dopamine receptor D2	Mus musculus	7-18
1767793-2	1991	Similar to bromocriptine (BR), HJ, in combination with sulpiride, suppressed plasma prolactin levels raised by sulpiride alone.	Sulpiride	55-64	prolactin	Rattus norvegicus	84-93
1767793-2	1991	Similar to bromocriptine (BR), HJ, in combination with sulpiride, suppressed plasma prolactin levels raised by sulpiride alone.	Sulpiride	111-120	prolactin	Rattus norvegicus	84-93
1916652-4	1991	After sulpiride administration the incremental area under the PRL profile in PCOS was significantly lower than in normal subjects (p less than 0.01).	Sulpiride	6-15	prolactin	Homo sapiens	62-65
1676524-5	1991	Sulpiride increased prolactin levels at much lower plasma concentrations than remoxipride, and sulpiride"s effect on prolactin lasted for considerably longer than remoxipride"s.	Sulpiride	0-9	prolactin	Homo sapiens	20-29
1676524-5	1991	Sulpiride increased prolactin levels at much lower plasma concentrations than remoxipride, and sulpiride"s effect on prolactin lasted for considerably longer than remoxipride"s.	Sulpiride	95-104	prolactin	Homo sapiens	117-126
1979719-3	1990	The inhibition induced by DA (10(-6) M) was attenuated in the presence of either of the two DA2-specific antagonists S-sulpiride and YM 09151 at 10(-5) M and in the presence of the DA1 antagonist SCH 23390 (10(-5) M).	Sulpiride	117-128	immunoglobulin heavy diversity 4-11 (non-functional)	Homo sapiens	181-184
2096297-6	1990	Inhibitory responses to either dopamine or cocaine were blocked by the specific D2 dopamine receptor antagonist sulpiride.	Sulpiride	112-121	dopamine receptor D2	Homo sapiens	80-100
1981481-3	1990	The sulpiride-mediated increase in [3H]DA release and the release induced by NT were additive.	Sulpiride	4-13	neurotensin	Rattus norvegicus	77-79
1969506-3	1990	However, some recent studies have indicated that the stimulatory effects of B-HT 920 are sensitive to blockade by sulpiride and haloperidol, suggesting a postsynaptic D2-dopamine receptor action.	Sulpiride	114-123	dopamine receptor D2	Homo sapiens	167-187
1982657-3	1990	The decreases in the rate of GABA formation were prevented by the dopamine D2 receptor antagonist S(-)-sulpiride.	Sulpiride	99-112	dopamine receptor D2	Mus musculus	66-86
2290625-2	1990	Haloperidol as preferential D2 and the "pure" dopamine D2 receptor antagonist sulpiride significantly reduced the level of the reflex response in the gastrocnemius muscle following backward perturbation.	Sulpiride	78-87	dopamine receptor D2	Homo sapiens	46-66
1695244-8	1990	The dopamine-mediated suppression of activity was significantly inhibited by pertussis toxin and by spiperone and sulpiride, both D2-dopamine receptor antagonists, but not by SCH 23390, a D1-dopamine receptor blocker, or antagonists of alpha-adrenergic, beta-adrenergic, or serotonergic receptors.	Sulpiride	114-123	dopamine receptor D2	Gallus gallus	130-150
1971007-4	1990	Chronic treatment with the specific dopamine D2 antagonist sulpiride also caused elevation in PEK mRNA levels in all three brain regions studied whereas the specific serotonin S2 receptor blocker, cinanserin, had no significant effects on PEK mRNA levels.	Sulpiride	59-68	proenkephalin	Rattus norvegicus	94-97
2204052-0	1990	[The effect of luliberin and sulpiride on the secretion of gonadotropic hormones and prolactin in patients with obesity].	Sulpiride	29-38	prolactin	Homo sapiens	85-94
1688845-10	1990	Antagonism of dopamine-induced inhibition of VIP-enhanced cAMP levels by spiperone, (+)-butaclamol, (-)-sulpiride, and SCH23390 occurred at concentrations expected from KI values for these antagonists at the D2-receptor and was stereoselective.	Sulpiride	100-113	vasoactive intestinal peptide	Rattus norvegicus	45-48
34662693-6	2022	Intra-NAc administration of either SCH23390 or Sulpiride impaired Cannabidiol"s suppressive impact on the expression phase, while just Sulpiride could suppress the Cannabidiol"s impact on the acquisition phase of the MET-induced CPP.	Sulpiride	135-144	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	217-220
2163481-0	1990	The effects of dopaminergic antagonism by sulpiride on TRH and VIP-induced prolactin release in nonsuckled lactating rats.	Sulpiride	42-51	thyrotropin releasing hormone	Rattus norvegicus	55-58
2163481-0	1990	The effects of dopaminergic antagonism by sulpiride on TRH and VIP-induced prolactin release in nonsuckled lactating rats.	Sulpiride	42-51	vasoactive intestinal peptide	Rattus norvegicus	63-66
2201990-3	1990	However, at low doses, both sulpiride and SCH-23390, tested in the ALT-3 and ALT-2 procedures, caused effects compatible with selective motivational impairments.	Sulpiride	28-37	glutamic--pyruvic transaminase 2	Homo sapiens	77-82
34662693-7	2022	Also, the inhibitory impact of Sulpiride was stranger in both phases of MET reward.	Sulpiride	31-40	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	72-75
34737042-10	2021	Our results suggested: (1) NO and dopamine D2 receptor mechanisms affect anxiety and memory in PD mice; (2) L-NAME reversed anxiogenic and memory-improvement effect induced by sulpiride; (3) Anxiolytic and amnesic effects induced by quinpirole reversed by L-arginine; (4) There is a synergistic effect between dopamine D2 receptor and NO systems on the modulation of anxiety and memory.	Sulpiride	176-185	dopamine receptor D2	Mus musculus	34-54
11445186-8	2001	The "D2 like" antagonist sulpiride (10 microM), while having no effect alone, blocked the action of dopamine.	Sulpiride	25-34	immunoglobulin heavy diversity 2-15	Homo sapiens	4-7
34737042-10	2021	Our results suggested: (1) NO and dopamine D2 receptor mechanisms affect anxiety and memory in PD mice; (2) L-NAME reversed anxiogenic and memory-improvement effect induced by sulpiride; (3) Anxiolytic and amnesic effects induced by quinpirole reversed by L-arginine; (4) There is a synergistic effect between dopamine D2 receptor and NO systems on the modulation of anxiety and memory.	Sulpiride	176-185	dopamine receptor D2	Mus musculus	310-330
34811469-8	2021	Both FC- and TFB-TBOA-mediated synaptic depression were inhibited in brain slices pre-treated with the dopamine D2 receptor antagonist sulpiride, but insensitive to agents acting on presynaptic glutamatergic autoreceptors, NMDA receptors, gap junction coupling, cannabinoid 1 receptors, micro-opioid receptors, P2 receptors or GABAA receptors.	Sulpiride	135-144	dopamine receptor D2	Homo sapiens	103-123
34429055-6	2021	In contrast, blockade of D2-like dopaminergic receptor by sulpiride decreased dopamine"s inhibitory effect on IL-17 secretion in both groups and GM-CSF and IL-21 production in MS patients.	Sulpiride	58-67	interleukin 17A	Homo sapiens	110-115
34429055-6	2021	In contrast, blockade of D2-like dopaminergic receptor by sulpiride decreased dopamine"s inhibitory effect on IL-17 secretion in both groups and GM-CSF and IL-21 production in MS patients.	Sulpiride	58-67	colony stimulating factor 2	Homo sapiens	145-151
34429055-6	2021	In contrast, blockade of D2-like dopaminergic receptor by sulpiride decreased dopamine"s inhibitory effect on IL-17 secretion in both groups and GM-CSF and IL-21 production in MS patients.	Sulpiride	58-67	interleukin 21	Homo sapiens	156-161
35150853-1	2022	Sulpiride in vegetable shortening (VS) stimulates prolactin in horses for up to 10 days.	Sulpiride	0-9	prolactin	Equus caballus	50-59
35150853-5	2022	Sulpiride stimulated (P < .01) prolactin similarly between vehicles.	Sulpiride	0-9	prolactin	Equus caballus	31-40
35150853-6	2022	Geldings pre-treated with EB had higher (P < .05) prolactin responses to sulpiride compared to ECP-treated geldings on days 5, 6 and 9.	Sulpiride	73-82	prolactin	Equus caballus	50-59
35079131-7	2022	Furthermore, M2-induced enhancement of sEPSC frequency was abolished by sulpiride (10 microM), a dopamine D2 receptor antagonist, but not by the dopamine receptor D1 antagonist, SCH23390 (10 muM).	Sulpiride	72-81	dopamine receptor D2	Mus musculus	97-117
35078262-8	2022	Furthermore, sulpiride decreased retinal haemorrhages in response to the intravitreal administration of vascular endothelial growth factor (VEGF).	Sulpiride	13-22	vascular endothelial growth factor A	Rattus norvegicus	104-138
35078262-8	2022	Furthermore, sulpiride decreased retinal haemorrhages in response to the intravitreal administration of vascular endothelial growth factor (VEGF).	Sulpiride	13-22	vascular endothelial growth factor A	Rattus norvegicus	140-144
35078262-10	2022	We conclude that sulpiride-induced hyperprolactinaemia inhibits the diabetes- and VEGF-mediated increase in retinal vasopermeability by promoting the intraocular conversion of endogenous PRL to vasoinhibin.	Sulpiride	17-26	prolactin	Rattus norvegicus	187-190
35050306-3	2022	Mice in both groups received daily intraperitoneal injections of either the D2R antagonist sulpiride (8 microg/g) or vehicle alone.	Sulpiride	91-100	dopamine receptor D2	Mus musculus	76-79
2574975-3	1989	In the present study, it was found that the effects of the DA-acting drugs (apomorphine, LY 171555, SKF 38393, sulpiride, Sch 23390 and gamma-butyrolactone) on PKC activity were prevented by prior diminution of the endogenous stores of DA with alpha-methyl-p-tyrosine (alpha-MT) or reserpine.	Sulpiride	111-120	proline rich transmembrane protein 2	Homo sapiens	160-163
2570858-4	1989	The enhanced motor activity was inhibited by the D2- receptor antagonist sulpiride or the D1- receptor antagonist SCH 23390, indicating that it was caused by stimulation of both receptor types.	Sulpiride	73-82	dopamine receptor D2	Mus musculus	49-61
2479528-4	1989	While an iv injection of 2 micrograms synthetic human GH-releasing factor-(1-44)-NH2 (hGRF) induced GH rises in prazosin-, HAL-, pimozide-, sulpiride-, and YM-treated rabbits as well as control rabbits, YOM and CPZ completely abolished these GH responses to hGRF injection.	Sulpiride	140-149	growth hormone releasing hormone	Homo sapiens	86-90
2479528-4	1989	While an iv injection of 2 micrograms synthetic human GH-releasing factor-(1-44)-NH2 (hGRF) induced GH rises in prazosin-, HAL-, pimozide-, sulpiride-, and YM-treated rabbits as well as control rabbits, YOM and CPZ completely abolished these GH responses to hGRF injection.	Sulpiride	140-149	somatotropin	Oryctolagus cuniculus	54-56
2531718-4	1989	Nevertheless, sulpiride-induced prolactin secretion was significantly lower after Alpha-hANP administration than after placebo pre-treatment (p values ranging between 0.01 and 0.001).	Sulpiride	14-23	prolactin	Homo sapiens	32-41
2541855-12	1989	The effect induced by imipramine plus TRH was also blocked by sulpiride (16 mg kg-1, i.p.).	Sulpiride	62-71	thyrotropin releasing hormone	Mus musculus	38-41
2759205-0	1989	Lesions in suprachiasmatic nuclei simulate effects of pinealectomy on prolactin release in ovariectomized and sulpiride-treated female rats.	Sulpiride	110-119	prolactin	Rattus norvegicus	70-79
2759205-3	1989	Melatonin, but not other pineal indoles, also prevented sulpiride-induced prolactin secretion in pinealectomized or suprachiasmatic nuclei-lesioned and ovariectomized rats, which suggested that the pineal gland can modulate prolactin secretion by acting through a dopamine mechanism independent of hypothalamic suprachiasmatic structures.	Sulpiride	56-65	prolactin	Rattus norvegicus	74-83
2521903-4	1989	The methamphetamine-induced increase in total PPT messenger RNA could be blocked by either a D-1 or a D-2 selective DA antagonist (SCH 23390 and sulpiride, respectively).	Sulpiride	145-154	tachykinin, precursor 1	Rattus norvegicus	46-49
2780786-8	1989	The well known hyperprolactinemia, induced by the pituitary D2 dopamine receptor blockade, might bring about an impairment of the steroidogenesis with subsequent decrease in estrogens level, which in turn might be responsible for the hyperphagia and body weight increase induced by systemic injections of sulpiride.	Sulpiride	305-314	dopamine receptor D2	Rattus norvegicus	60-80
2546461-3	1989	Using 10 nM 3H-spiperone and sulpiride to determine nonspecific binding, specific binding of D-2 receptors increased significantly (46%) in the striata of ACTH-treated rats when compared to controls.	Sulpiride	29-38	proopiomelanocortin	Homo sapiens	155-159
2540019-4	1989	Sulpiride, a D2-dopamine receptor antagonist, at a concentration of 10(-6) M, induced a significant (P less than 0.05) increase of both basal and potassium-stimulated alpha-MSH release to 203 +/- 21% and 447 +/- 88% of basal release in normal ACSF respectively.	Sulpiride	0-9	dopamine receptor D2	Rattus norvegicus	13-33
2540019-4	1989	Sulpiride, a D2-dopamine receptor antagonist, at a concentration of 10(-6) M, induced a significant (P less than 0.05) increase of both basal and potassium-stimulated alpha-MSH release to 203 +/- 21% and 447 +/- 88% of basal release in normal ACSF respectively.	Sulpiride	0-9	proopiomelanocortin	Rattus norvegicus	167-176
2531902-1	1989	Feeding elicited by the 5HT1A agonist 8-OH-DPAT was blocked by pretreatment with the DA antagonists SCH-23390 and sulpiride, in two experiments conducted in non-deprived rats and in three experiments conducted after 4 h food deprivation.	Sulpiride	114-123	5-hydroxytryptamine receptor 1A	Rattus norvegicus	24-29
2855331-5	1988	Selective DA-2 antagonists domperidone and (-)-sulpiride and combined DA-2/DA-1 antagonists haloperidol, fluphenazine and (+)-sulpiride were active in this model, whereas the DA-1 antagonist SCH 23390 and the alpha-2 adrenoceptor antagonist idazoxan (RX-781094) were inactive.	Sulpiride	122-135	RT1 class II, locus Da	Rattus norvegicus	75-79
2855331-5	1988	Selective DA-2 antagonists domperidone and (-)-sulpiride and combined DA-2/DA-1 antagonists haloperidol, fluphenazine and (+)-sulpiride were active in this model, whereas the DA-1 antagonist SCH 23390 and the alpha-2 adrenoceptor antagonist idazoxan (RX-781094) were inactive.	Sulpiride	122-135	RT1 class II, locus Da	Rattus norvegicus	175-179
3182393-0	1988	Effects of chronic sulpiride-induced hyperprolactinemia on plasma testosterone and its responses to hCG in normal men.	Sulpiride	19-28	hypertrichosis 2 (generalised, congenital)	Homo sapiens	100-103
2852446-3	1988	The effect was blocked by either the D2-receptor antagonist sulpiride or the D1-receptor antagonist SCH 23 390, indicating that motor activity is dependent on simultaneous activation of both dopamine receptor types.	Sulpiride	60-69	dopamine receptor D2	Mus musculus	37-48
2458445-7	1988	Indeed, selective D-2 agonists were more effective than DA in inhibiting the glomerulosa cell responses to AII; in addition, the effects of DA on both aldosterone secretion and cAMP formation were prevented by D-2 antagonists, such as (-)-sulpiride and domperidone, but not by the selective D-1 antagonist SCH 23390.	Sulpiride	235-248	angiotensinogen	Homo sapiens	107-110
3143926-5	1988	The selective D2-antagonist sulpiride also showed a tendency to reduce the number of neuropeptide Y immunoreactive cells, whereas the selective D1 antagonist SCH 23390 induced a small but constant increase in this number.	Sulpiride	28-37	neuropeptide Y	Rattus norvegicus	85-99
2839528-2	1988	In the hippocampus, marked differences were noted in the stratum (sr.) pyramidale of the CA1 subfield where opioid and spirodecanone (assayed in the presence of mianserin and sulpiride) binding activities were very low in gerbils, but high in rats.	Sulpiride	175-184	carbonic anhydrase 1	Rattus norvegicus	89-92
3346364-5	1988	Compared with the placebo group, which had the expected postpartum plasma PRL decline, the sulpiride-treated women maintained significantly elevated basal plasma PRL values up to the 90th postpartum day.	Sulpiride	91-100	prolactin	Homo sapiens	74-77
2842496-1	1988	Ovulation induced by hCG in rabbits was reduced significantly (P less than 0.005) by sulpiride-induced hyperprolactinaemia.	Sulpiride	85-94	hypertrichosis 2 (generalised, congenital)	Homo sapiens	21-24
3183301-4	1988	The serum prolactin levels of 51-100 ng/ml in 11 subjects may have been induced by drugs (sulpiride) or unknown factors.	Sulpiride	90-99	prolactin	Homo sapiens	10-19
2902647-5	1988	Similarly, in mice pretreated with the D2 receptor antagonist sulpiride before EEDQ and again challenged with the D1 and D2 agonists 24 hours later, the rotational response to SKF 38393 was still inhibited but the response to quinpirole was no longer inhibited.	Sulpiride	62-71	dopamine receptor D2	Mus musculus	39-50
2902647-5	1988	Similarly, in mice pretreated with the D2 receptor antagonist sulpiride before EEDQ and again challenged with the D1 and D2 agonists 24 hours later, the rotational response to SKF 38393 was still inhibited but the response to quinpirole was no longer inhibited.	Sulpiride	62-71	deiodinase, iodothyronine, type I	Mus musculus	114-123
3346364-5	1988	Compared with the placebo group, which had the expected postpartum plasma PRL decline, the sulpiride-treated women maintained significantly elevated basal plasma PRL values up to the 90th postpartum day.	Sulpiride	91-100	prolactin	Homo sapiens	162-165
2830786-3	1988	Before glucocorticoid replacement therapy, both TRH and sulpiride administration resulted in PRL hyper-responsiveness.	Sulpiride	56-65	prolactin	Homo sapiens	93-96
2830786-4	1988	The sulpiride-induced PRL increase was higher than that induced by TRH.	Sulpiride	4-13	prolactin	Homo sapiens	22-25
2830786-2	1988	Prolactin (PRL) secretory dynamics were evaluated by several stimulation (thyrotropin-releasing hormone [TRH], sulpiride) and suppression (L-dopa) tests.	Sulpiride	111-120	prolactin	Homo sapiens	0-9
2830786-6	1988	Following glucocorticoid replacement therapy, the elevated basal PRL level returned to normal, and PRL hyper-responsiveness to TRH or sulpiride also returned to normal.	Sulpiride	134-143	prolactin	Homo sapiens	99-102
2835690-10	1988	In the presence of (-)sulpiride, relatively similar results were obtained following all MAO inhibitor treatments.	Sulpiride	19-31	monoamine oxidase A	Rattus norvegicus	88-91
2448600-5	1988	Sulpiride, a potent antipsychotic with weak anti-calmodulin activity, was a relatively weak inhibitor of Ca-activated K channels.	Sulpiride	0-9	calmodulin 1	Rattus norvegicus	49-59
2905878-7	1988	Dopamine D2 receptor-selective antagonists such as sulpiride seem to cause selective D2 receptor up-regulation.	Sulpiride	51-60	dopamine receptor D2	Homo sapiens	0-20
2892477-7	1988	In a sulpiride-treated patient, the dosage was reduced in four steps over a nine-week period and a curvilinear relationship was demonstrated between central D2-dopamine receptor occupancy and serum drug concentrations.	Sulpiride	5-14	dopamine receptor D2	Homo sapiens	157-177
3368011-2	1988	), increasing doses of the D-2 antagonist sulpiride had varying effects on locomotor activity induced by the mixed D-1/D-2 agonist pergolide (2 mg/kg, s.c.).	Sulpiride	42-51	deiodinase, iodothyronine, type I	Mus musculus	115-118
3141611-11	1988	In adult or 15 day-old neonates administration of TRH or sulpiride resulted in a marked increase in serum PRL levels.	Sulpiride	57-66	prolactin	Rattus norvegicus	106-109
2907661-3	1988	Administration of the selective D2 receptor antagonist (-)-sulpiride (25 mg/kg) before the challenge dose of cocaine completely antagonized the increase in defensive behaviour, while the selective D1 receptor antagonist SCH 23390 (0.25-0.50 mg/kg) did not significantly affect defensive behavioural patterns.	Sulpiride	55-68	dopamine receptor D2	Mus musculus	32-43
2825061-3	1987	A single administration of haloperidol decreased the CCK-8 IR in the corpus striatum and that of racemic sulpiride significantly decreased the CCK-8 IR in the frontal cortex and the limbic system.	Sulpiride	105-114	cholecystokinin	Rattus norvegicus	143-146
3121569-4	1987	Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10).	Sulpiride	11-20	dopamine receptor D2	Homo sapiens	24-45
3121569-4	1987	Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10).	Sulpiride	11-20	prolactin	Homo sapiens	84-93
3121569-4	1987	Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10).	Sulpiride	11-20	prolactin	Homo sapiens	165-174
3121569-4	1987	Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10).	Sulpiride	11-20	prolactin	Homo sapiens	165-174
3121569-4	1987	Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10).	Sulpiride	248-257	prolactin	Homo sapiens	84-93
3126503-9	1988	The response to TRH, but not to VIP, was significantly greater following sulpiride than in animals treated with sulpiride vehicle.	Sulpiride	73-82	thyrotropin releasing hormone	Rattus norvegicus	16-19
3126503-9	1988	The response to TRH, but not to VIP, was significantly greater following sulpiride than in animals treated with sulpiride vehicle.	Sulpiride	112-121	thyrotropin releasing hormone	Rattus norvegicus	16-19
2825061-6	1987	After chronic administration of racemic sulpiride or methaphetamine, CCK-8 IR in various brain regions exhibited a tendency close to that of control.	Sulpiride	40-49	cholecystokinin	Rattus norvegicus	69-72
3655615-4	1987	Increasing concentrations of prolactin by daily injections of sulpiride mimicked the effect of the odorant stimulation in males receiving only fresh non-odorized air.	Sulpiride	62-71	prolactin	Mus musculus	29-38
2819791-2	1987	D1- and D2 receptor-mediated effects were investigated in the presence of 2 microM (-)-sulpiride and 0.1 microM SCH 23390, respectively.	Sulpiride	83-96	dopamine receptor D1	Mus musculus	0-19
3620290-0	1987	Prolactin response to low dose sulpiride.	Sulpiride	31-40	prolactin	Homo sapiens	0-9
3620290-1	1987	1 Prolactin levels in response to sulpiride were studied in healthy volunteers.	Sulpiride	34-43	prolactin	Homo sapiens	2-11
3620290-5	1987	6 These results indicate that sulpiride retains its potent ability to produce prolactin release even at the low doses studied here.	Sulpiride	30-39	prolactin	Homo sapiens	78-87
2954994-0	1987	D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men.	Sulpiride	54-63	transient receptor potential cation channel subfamily C member 6	Homo sapiens	2-6
2954994-1	1987	The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men.	Sulpiride	95-104	gonadotropin releasing hormone 1	Homo sapiens	43-47
2954994-1	1987	The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men.	Sulpiride	95-104	gonadotropin releasing hormone 1	Homo sapiens	56-60
2954994-5	1987	These data demonstrate that administration of LHRH agonist can inhibit the hyperprolactinemic effect of sulpiride, suggesting a direct action of the analog on the pituitary gland to modulate PRL secretion.	Sulpiride	104-113	gonadotropin releasing hormone 1	Homo sapiens	46-50
2943108-9	1986	(Normal values of prolactin were on the average achieved on the 4th day after sulpiride discontinuation).	Sulpiride	78-87	prolactin	Homo sapiens	18-27
3618084-2	1987	The sulpiride dose PRL response relationship in 10-25 day old neonatal rats was similar to that found in lactating rats, with a threshold sensitivity around 29 nmol sulpiride/kg body weight and a maximal response at about 2.9 mumol/kg.	Sulpiride	4-13	prolactin	Rattus norvegicus	19-22
3569131-8	1987	However, stimulation of PRL release by sulpiride was observed consistently in rats ovariectomized on or after 1 week of age.	Sulpiride	39-48	prolactin	Rattus norvegicus	24-27
3569131-12	1987	Sulpiride stimulated PRL release in NC females that had been treated neonatally (postnatal days 3-9) with either E2 or P. This effect was accompanied by an increase in the AP PRL content.	Sulpiride	0-9	prolactin	Rattus norvegicus	21-24
3569131-12	1987	Sulpiride stimulated PRL release in NC females that had been treated neonatally (postnatal days 3-9) with either E2 or P. This effect was accompanied by an increase in the AP PRL content.	Sulpiride	0-9	prolactin	Rattus norvegicus	175-178
2949800-0	1987	Effects of sulpiride and apomorphine on prolactin release in adrenalectomized animals.	Sulpiride	11-20	prolactin	Rattus norvegicus	40-49
2962878-0	1987	Reversal by the selective D-2 dopamine receptor blocker sulpiride of the hypotensive effect of co-dergocrine in elderly hypertensives.	Sulpiride	56-65	dopamine receptor D2	Homo sapiens	26-47
3613693-2	1987	Sulpiride (200 mg) was used as a control drug; it raised PRL by almost 800%.	Sulpiride	0-9	prolactin	Homo sapiens	57-60
3098885-5	1986	The specific D2 agonist LY 171555 also inhibited tyrosinase activity in the skin explants in a dose-related manner and the effect was blocked by sulpiride, a D2-receptor antagonist.	Sulpiride	145-154	tyrosinase	Mus musculus	49-59
3098885-5	1986	The specific D2 agonist LY 171555 also inhibited tyrosinase activity in the skin explants in a dose-related manner and the effect was blocked by sulpiride, a D2-receptor antagonist.	Sulpiride	145-154	dopamine receptor D2	Mus musculus	158-169
2874213-4	1986	The inhibitory effect of fenoldopam was antagonized by the DA1 receptor antagonist R-sulpiride but not by the DA2 receptor antagonist S-sulpiride.	Sulpiride	83-94	RT1 class II, locus Da	Rattus norvegicus	59-62
3526066-2	1986	Haloperidol, a D-2 dopamine receptor antagonist which blocks the dopamine-sensitive adenylate cyclase and (-) sulpiride, a selective D-2 dopamine receptor blocker, which does not block the dopamine-sensitive adenylate cyclase, failed to change both the Bmax and KD of 3H-SCH 23390 binding.	Sulpiride	106-119	dopamine receptor D2	Rattus norvegicus	15-36
3761757-0	1986	Comparison of effects of tiapride and sulpiride on D-1, D-2, D-3 and D-4 subtypes of dopamine receptors in rat striatal and bovine caudate nucleus membranes.	Sulpiride	38-47	solute carrier family 3 member 1	Rattus norvegicus	56-64
3761757-2	1986	The IC50 values of tiapride, sulpiride and haloperidol were estimated as follows: 1440, 132 and 0.295 microM for D-1; 45.8, 8.8 and 0.004 microM for D-2; greater than 100, greater than 100 and 0.64 microM for D-3; 11.7, 2.88 and 0.0044 microM for D-4, respectively.	Sulpiride	29-38	solute carrier family 3 member 1	Rattus norvegicus	149-152
3761757-5	1986	In the D-2 receptor assay, the IC50 values of tiapride and sulpiride were 1/22.7 and 1/19.1 of those in the presence of 100 mM NaCl, respectively, suggesting that benzamide drug binds to the D-2 subtype with higher affinity in the presence of Na+ than in the control.	Sulpiride	59-68	solute carrier family 3 member 1	Rattus norvegicus	7-10
3761757-5	1986	In the D-2 receptor assay, the IC50 values of tiapride and sulpiride were 1/22.7 and 1/19.1 of those in the presence of 100 mM NaCl, respectively, suggesting that benzamide drug binds to the D-2 subtype with higher affinity in the presence of Na+ than in the control.	Sulpiride	59-68	solute carrier family 3 member 1	Rattus norvegicus	191-194
2423911-2	1986	The most marked effect was a decrease in NKA-LI levels in n.accumbens after treatment with both sulpiride and haloperidol.	Sulpiride	96-105	Natural killer alloreactivity QTL 1	Rattus norvegicus	41-44
2423911-5	1986	A low dose of sulpiride increased both NKA-LI and SP-LI levels in ventral tegmental area/n.interpeduncularis.	Sulpiride	14-23	Natural killer alloreactivity QTL 1	Rattus norvegicus	39-42
3618084-4	1987	Treatment of lactating mothers with a maximally stimulatory dose of sulpiride (2.9 mumol/kg) twice daily for 4 days resulted in small but highly significant increases in neonatal PRL on days 1 and 2 but complete loss of response by day 4.	Sulpiride	68-77	prolactin	Rattus norvegicus	179-182
3618084-6	1987	The subsequent loss of the neonatal PRL response on chronic exposure to sulpiride may indicate a degree of disturbance of hypothalamic dopaminergic mechanisms.	Sulpiride	72-81	prolactin	Rattus norvegicus	36-39
2887436-0	1987	Repeated administration of (-)sulpiride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in cortical-limbic brain regions.	Sulpiride	30-39	dopamine receptor D2	Rattus norvegicus	89-110
3108355-8	1987	In the first protocol, PRL showed a significant increase (peak values at 30 min) after SUL administration in both phases (phase A: 54.8 +/- 5.6 ng/ml, mean +/- SE vs 6.4 +/- 0.3, p less than 0.001.	Sulpiride	87-90	prolactin	Homo sapiens	23-26
3108355-11	1987	Also in the second protocol, SUL alone induced a significant PRL increase (peak values at 30 min: 47.1 +/- 7.2 vs 4.2 +/- 0.5, p less than 0.005).	Sulpiride	29-32	prolactin	Homo sapiens	61-64
3299396-2	1987	The substituted benzamide, sulpiride, a selective dopamine D-2 receptor antagonist, significantly increased the consumption of water and hypotonic saline at 30 mg/kg.	Sulpiride	27-36	solute carrier family 3 member 1	Rattus norvegicus	59-62
3299396-6	1987	The increase in drinking produced by sulpiride indicates that dopamine may act at D-2 receptors to inhibit the consumption of water and hypotonic saline, but not of stronger salt solutions.	Sulpiride	37-46	solute carrier family 3 member 1	Rattus norvegicus	82-85
3556197-6	1987	However this latter compound prevented SCH 23390 as well as sulpiride from increasing the PRL concentrations above the control values.	Sulpiride	60-69	prolactin	Rattus norvegicus	90-93
3096790-3	1986	Daily administration of sulpiride (150 mg orally) significantly elevated serum prolactin (PRL) levels in all six women.	Sulpiride	24-33	prolactin	Homo sapiens	79-88
3096790-3	1986	Daily administration of sulpiride (150 mg orally) significantly elevated serum prolactin (PRL) levels in all six women.	Sulpiride	24-33	prolactin	Homo sapiens	90-93
2948613-3	1986	Addition of 10 microM of (-)-sulpiride, a specific D-2 DA receptor antagonist, blocked the inhibitory effect of 100 nM of LY-141865 on the release of CCK-LI.	Sulpiride	25-38	cholecystokinin	Rattus norvegicus	150-153
2878679-3	1986	Intra-arterial fenoldopam markedly increased forearm blood flow, this effect was antagonised by (R) sulpiride, a vascular dopamine (DA1) antagonist, but not by metoclopramide, a neuronal (DA2) antagonist, or by guanethidine, an adrenergic neurone blocking agent.	Sulpiride	96-109	immunoglobulin heavy diversity 4-11 (non-functional)	Homo sapiens	132-135
2876053-8	1986	Under depolarizing conditions, the blockade by (-)-sulpiride of the stimulation of DA autoreceptors by endogenous DA was associated with a marked activation of TH.	Sulpiride	47-60	tyrosine hydroxylase	Rattus norvegicus	160-162
3122863-1	1986	Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration.	Sulpiride	49-58	prolactin	Homo sapiens	7-16
3122863-1	1986	Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration.	Sulpiride	49-58	gamma-glutamyl hydrolase	Homo sapiens	21-23
3008378-0	1986	Modulation of ovarian LH receptor and serum hormone levels in rats with hyperprolactinemia induced by administration of ovine prolactin or sulpiride.	Sulpiride	139-148	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	22-33
3701233-2	1986	Administration of sulpiride or oestradiol released prolactin and stimulated cell proliferation in the anterior pituitary gland of adult male rats.	Sulpiride	18-27	prolactin	Rattus norvegicus	51-60
3701233-4	1986	Treatment with oestradiol plus sulpiride significantly increased serum prolactin concentrations and the mitotic index compared with the sum of the stimulation produced by both drugs separately.	Sulpiride	31-40	prolactin	Rattus norvegicus	71-80
3701233-8	1986	The number of prolactin-secreting cells in the anterior pituitary gland significantly increased after the administration of oestradiol or sulpiride.	Sulpiride	138-147	prolactin	Rattus norvegicus	14-23
3008378-0	1986	Modulation of ovarian LH receptor and serum hormone levels in rats with hyperprolactinemia induced by administration of ovine prolactin or sulpiride.	Sulpiride	139-148	prolactin	Rattus norvegicus	77-86
3008378-1	1986	Hyperprolactinemia was experimentally produced in rats by administration of ovine prolactin (oPRL) and sulpiride, and tried to evaluate the effect of hyperprolactinemia on ovarian receptor for luteinizing hormone (LH) as well as that on serum gonadotropin and steroid hormone levels.	Sulpiride	103-112	prolactin	Rattus norvegicus	5-14
3008378-6	1986	Serum prolactin levels decreased in rats treated with larger doses of oPRL, but increased with larger doses of sulpiride.	Sulpiride	111-120	prolactin	Rattus norvegicus	6-15
2947428-3	1986	The DA agonist-induced SMB behavior is abolished by pretreatment of the monkeys with either the D1 DA antagonist SCH 23390 or with the mixed D1/D2 antagonist fluphenazine, but not with the selective D2 antagonist (+/-) sulpiride.	Sulpiride	219-228	small nuclear ribonucleoprotein polypeptides B and B1	Rattus norvegicus	23-26
3783151-5	1986	These data suggest that APO-induced increased jump latencies are at least partly related with hypothermia and endogenous opioid systems, whereas APO effect on the writhing test depends on the stimulation of dopamine receptors particularly sensitive to sulpiride and is independent from body temperature and opioidergic transmissions.	Sulpiride	252-261	anterior polar opacity	Mus musculus	24-27
3783151-5	1986	These data suggest that APO-induced increased jump latencies are at least partly related with hypothermia and endogenous opioid systems, whereas APO effect on the writhing test depends on the stimulation of dopamine receptors particularly sensitive to sulpiride and is independent from body temperature and opioidergic transmissions.	Sulpiride	252-261	anterior polar opacity	Mus musculus	145-148
3088638-3	1986	Pharmacological and biochemical properties of BRL 20596 are compared here in animals with chlorpromazine, clebopride, haloperidol and sulpiride.	Sulpiride	134-143	bromodomain containing 1	Homo sapiens	46-49
3785645-0	1986	Effect of sulpiride on plasma prolactin in healthy volunteers and depressed patients.	Sulpiride	10-19	prolactin	Homo sapiens	30-39
3104946-6	1986	Pretreatment of the animals with sulpiride, a D2-antagonist, prevented the hypothermia-induced inhibition of PRL release.	Sulpiride	33-42	prolactin	Rattus norvegicus	109-112
3931501-4	1985	A reduced LH response to LHRH during sulpiride intake was seen, whereas the FSH response was unchanged.	Sulpiride	37-46	gonadotropin releasing hormone 1	Homo sapiens	25-29
4067488-1	1985	In this study, aimed at investigating whether dopaminergic regulation of prolactin could be implicated in the hypoprolactinaemia observed in the IPL nude rat, dopaminergic inhibition of prolactin was suppressed using a catecholamine synthesis inhibitor alpha-methyltyrosine (MT) and a dopaminergic antagonist sulpiride.	Sulpiride	309-318	prolactin	Rattus norvegicus	73-82
4067488-9	1985	Plasma prolactin levels, compared with basal values, were increased in rats injected with sulpiride by 9.2 +/- 1.8 and 3.4 +/- 0.7-fold in IPL nude and normal rats respectively.	Sulpiride	90-99	prolactin	Rattus norvegicus	7-16
4067488-10	1985	The pituitary prolactin content was reduced more in IPL nude than in normal sulpiride-injected rats.	Sulpiride	76-85	prolactin	Rattus norvegicus	14-23
2417870-3	1985	Upon selective D-1 dopamine receptor activation with 30 microM dopamine in the presence of 10 microM of the D-2 dopamine receptor antagonist (-)sulpiride, the enhanced efflux of cyclic AMP was reduced by all three opioid receptor agonists, but only the effect of morphine was antagonized by 0.1 microM naloxone.	Sulpiride	141-153	dopamine receptor D2	Rattus norvegicus	108-129
3935458-11	1985	reversed the blunted response of PRL after sulpiride, 25 mg, in presence of naloxone.	Sulpiride	43-52	prolactin	Homo sapiens	33-36
3935458-13	1985	inactive per se on basal PRL levels, is able to blunt significantly sulpiride-induced hyperprolactinaemia.	Sulpiride	68-77	prolactin	Homo sapiens	25-28
3935351-0	1985	[Plasma prolactin and GH response after thyrotropin-releasing hormone (TRH), L-DOPA and sulpiride in patients with senile dementia of Alzheimer type].	Sulpiride	88-97	gamma-glutamyl hydrolase	Homo sapiens	22-24
2863153-9	1985	SCH counteracted the inhibiting effect of apomorphine on PRL release and potentiated the stimulation effect of low doses of sulpiride on PRL secretion.	Sulpiride	124-133	prolactin	Rattus norvegicus	137-140
4001434-1	1985	The relationship between erectile dysfunction and sulpiride stimulatory effect on prolactin secretion was studied in 13 married male psychiatric outpatients.	Sulpiride	50-59	prolactin	Homo sapiens	82-91
4030988-3	1985	Internal standards were a new substituted benzamide (N-[(ethyl-1-pyrrolidinyl-2)methyl] methoxy-2-ethylsulphonyl-5-benzamide, DAN) for the sulpiride assay and sulpiride for the sultopride assay.	Sulpiride	139-148	NBL1, DAN family BMP antagonist	Homo sapiens	126-129
4030988-3	1985	Internal standards were a new substituted benzamide (N-[(ethyl-1-pyrrolidinyl-2)methyl] methoxy-2-ethylsulphonyl-5-benzamide, DAN) for the sulpiride assay and sulpiride for the sultopride assay.	Sulpiride	159-168	NBL1, DAN family BMP antagonist	Homo sapiens	126-129
4031381-9	1985	0.2 mg terguride bid given for 15 days to 7 healthy volunteers significantly reduced both basal and sulpiride (25 mg im)-stimulated PRL levels.	Sulpiride	100-109	prolactin	Homo sapiens	132-135
3888233-0	1985	Prolactin response to sulpiride in non insulin dependent diabetes mellitus.	Sulpiride	22-31	prolactin	Homo sapiens	0-9
3888233-3	1985	Prolactin response to sulpiride was significantly higher in diabetics than in controls (at 20 min., p less than 0.01; at 30 and 60 min., p less than 0.005; at 90 min., p less than 0.01; at 120 min., p less than 0.05).	Sulpiride	22-31	prolactin	Homo sapiens	0-9
3888233-5	1985	Prolactin response to sulpiride was the same in diabetics with and in those without retinal changes.	Sulpiride	22-31	prolactin	Homo sapiens	0-9
3979429-4	1985	The inhibitory effects of (+)3-PPP on both transmitter and alpha-MSH release were antagonized by the selective D-2 receptor antagonist (-)-sulpiride.	Sulpiride	135-148	proopiomelanocortin	Rattus norvegicus	59-68
2994707-7	1985	The increase in ACTH, however, was greatest in the sulpiride group, intermediate in the controls and correct in the propranolol group.	Sulpiride	51-60	proopiomelanocortin	Homo sapiens	16-20
3157586-9	1985	The results, compared with those in our previous report, show that the D-2 dopamine antagonist sulpiride was 1000 times more potent in inhibiting the pergolide than the apomorphine rotation.	Sulpiride	95-104	solute carrier family 3 member 1	Rattus norvegicus	71-74
4040306-5	1985	The LH and FSH responses to LHRH were similar to those of XXY controls, and the variation of prolactin levels after sulpiride stimulus was in the normal range.	Sulpiride	116-125	prolactin	Homo sapiens	93-102
3988149-4	1985	Sulpiride resulted in a much greater PRL response.	Sulpiride	0-9	prolactin	Homo sapiens	37-40
3014581-4	1985	Sulpiride tended to overcome the locomotor activity-decreasing effect of ATII.	Sulpiride	0-9	angiotensinogen	Rattus norvegicus	73-77
3159009-0	1985	Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.	Sulpiride	114-123	solute carrier family 3 member 1	Rattus norvegicus	27-47
4089188-0	1985	Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine.	Sulpiride	68-77	prolactin	Homo sapiens	30-39
3159009-7	1985	In general, both sulpiride and clozapine enhanced D-1 function as assessed by dopamine-stimulated adenylate cyclase or 3H-piflutixol binding.	Sulpiride	17-26	leiomodin 1	Homo sapiens	50-53
3159009-8	1985	On acute administration sulpiride and clozapine appear to act at D-2 sites, but continuous chronic administration of these compounds does not result in the development of striatal D-2 receptor hypersensitivity.	Sulpiride	24-33	solute carrier family 3 member 1	Rattus norvegicus	65-68
6438254-5	1984	In the hyperprolactinemic state caused by PIF inhibition by sulpiride it was indicated that there was a limit to prolactin secretion and release by the pituitary gland.	Sulpiride	60-69	PIF1 5'-to-3' DNA helicase	Homo sapiens	42-45
6528338-8	1984	Plasma PRL response to sulpiride also became exaggerated during the treatment.	Sulpiride	23-32	prolactin	Homo sapiens	7-10
6094048-0	1984	Acute dopaminergic blockade by sulpiride stimulates beta-endorphin secretion in pregnant women.	Sulpiride	31-40	proopiomelanocortin	Homo sapiens	52-66
6094048-5	1984	The present study demonstrates that an acute dopaminergic blockade by sulpiride dramatically increases plasma concentrations of beta-endorphin in pregnant women but not in non-pregnant women providing functional evidence for the intermediate lobe hypothesis.	Sulpiride	70-79	proopiomelanocortin	Homo sapiens	128-142
6440785-3	1984	Mean (+/- SE) plasma levels of PRL on day 7 in the sulpiride treated cycle were significantly higher than those in the control cycle (118 +/- 24 ng/ml vs. 14 +/- 4 ng/ml, p less than 0.001).	Sulpiride	51-60	prolactin	Homo sapiens	31-34
6090494-3	1984	Long term administration of sulpiride to normal women increased both serum PRL and DHEA-S, whereas acute elevation of PRL after a single iv dose of domperidone had no influence on the serum DHEA-S levels.	Sulpiride	28-37	prolactin	Homo sapiens	75-78
6701910-4	1984	The decreased [3H]sulpiride binding in the pituitary is consistent with the elevated serum PRL concentrations previously described in lead-exposed rats.	Sulpiride	18-27	prolactin	Rattus norvegicus	91-94
6394371-7	1984	Moreover another antagonist, sulpiride also increased PRL but contrary tended to decrease PAC.	Sulpiride	29-38	prolactin	Homo sapiens	54-57
6738827-4	1984	This reversed stereospecificity of sulpiride interactions with CNS D-1 and D-2 dopamine receptors is similar to the stereospecificity of sulpiride interactions at DA1 and DA2 dopamine receptors in peripheral vascular beds.	Sulpiride	137-146	RT1 class II, locus Da	Rattus norvegicus	163-166
6429896-0	1984	Plasma growth hormone responses to sulpiride in patients with acromegaly.	Sulpiride	35-44	growth hormone 1	Homo sapiens	7-21
6424592-2	1984	Sultopride was 4-6 times as potent as sulpiride in stimulating prolactin secretion.	Sulpiride	38-47	prolactin	Rattus norvegicus	63-72
6424592-10	1984	These results suggest that sultopride, like sulpiride, stimulates prolactin secretion by blocking the dopamine receptor in the pituitary.	Sulpiride	44-53	prolactin	Rattus norvegicus	66-75
6142590-3	1984	Sulpiride, a selective D-2 dopamine receptor blocker, is able to suppress TD without producing a reciprocal aggravation in parkinsonism, although in vulnerable patients it may induce/aggravate parkinsonian symptoms.	Sulpiride	0-9	dopamine receptor D2	Homo sapiens	23-44
6421041-7	1984	When perifused simultaneously with dopamine, sulpiride (D2-selective dopamine receptor blocker, 5 X 10(-7) M) blocked the inhibitory effect of dopamine on Prl release in 3 of the 4 dopamine-sensitive prolactinomas.	Sulpiride	45-54	prolactin	Homo sapiens	155-158
6199949-9	1984	Although sulpiride passed into the CSF, transport between serum and CSF was restricted.	Sulpiride	9-18	colony stimulating factor 2	Homo sapiens	35-38
6439566-0	1984	Possible mechanism of prolactin unresponsiveness to repeated sulpiride administration in man.	Sulpiride	61-70	prolactin	Homo sapiens	22-31
6199949-10	1984	In the sulpiride group, improvement of psychotic morbidity and HVA elevation in CSF tended to be negatively related to the drug concentrations in serum.	Sulpiride	7-16	colony stimulating factor 2	Homo sapiens	80-83
6199950-0	1984	Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients.	Sulpiride	27-36	prolactin	Homo sapiens	84-93
6199950-7	1984	There were significantly higher PRL levels in sulpiride- than in chlorpromazine-treated patients.	Sulpiride	46-55	prolactin	Homo sapiens	32-35
6199950-9	1984	The HVA/PRL ratio in CSF was significantly reduced in the sulpiride but not in the chlorpromazine group.	Sulpiride	58-67	prolactin	Homo sapiens	8-11
6199950-15	1984	The different effects of the drugs on PRL, 5-HIAA and MOPEG levels indicate that sulpiride has a more specific effect than chlorpromazine on dopaminergic mechanisms.	Sulpiride	81-90	prolactin	Homo sapiens	38-41
6152598-1	1984	The acute administration of the 1,5 benzodiazepine clobazam (20 and 100 mg/kg orally) reduces the sulpiride-induced release of prolactin in the male rat.	Sulpiride	98-107	prolactin	Rattus norvegicus	127-136
6146579-0	1984	Prolactin response to sulpiride in ovulatory women (a clue for the screening of hyperprolactinemic states).	Sulpiride	22-31	prolactin	Homo sapiens	0-9
6146579-2	1984	The dynamics of prolactin secretion was investigated in 30 ovulatory females subjected to sulpiride stimulation.	Sulpiride	90-99	prolactin	Homo sapiens	16-25
6146579-5	1984	We conclude that basal prolactin levels and the 30-min value after sulpiride administration seem to be sufficient and valid representative estimations in the screening of abnormal prolactin secretion states.	Sulpiride	67-76	prolactin	Homo sapiens	180-189
6361642-4	1984	The concentration of prolactin in maternal serum was higher (P less than .001) during sulpiride than placebo treatment at one week (380 +/- 43 ng/ml vs 23 +/- 7 ng/ml, mean +/- SE) and two weeks of treatment (381 +/- 38 ng/ml vs 34 +/- 10 ng/ml).	Sulpiride	86-95	prolactin	Homo sapiens	21-30
6323689-0	1984	Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.	Sulpiride	56-65	calmodulin 1	Rattus norvegicus	8-18
6323689-7	1984	Therefore, the increased sensitivity of the calmodulin-dependent system seen in chronic sulpiride-treated rats correlates with the increased number of D2 receptors in striatal dopamine receptor supersensitivity.	Sulpiride	88-97	calmodulin 1	Rattus norvegicus	44-54
6648972-0	1983	The effect of sulpiride administration on maternal and fetal plasma prolactin levels, and fetal growth in rats.	Sulpiride	14-23	prolactin	Rattus norvegicus	68-77
6648972-4	1983	The maternal serum and fetal plasma PRL levels were significantly higher in the sulpiride-treated group than in the saline control group.	Sulpiride	80-89	prolactin	Rattus norvegicus	36-39
6648972-6	1983	These results suggest that sulpiride which reached the fetus stimulates fetal PRL secretion and that PRL may exert a growth-promoting effect on the fetus.	Sulpiride	27-36	prolactin	Rattus norvegicus	78-81
6139285-6	1983	Administration of the same dose of domperidone or sulpiride (5 mg/kg i.p., 21 days), compounds which penetrate poorly into brain, also elevated plasma prolactin levels, but failed to alter cerebral dopamine function.	Sulpiride	50-59	prolactin	Homo sapiens	151-160
6680345-0	1983	[Effect of sulpiride on the secretion of prolactin and somatotropic hormone in premenopausal women affected by fibrocystic mastopathy].	Sulpiride	11-20	prolactin	Homo sapiens	41-50
6616329-1	1983	While a first injection of the antidopaminergic benzamide drug, sulpiride, induced a large rise in plasma prolactin (PRL) levels in chronically cannulated adult male rats, a second injection given 2 h later was totally inactive although the pituitary content of the hormone was still 76% of the initial value.	Sulpiride	64-73	prolactin	Rattus norvegicus	106-115
6616329-1	1983	While a first injection of the antidopaminergic benzamide drug, sulpiride, induced a large rise in plasma prolactin (PRL) levels in chronically cannulated adult male rats, a second injection given 2 h later was totally inactive although the pituitary content of the hormone was still 76% of the initial value.	Sulpiride	64-73	prolactin	Rattus norvegicus	117-120
6616329-4	1983	Two hours after an injection of sulpiride, a 30-min period of immobilization stress induced a significant rise in plasma PRL levels.	Sulpiride	32-41	prolactin	Rattus norvegicus	121-124
6616329-5	1983	A significant rise in plasma PRL levels was also observed when larger doses of sulpiride were given 2 h after a first injection of the drug.	Sulpiride	79-88	prolactin	Rattus norvegicus	29-32
6616329-6	1983	Apomorphine was at least as effective an inhibitor of PRL secretion when given 2 h after sulpiride than when injected after saline.	Sulpiride	89-98	prolactin	Rattus norvegicus	54-57
6616329-8	1983	These data suggest that the only plausible explanation for the ineffectiveness of the second of two consecutive injections of sulpiride is the development of a state of refractoriness of the mechanisms that subserve the release of PRL induced by suppression of the inhibitory dopaminergic tonus.	Sulpiride	126-135	prolactin	Rattus norvegicus	231-234
6884428-2	1983	The inhibition by (-)-NCA was reversible and antagonized by the benzamide neuroleptic S-sulpiride.	Sulpiride	86-97	CEA cell adhesion molecule 6	Homo sapiens	22-25
6873386-0	1983	[Effect of sulpiride on the hypothalamic monoaminergic regulation of prolactin formation and milk secretion].	Sulpiride	11-20	prolactin	Rattus norvegicus	69-78
6226542-1	1983	In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally.	Sulpiride	276-285	prolactin	Homo sapiens	73-82
6226542-3	1983	Sulpiride given orally for 12 consecutive days in the luteal phase of the menstrual cycle caused a significant increase in the plasma PRL level.	Sulpiride	0-9	prolactin	Homo sapiens	134-137
6414103-0	1983	Persistence of impaired PRL responses to sulpiride in patients with PRL secreting pituitary adenomas after successful hypophysectomy.	Sulpiride	41-50	prolactin	Homo sapiens	24-27
6414103-0	1983	Persistence of impaired PRL responses to sulpiride in patients with PRL secreting pituitary adenomas after successful hypophysectomy.	Sulpiride	41-50	prolactin	Homo sapiens	68-71
6414103-5	1983	On the other hand, the PRL responses to sulpiride in both Groups I and II improved markedly after the hypophysectomy, but the absolute response in operated Group I patients was still lower than that in normal subjects.	Sulpiride	40-49	prolactin	Homo sapiens	23-26
6414103-7	1983	It is concluded 1) that even in hypophysectomized normoprolactinemic patients the circulating PRL may originate mainly from the residual tumor cells, and 2) that the sulpiride test is useful to detect the abnormalities of hypothalamo-pituitary axis in operated patients with PRL-secreting adenomas, whereas TRH, arginine, and L-dopa tests are less useful for such purposes.	Sulpiride	166-175	prolactin	Homo sapiens	94-97
6414103-7	1983	It is concluded 1) that even in hypophysectomized normoprolactinemic patients the circulating PRL may originate mainly from the residual tumor cells, and 2) that the sulpiride test is useful to detect the abnormalities of hypothalamo-pituitary axis in operated patients with PRL-secreting adenomas, whereas TRH, arginine, and L-dopa tests are less useful for such purposes.	Sulpiride	166-175	prolactin	Homo sapiens	275-278
6133578-0	1983	(-)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanesthetized rats.	Sulpiride	0-13	tyrosine hydroxylase	Rattus norvegicus	44-64
6402870-4	1983	Sulpiride treatment induced (1) an increase in the serum Prl and a decrease in the serum LH, (2) an increase in the pituitary FSH and LH contents, (3) an increase in the MBH LRH concentration, and (4) an increase in the MBH dopamine (DA) turnover.	Sulpiride	0-9	prolactin	Rattus norvegicus	57-60
6642291-0	1983	Prolactin response to the dopamine antagonists sulpiride and domperidone.	Sulpiride	47-56	prolactin	Homo sapiens	0-9
6403571-5	1983	Conversely, an iv bolus of sulpiride (25 mg), a dopaminergic antagonist, given to four subjects after 240 min, brought about a marked increase in serum PRL values above the plateau level.	Sulpiride	27-36	prolactin	Homo sapiens	152-155
6827904-6	1983	Plasma prolactin concentrations increased after injection of both chlorpromazine and sulpiride.	Sulpiride	85-94	prolactin	Oryctolagus cuniculus	7-16
6851194-5	1983	Conversely, sulpiride and domperidone strikingly stimulated PRL secretion in normoprolactinaemic and post-partum women, but only slightly enhanced base-line PRL levels in women with prolactinomas.	Sulpiride	12-21	prolactin	Homo sapiens	60-63
6843693-3	1983	The inhibitory effect of lisuride was reversed by more than 50% not only by the D1-D2 dopamine receptor blocker haloperidol but also by the D2 dopamine receptor blocker(-)-sulpiride.	Sulpiride	168-181	dopamine receptor D2	Homo sapiens	140-160
6336914-8	1983	Intrarenal infusion of sulpiride and haloperidol, dopamine antagonists, significantly inhibited dopamine-induced renin release and renal vasodilatation.	Sulpiride	23-32	renin	Canis lupus familiaris	113-118
6628512-1	1983	The prolactin (PRL) response to repeated injections of sulpiride, a dopamine antagonist, was evaluated in 18 healthy young men.	Sulpiride	55-64	prolactin	Homo sapiens	4-13
6628512-1	1983	The prolactin (PRL) response to repeated injections of sulpiride, a dopamine antagonist, was evaluated in 18 healthy young men.	Sulpiride	55-64	prolactin	Homo sapiens	15-18
6628512-4	1983	The second injection up to 24 h had no effect on serum PRL, but when two sulpiride injections were given at a 48 h-interval, both caused a sharp increase in PRL.	Sulpiride	73-82	prolactin	Homo sapiens	157-160
6628512-5	1983	To conclude, PRL cells in man, after a sulpiride injection, may therefore be unresponsive to a second sulpiride injection for more than 24 h.	Sulpiride	39-48	prolactin	Homo sapiens	13-16
6628519-0	1983	Effect of sulpiride isomers on gastric acid and gastrin secretion in healthy man.	Sulpiride	10-19	gastrin	Homo sapiens	48-55
6090657-5	1983	Serum levels of Prl were significantly higher in sulpiride-treated animals, whereas bromocriptine administration rendered undetectable values.	Sulpiride	49-58	prolactin	Rattus norvegicus	16-19
6090657-6	1983	Prolactin and sulpiride treatment significantly reduced Prl binding to the adrenal gland and Langerhans islets, whereas it greatly increased Prl binding to the liver.	Sulpiride	14-23	prolactin	Rattus norvegicus	56-59
7102768-5	1982	Determinations of daily serum levels of prolactin in 20 primiparous women revealed significantly higher concentrations in the sulpiride group.	Sulpiride	126-135	prolactin	Homo sapiens	40-49
6828202-1	1983	Haloperidol, sulpiride, domperidone and apomorphine, drugs which influence dopamine (DA) receptors and in turn prolactin (PRL) secretion have been shown to induce parallel changes in medial basal hypothalamic (MBH) glutamate decarboxylase (GAD) activity and serum PRL levels.	Sulpiride	13-22	prolactin	Rattus norvegicus	122-125
6828202-1	1983	Haloperidol, sulpiride, domperidone and apomorphine, drugs which influence dopamine (DA) receptors and in turn prolactin (PRL) secretion have been shown to induce parallel changes in medial basal hypothalamic (MBH) glutamate decarboxylase (GAD) activity and serum PRL levels.	Sulpiride	13-22	glutamate-ammonia ligase	Rattus norvegicus	215-238
6828202-1	1983	Haloperidol, sulpiride, domperidone and apomorphine, drugs which influence dopamine (DA) receptors and in turn prolactin (PRL) secretion have been shown to induce parallel changes in medial basal hypothalamic (MBH) glutamate decarboxylase (GAD) activity and serum PRL levels.	Sulpiride	13-22	glutamate-ammonia ligase	Rattus norvegicus	240-243
6815597-0	1982	Pituitary and ovarian response to luteinizing hormone releasing factor in normal and sulpiride-induced hyperprolactinemic women.	Sulpiride	85-94	CREB3 regulatory factor	Homo sapiens	34-70
6815597-2	1982	The mean responses of luteinizing hormone and follicle-stimulating hormone to LRF in the sulpiride group were higher than those in the controls.	Sulpiride	89-98	CREB3 regulatory factor	Homo sapiens	78-81
6812343-4	1982	Serum Prl levels after sulpiride were higher in the patients than in the controls (P less than 0.01).	Sulpiride	23-32	prolactin	Homo sapiens	6-9
6812343-7	1982	The markedly enhanced Prl response to sulpiride in our patients with galactorrhoea could be due to a functional disorder of the hypothalamic-pituitary axis or to a lactotrope hyperplasia.	Sulpiride	38-47	prolactin	Homo sapiens	22-25
6828202-1	1983	Haloperidol, sulpiride, domperidone and apomorphine, drugs which influence dopamine (DA) receptors and in turn prolactin (PRL) secretion have been shown to induce parallel changes in medial basal hypothalamic (MBH) glutamate decarboxylase (GAD) activity and serum PRL levels.	Sulpiride	13-22	prolactin	Rattus norvegicus	264-267
6129151-2	1982	D2-dopamine receptor stimulation did not change the release of [3H]GABA, [3H]glutamate and [3H]serotonin, but inhibited the release of both [3H]dopamine and [14C]acetylcholine; this inhibition was antagonized by (-)-sulpiride.	Sulpiride	212-225	dopamine receptor D2	Rattus norvegicus	0-20
7138674-6	1982	Hyperprolactinemia induced by anterior pituitary homograft under the kidney capsule or systemic sulpiride injection significantly increases GAD activity.	Sulpiride	96-105	glutamate-ammonia ligase	Homo sapiens	140-143
6124605-0	1982	Pre- and postsynaptic effects of sulpiride in the rat isolated vas deferens.	Sulpiride	33-42	arginine vasopressin	Rattus norvegicus	63-66
7139355-0	1982	Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion.	Sulpiride	10-19	growth hormone 1	Homo sapiens	69-83
7139355-1	1982	Sulpiride (100 mg IM), an atypical neuroleptic, which does not block dopamine (DA) receptors that are linked to adenylate cyclase, abolished the growth hormone (GH) response to the DA receptor agonist, apomorphine (Apo) HCl (0.5 mg SC) in seven healthy male subjects.	Sulpiride	0-9	growth hormone 1	Homo sapiens	145-159
7139355-1	1982	Sulpiride (100 mg IM), an atypical neuroleptic, which does not block dopamine (DA) receptors that are linked to adenylate cyclase, abolished the growth hormone (GH) response to the DA receptor agonist, apomorphine (Apo) HCl (0.5 mg SC) in seven healthy male subjects.	Sulpiride	0-9	growth hormone 1	Homo sapiens	161-163
6807435-4	1982	In the sulpiride-treatment group the mean maternal serum prolactin concentration rose from 49.0 +/- SE 3.6 micrograms/l to a maximum of 402.1 +/0 43.2 micrograms/l at two weeks; in the placebo-treated group, however, the concentration fell during the trial (from 84.7 +/- 24.0 micrograms/l to 47.8 +/- 8.6 micrograms/l).	Sulpiride	7-16	prolactin	Homo sapiens	57-66
7094872-3	1982	Very significant changes in GAD activity were only observed with sulpiride and nomifensine, two atypical antidepressants that selectively influence dopaminergic transmission and, in turn, prolactin secretion.	Sulpiride	65-74	glutamate decarboxylase 1	Homo sapiens	28-31
7171172-0	1982	Possible involvement of prolactin in sulpiride-induced changes in nigral and striatal GAD activity.	Sulpiride	37-46	prolactin	Homo sapiens	24-33
7094872-3	1982	Very significant changes in GAD activity were only observed with sulpiride and nomifensine, two atypical antidepressants that selectively influence dopaminergic transmission and, in turn, prolactin secretion.	Sulpiride	65-74	prolactin	Homo sapiens	188-197
7152714-0	1982	Effects of sulpiride treatment on plasma prolactin and steroid hormones in early human pregnancy.	Sulpiride	11-20	prolactin	Homo sapiens	41-50
7327523-0	1981	Prolactin responsiveness to repeated decremental doses of sulpiride.	Sulpiride	58-67	prolactin	Homo sapiens	0-9
7033479-3	1982	This reduction in vasopressin secretion was prevented by the dopamine antagonist sulpiride (10(-6) M).	Sulpiride	81-90	arginine vasopressin	Homo sapiens	18-29
7155354-2	1982	Prolonged treatment with either domperidone or sulpiride, both dopamine-receptor blockers, elevated prolactin levels in serum and cerebrospinal fluid proportionally equally, so that the cerebrospinal fluid serum ratio was unchanged from controls (circa 12-20%).	Sulpiride	47-56	prolactin	Macaca mulatta	100-109
7155354-4	1982	Following acute elevations of blood prolactin after a single injection of either sulpiride or ovine prolactin, cerebrospinal fluid levels increased linearly over a 90 min sampling period, despite falling serum levels.	Sulpiride	81-90	prolactin	Macaca mulatta	36-45
6805007-0	1982	Prolactin response following intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations.	Sulpiride	50-59	prolactin	Homo sapiens	0-9
6805007-0	1982	Prolactin response following intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations.	Sulpiride	101-110	prolactin	Homo sapiens	0-9
6805007-2	1982	Serum concentrations of sulpiride and prolactin were followed for 36 h. Both routes of drug administration resulted in a pronounced and sustained increase in serum prolactin concentration.	Sulpiride	24-33	prolactin	Homo sapiens	164-173
6805007-6	1982	The sustained prolactin elevation may be due to high affinity and strong binding of the compound to the regulating receptors or the formation of an active sulpiride metabolite.	Sulpiride	155-164	prolactin	Homo sapiens	14-23
6805007-7	1982	Prolactin and sulpiride concentrations were significantly correlated during the initial phase after intravenous sulpiride.	Sulpiride	112-121	prolactin	Homo sapiens	0-9
6805007-8	1982	Following intravenous and oral sulpiride the area under the concentration-time curve (AUC) for prolactin was similar despite a considerable difference in the sulpiride concentration.	Sulpiride	31-40	prolactin	Homo sapiens	95-104
7327523-1	1981	The variation in the prolactin response to sulpiride was studied in six normal men by repeating the same dose of the drug (50 mg) after 24 hours and on three subsequent occasions, repeating this 2 day test at an interval of 6 days with progressively halved doses of sulpiride.	Sulpiride	43-52	prolactin	Homo sapiens	21-30
7327523-5	1981	The delta PRL increment on the second day was inversely proportional to the dose of sulpiride; the differences in delta PRL between periods 1 and 3 and periods 1 and 4 being highly significant (P less than 0.001).	Sulpiride	84-93	prolactin	Homo sapiens	10-13
7327523-5	1981	The delta PRL increment on the second day was inversely proportional to the dose of sulpiride; the differences in delta PRL between periods 1 and 3 and periods 1 and 4 being highly significant (P less than 0.001).	Sulpiride	84-93	prolactin	Homo sapiens	120-123
7327523-6	1981	This study suggests that a much lower dose of sulpiride than that normally used is adequate to stimulate PRL secretion and that care must be taken in the timing of repeat testing.	Sulpiride	46-55	prolactin	Homo sapiens	105-108
6788792-0	1981	Prolactin response to sulpiride in hypogonadotropic, normogonadotropic, and hypergonadotropic primary amenorrhea.	Sulpiride	22-31	prolactin	Homo sapiens	0-9
6789593-0	1981	Dynamic evaluation of prolactin secretion with sulpiride and thyrotrophin releasing hormone in amenorrhoeic and normally menstruating women.	Sulpiride	47-56	prolactin	Homo sapiens	22-31
7311080-0	1981	[The inhibitory effect of sulpiride on arginine-stimulated serum gastrin and growth hormone in normal subjects and peptic ulcer patients (author"s transl)].	Sulpiride	26-35	gastrin	Homo sapiens	65-72
7311080-0	1981	[The inhibitory effect of sulpiride on arginine-stimulated serum gastrin and growth hormone in normal subjects and peptic ulcer patients (author"s transl)].	Sulpiride	26-35	growth hormone 1	Homo sapiens	77-91
7296596-0	1981	Effects of long-lasting sulpiride therapy on growth hormone secretion in mentally disturbed children.	Sulpiride	24-33	growth hormone 1	Homo sapiens	45-59
6785431-0	1981	Serum prolactin concentrations in mangabey (Cercocebus atys lunulatus) and patas (Erythrocebus patas) monkeys in response to stress, ketamine, TRH, sulpiride and levodopa.	Sulpiride	148-157	prolactin	Homo sapiens	6-15
6785431-11	1981	The variations in serum prolactin levels observed in these monkeys under the influence of stress, TRH, sulpiride and levodopa are similar to those observed in man to the same stimuli, although the experimental conditions were quite different.	Sulpiride	103-112	prolactin	Homo sapiens	24-33
7238586-3	1981	Conversely, a return to normal of the GAD activity associated with high plasma PRL levels was induced by chronic haloperidol and sulpiride treatment.	Sulpiride	129-138	prolactin	Rattus norvegicus	79-82
6781872-1	1981	Hyperprolactinemia induced in immature female rats by treatment with sulpiride, a dopaminergic receptor blocker, increased the in vitro release of ovarian progesterone (P) in response to different doses of both highly purified hCG and human FSH.	Sulpiride	69-78	hypertrichosis 2 (generalised, congenital)	Homo sapiens	227-230
7243090-5	1981	Hyperprolactinemia induced by the sulpiride treatment was accompanied by a significant decrease in hCG concentration, whereas no difference in hCG was seen between hypoprolactinemia and control groups.	Sulpiride	34-43	chorionic gonadotropin subunit beta 5	Homo sapiens	99-102
7243090-6	1981	This may suggest a synergistic action of hCG and PRL, or a direct effect of sulpiride on hCG, but the final mechanism and biologic importance of the phenomenon remain to be investigated.	Sulpiride	76-85	chorionic gonadotropin subunit beta 5	Homo sapiens	89-92
6762263-8	1982	Plasma PRL levels resulted significantly higher in sulpiride treated groups than in placebo group.	Sulpiride	51-60	prolactin	Homo sapiens	7-10
7296596-1	1981	The effects of chronic sulpiride therapy on growth hormone (GH) secretion were studied in 11 mentally disturbed children, aged 5 to 13 years, five with personality disorders, three with childhood psychoses, one with hysteria, one with anxiety reactions, and one with neurosis.	Sulpiride	23-32	growth hormone 1	Homo sapiens	44-58
7296596-1	1981	The effects of chronic sulpiride therapy on growth hormone (GH) secretion were studied in 11 mentally disturbed children, aged 5 to 13 years, five with personality disorders, three with childhood psychoses, one with hysteria, one with anxiety reactions, and one with neurosis.	Sulpiride	23-32	growth hormone 1	Homo sapiens	60-62
6112770-5	1981	Sulpiride, on the contrary, inhibited only the binding to the dopamine D2 receptor, CPZ and HPD antagonized [3H]dopamine nonselectively at the two distinct dopaminergic receptors.	Sulpiride	0-9	dopamine receptor D2	Homo sapiens	62-82
6107242-3	1980	The dopamine receptor in the IL can be assigned to the category of dopamine receptor designated D-2 on the basis of the following criteria: 1) occupancy of the dopamine receptor does not result in enhancement of adenylate cyclase activity or an accumulation of cAMP, 2) the dopaminergic ergots and apomorphine mimic the inhibitory effect of dopamine upon cAMP formation or alpha MSH release, and 3) metoclopramide and sulpiride, substituted benzamides, block the inhibitory effect of dopamine.	Sulpiride	418-427	solute carrier family 3 member 1	Rattus norvegicus	96-99
7211478-0	1980	Sulpiride stimulation of prolactin secretion in adolescents with gynecomastia: relation to the circulating levels of estradiol.	Sulpiride	0-9	prolactin	Homo sapiens	25-34
6254696-1	1980	Sulpiride induces an increase in plasma prolactin and a simultaneous increase of aldosterone release in man.	Sulpiride	0-9	prolactin	Homo sapiens	40-49
7380989-3	1980	Sulpiride treatment induced significant (P less than 0.001) elevations of plasma PRL at 1 week [84.1 +/- 4.9 vs. 23.7 +/- 2.8 ng/ml (mean +/- SE)] and 2 weeks (83.0 +/- 4.1 vs. 31.9 +/- 4.1 ng/ml).	Sulpiride	0-9	prolactin	Homo sapiens	81-84
6785978-3	1980	After sulpiride loading, maximum changes in prolactin level were significantly smaller in acromegalic patients, irrespective of the basal prolactin concentration.	Sulpiride	6-15	prolactin	Homo sapiens	44-53
7435113-0	1980	Effect of sulpiride on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia.	Sulpiride	10-19	prolactin	Homo sapiens	30-39
7435113-1	1980	The effect of 100 mg im sulpiride on plasma Prl levels was studied in 10 normal females, 21 patients with galactorrhoea and normal plasma Prl, 10 women with puerperal hyperprolactinaemia and 27 patients with amenorrhoea-galactorrhoea and high plasma Prl levels.	Sulpiride	24-33	prolactin	Homo sapiens	44-47
7435113-2	1980	The response to sulpiride in patients with galactorrhoea but normal PRL was slightly higher (P &lt; 0.05) than that observed in normal women, but only if expressed in per cent.	Sulpiride	16-25	prolactin	Homo sapiens	68-71
7435113-6	1980	In the last 3 patients with pathological hyperprolactinaemia in whom a consistent Prl increase after sulpiride was observed, hyperprolactinaemia was probably not of tumourous origin.	Sulpiride	101-110	prolactin	Homo sapiens	82-85
7435113-7	1980	On the basis of these results, the sulpiride test appears promising for discriminating between organic and "functional" cases of enhanced Prl secretion.	Sulpiride	35-44	prolactin	Homo sapiens	138-141
6773973-0	1980	Modifications in serum growth hormone concentration induced by sulpiride in acromegalic patients pretreated with dopamine, bromocriptine, and metergoline.	Sulpiride	63-72	growth hormone 1	Homo sapiens	23-37
6792868-2	1980	PRL-response to 200 micrograms of TRH was assessed in 41 cases, and PRL-response to sulpiride in 38 cases.	Sulpiride	84-93	prolactin	Homo sapiens	68-71
6792868-10	1980	PRL-response to sulpiride doesn"t differ from that of normal males in the 3 categories of SD.	Sulpiride	16-25	prolactin	Homo sapiens	0-3
6792868-11	1980	Research of linear correlations between scores of anxiety and depression and PRL maximal increments after TRH and sulpiride in EP and ANEJ is negative.	Sulpiride	114-123	prolactin	Homo sapiens	77-80
7380989-0	1980	Sulpiride treatment during early human pregnancy: effect on the levels of prolactin, six steroids, and placental lactogen.	Sulpiride	0-9	prolactin	Homo sapiens	74-83
7380989-0	1980	Sulpiride treatment during early human pregnancy: effect on the levels of prolactin, six steroids, and placental lactogen.	Sulpiride	0-9	chorionic somatomammotropin hormone 2	Homo sapiens	103-121
7386120-0	1980	Potentiation of sulpiride-induced prolactin secretion by sodium deprivation in man.	Sulpiride	16-25	prolactin	Homo sapiens	34-43
6785978-6	1980	Higher than normal basal prolactin levels in some of the acromegalic patients and abnormal prolactin responses following sulpiride and TRH loading in most of the patients with acromegaly are attributed to deranged hypothalamo-hypophyseal regulation.	Sulpiride	121-130	prolactin	Homo sapiens	91-100
7433912-1	1980	The effect of 1 week of oral treatment with four antidopaminergic drugs--metoclopramide, sulpiride, haloperidol, and pimozide--on fasting and meal-stimulated serum gastrin levels has been evaluated in healthy subjects.	Sulpiride	89-98	gastrin	Homo sapiens	164-171
474034-0	1979	Study on the reproducibility of human prolactin response to sulpiride, benserazide, insulin hypoglycaemia and arginine infusion.	Sulpiride	60-69	prolactin	Homo sapiens	38-47
474034-3	1979	In contrast to this, insulin hypoglycaemia yielded significantly lower PRL release, while the PRL response to the second sulpiride test was significantly higher than to the first one.	Sulpiride	121-130	prolactin	Homo sapiens	94-97
474034-4	1979	When an interval of 10 days was left between two consecutive sulpiride tests, an identical PRL release was observed.	Sulpiride	61-70	prolactin	Homo sapiens	91-94
474034-6	1979	Finally, sulpiride probably enhances both PRL release and synthesis thus making greater amounts of PRL available to a subsequent stimulus.	Sulpiride	9-18	prolactin	Homo sapiens	42-45
474034-6	1979	Finally, sulpiride probably enhances both PRL release and synthesis thus making greater amounts of PRL available to a subsequent stimulus.	Sulpiride	9-18	prolactin	Homo sapiens	99-102
111447-0	1979	Enhanced TSH stimulating effect of TRH by sulpiride in man.	Sulpiride	42-51	thyrotropin releasing hormone	Homo sapiens	35-38
111447-1	1979	Sulpiride, a specific dopaminergic blocker, was administered im to 6 normal male volunteers (100 mg) alone or in association with L-DOPA (500 mg per os, 90 min before sulpiride) or with TRH (400 micrograms iv in bolus, 30 min after sulpiride) and blood samples were obtained for TSH radioimmunoassay at various intervals before and after the treatments.	Sulpiride	0-9	thyrotropin releasing hormone	Homo sapiens	186-189
111447-3	1979	The previous administration of sulpiride resulted in a marked increase of the TSH response to TRH.	Sulpiride	31-40	thyrotropin releasing hormone	Homo sapiens	94-97
467503-1	1979	Sulpiride, which differs from classical neuroleptics by not producing major extrapyramidal side effects, is a potent antiemetic agent and stimulates prolactin secretion in both laboratory animals and man.	Sulpiride	0-9	prolactin	Homo sapiens	149-158
467503-4	1979	The interactions of these two ergot derivatives with sulpiride have been investigated on prolactin release and on striatal and limbic DOPAC accumulation.	Sulpiride	53-62	prolactin	Rattus norvegicus	89-98
467503-5	1979	Bromocriptine at all doses tested was able to suppress the increased in vivo prolactin secretion observed after sulpiride administration.	Sulpiride	112-121	prolactin	Rattus norvegicus	77-86
467503-6	1979	Metergoline antagonized the sulpiride-induced prolactin increase only at low doses; on the contrary higher doses potentiated it.	Sulpiride	28-37	prolactin	Rattus norvegicus	46-55
528995-0	1979	Prolactin releasing effect of sulpiride isomers in rats and man.	Sulpiride	30-39	prolactin	Rattus norvegicus	0-9
222600-0	1979	Decrease of cyclic GMP in cerebellar cortex by intrastriatal (--)-sulpiride.	Sulpiride	61-75	5'-nucleotidase, cytosolic II	Homo sapiens	19-22
680182-0	1978	Release of prolactin during pregnancy: effect of sulpiride.	Sulpiride	49-58	prolactin	Homo sapiens	11-20
680182-1	1978	The aim of this trial was to study the prolactin-releasing capacity of the pituitary during pregnancy by means of an acute stimulation with sulpiride.	Sulpiride	140-149	prolactin	Homo sapiens	39-48
680182-8	1978	The prolactin-releasing capacity of the pituitary, as judged by the response to sulpiride, seems to be maintained during pregnancy.	Sulpiride	80-89	prolactin	Homo sapiens	4-13
639330-5	1978	After sulpiride a 800-4200% increment of prolactin over control values was noted in the females and 1200-3500% increment in the males.	Sulpiride	6-15	prolactin	Homo sapiens	41-50
639331-5	1978	After sulpiride a marked increase (3--10 times over control values) in PRL was noted in all normal and short children without pituitary disease.	Sulpiride	6-15	prolactin	Homo sapiens	71-74
415471-4	1978	Two hundred microgram lisuride also decreased the high serum prolactin levels produced by im injection of 50 mg sulpiride, and conversely, sulpiride injection abolished the prolactin lowering effect of lisuride.	Sulpiride	112-121	prolactin	Homo sapiens	61-70
415471-4	1978	Two hundred microgram lisuride also decreased the high serum prolactin levels produced by im injection of 50 mg sulpiride, and conversely, sulpiride injection abolished the prolactin lowering effect of lisuride.	Sulpiride	139-148	prolactin	Homo sapiens	173-182
429499-1	1979	The effect of oral administration of sulpiride on PRL secretion and initiation of puerperal lactation was studied in 130 randomly selected primiparous nursing mothers.	Sulpiride	37-46	prolactin	Homo sapiens	50-53
429499-5	1979	Every other day determinations of serum PRL levels revealed significantly higher concentrations in the sulpiride group than in the control group.	Sulpiride	103-112	prolactin	Homo sapiens	40-43
429499-6	1979	A single oral dose of 50 mg sulpiride raised serum PRL levels for 12 h, with a peak level at 2 h after dosing in 7 women on the second postpartum day.	Sulpiride	28-37	prolactin	Homo sapiens	51-54
429499-7	1979	These data suggest that sulpiride given orally promotes the initiation of lactation in puerperal women by stimulating PRL secretion.	Sulpiride	24-33	prolactin	Homo sapiens	118-121
288372-2	1979	In rats, all functional dopamine antagonists (reserpine alone or combined with alpha-methyl-p-tyrosine or benserazide, haloperidol, spiroperidol, sulpiride) increased serum PRL levels.	Sulpiride	146-155	prolactin	Rattus norvegicus	173-176
288372-6	1979	This was suggested by the inhibitory effect of pretreatment with the dopamine antagonist spiroperidol or with sulpiride on the prolactin-lowering effect of lisuride.	Sulpiride	110-119	prolactin	Homo sapiens	127-136
42859-4	1979	Similarly, a much lower dose of haloperidol, clozapine, and the two enantiomers of sulpiride given into the 3rd cerebral ventricle for 3 consecutive days produced a marked crop-sac response.	Sulpiride	83-92	LUC7 like 3 pre-mRNA splicing factor	Homo sapiens	172-176
503288-0	1979	Restoration of the prolactin response to sulpiride by metergoline administration in hyperprolactinemic patients.	Sulpiride	41-50	prolactin	Homo sapiens	19-28
227434-1	1978	Tissue levels of cAMP in isolated bovine adrenal glands superfused with prolactin and sulpiride].	Sulpiride	86-95	cathelicidin-7	Bos taurus	17-21
709890-5	1978	Sulpiride prevented the inhibitory effect on PRL levels of 500 mg levodopa, administered orally simultaneously; levodopa administered 2 hours prior to sulpiride failed to counteract the PRL-stimulatory effect of sulpiride.	Sulpiride	0-9	prolactin	Homo sapiens	45-48
658587-1	1978	A culture of dispersed rat anterior pituitary cells was used to test the ability of pimozide and sulpiride to affect the basal gonadotropin release and their effects on the response to Gn-RH.	Sulpiride	97-106	gonadotropin releasing hormone 1	Rattus norvegicus	185-190
564936-2	1978	In acute experiments in which clozapine, sulpiride and chlorpromazine were administered orally to rats of both sexes, there were rapid increases in the level of prolactin in the serum with peak values between 15 and 60 min.	Sulpiride	41-50	prolactin	Rattus norvegicus	161-170
563826-0	1978	Inhibition of gastrin secretion by sulpiride treatment in duodenal ulcer patients.	Sulpiride	35-44	gastrin	Homo sapiens	14-21
563826-1	1978	The serum gastrin response to whole beef extract was measured in 14 duodenal ulcer patients before and after sulpiride administration.	Sulpiride	109-118	gastrin	Homo sapiens	10-17
563826-4	1978	Although the mechanism of the gastrin-lowering action of sulpiride is unknown, it could be mediated by some known effects(s) of the drug, such as modifications in brain monoamine metabolism or perhaps reduced growth hormone secretion.	Sulpiride	57-66	gastrin	Homo sapiens	30-37
580204-0	1978	Serum prolactin levels after a single and subchronic oral administration of chlorpromazine and sulpiride.	Sulpiride	95-104	prolactin	Homo sapiens	6-15
580204-8	1978	Prolactin concentrations remained raised for at least 6 h. The initial raised prolactin concentration induced by sulpiride was associated with antidiuresis.	Sulpiride	113-122	prolactin	Homo sapiens	0-9
580204-2	1978	The effect of a single antianxiety dose of chlorpromazine (100 mg) and sulpiride (200 mg) on serum prolactin and gonadotrophins was studied in 6 healthy women in a cross-over study.	Sulpiride	71-80	prolactin	Homo sapiens	99-108
580204-8	1978	Prolactin concentrations remained raised for at least 6 h. The initial raised prolactin concentration induced by sulpiride was associated with antidiuresis.	Sulpiride	113-122	prolactin	Homo sapiens	78-87
580204-11	1978	It is concluded that in doses useful in the treatment of neurotic patients sulpiride causes a greater increase in serum prolactin levels than does chlorpromazine.	Sulpiride	75-84	prolactin	Homo sapiens	120-129
580204-7	1978	In acute study sulpiride caused a fivefold increase in serum prolactin at 1 h. Chlorpromazine induced a slower and smaller increase.	Sulpiride	15-24	prolactin	Homo sapiens	61-70
410826-0	1977	Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects.	Sulpiride	74-83	prolactin	Homo sapiens	52-61
923106-2	1977	The prolactin lowering effect of this drug was abolished by sulpiride.	Sulpiride	60-69	prolactin	Homo sapiens	4-13
738536-1	1978	Serum prolactin levels were determined following stimulation by sulpiride in 20 patients with nonalcoholic liver cirrhosis and 10 normal controls.	Sulpiride	64-73	prolactin	Homo sapiens	6-15
738536-3	1978	Only 5 cirrhotics, all with ascites, showed a lower prolactin response after sulpiride stimulation.	Sulpiride	77-86	prolactin	Homo sapiens	52-61
21571-0	1977	An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.	Sulpiride	51-60	prolactin	Homo sapiens	79-88
578618-0	1977	Stimulating action of sulpiride and pimozide on prolactin release.	Sulpiride	22-31	prolactin	Homo sapiens	48-57
578618-2	1977	In order to evaluate the mechanism of action of metergoline, an antiserotonin agent, the effect of pre-treatment with metergoline on prolactin (PRL) release induced by sulpiride was compared to that obtained after bromocriptine administration in normal subjects.	Sulpiride	168-177	prolactin	Homo sapiens	133-142
578618-2	1977	In order to evaluate the mechanism of action of metergoline, an antiserotonin agent, the effect of pre-treatment with metergoline on prolactin (PRL) release induced by sulpiride was compared to that obtained after bromocriptine administration in normal subjects.	Sulpiride	168-177	prolactin	Homo sapiens	144-147
410826-3	1977	In four hyperprolactinemic women showing an impaired PRL response to sulpiride, dopamine infusion was effective both in lowering PRL circulating levels and in restoring an evident response to sulpiride.	Sulpiride	69-78	prolactin	Homo sapiens	53-56
578053-0	1977	The stimulation of prolactin secretion by sulpiride in "adolescent gynaecomastia".	Sulpiride	42-51	prolactin	Homo sapiens	19-28
406134-0	1977	Effect of sulpiride on serum growth hormone and prolactin concentrations following L-DOPA administration in man.	Sulpiride	10-19	growth hormone 1	Homo sapiens	29-43
874063-1	1977	Pasma prolactin response to the acute injection of sulpiride (1.5 mg/k BW im) was measured at 0800-0900h in 4 girls with idiopathic precocious puberty before and after 6 to 11 months of continuous therapy with 50 mg daily of cyproterone acetate (CA) orally administered.	Sulpiride	51-60	prolactin	Homo sapiens	6-15
406134-0	1977	Effect of sulpiride on serum growth hormone and prolactin concentrations following L-DOPA administration in man.	Sulpiride	10-19	prolactin	Homo sapiens	48-57
406134-1	1977	The effect of chronic administration of sulpiride on serum human growth hormone (hGH), prolactin and thyroid stimulating hormone (TSH) was examined in 6 normal subjects.	Sulpiride	40-49	growth hormone 1	Homo sapiens	65-79
406134-1	1977	The effect of chronic administration of sulpiride on serum human growth hormone (hGH), prolactin and thyroid stimulating hormone (TSH) was examined in 6 normal subjects.	Sulpiride	40-49	prolactin	Homo sapiens	87-96
406134-4	1977	Sulpiride raised serum prolactin levels in all subjects examined.	Sulpiride	0-9	prolactin	Homo sapiens	23-32
406134-6	1977	Sulpiride treatment appeared to antagonize partially the inhibitory effect of L-dopa on prolactin release.	Sulpiride	0-9	prolactin	Homo sapiens	88-97
406134-7	1977	Following thyrotropin-releasing hormone (TRH) injection, the percent increment in prolactin levels from the baseline in sulpiride-treated subjects was less than in controls without sulpiride.	Sulpiride	120-129	thyrotropin releasing hormone	Homo sapiens	10-39
406134-7	1977	Following thyrotropin-releasing hormone (TRH) injection, the percent increment in prolactin levels from the baseline in sulpiride-treated subjects was less than in controls without sulpiride.	Sulpiride	120-129	prolactin	Homo sapiens	82-91
406134-7	1977	Following thyrotropin-releasing hormone (TRH) injection, the percent increment in prolactin levels from the baseline in sulpiride-treated subjects was less than in controls without sulpiride.	Sulpiride	181-190	thyrotropin releasing hormone	Homo sapiens	10-39
406134-9	1977	These observations suggest that sulpiride suppresses L-dopa-induced hGH release and stimulates prolactin release, presumably by acting against the dopaminergic mechanism either on the hypothalamus or on the pituitary.	Sulpiride	32-41	prolactin	Homo sapiens	95-104
406134-10	1977	The decreased prolactin response to TRH after sulpiride treatment may indicate a diminished reserve capacity in pituitary prolactin release.	Sulpiride	46-55	prolactin	Homo sapiens	14-23
406134-10	1977	The decreased prolactin response to TRH after sulpiride treatment may indicate a diminished reserve capacity in pituitary prolactin release.	Sulpiride	46-55	prolactin	Homo sapiens	122-131
577162-1	1977	N-[(1-Ethyl-pyrrolidin-2-yl)-methyl]-2-methoxy-5-sulf-amoyl-benzamide (sulpiride, Dogmatil) inhibits acetylcholinesterase of rat brain in a mixed-type manner (Ki 0.3 mM; Ki 1.8 mM) as well as serum cholinesterase of the rat competitively (Ki 0.37 mM).	Sulpiride	71-80	butyrylcholinesterase	Rattus norvegicus	107-121
853259-0	1977	Mechanism of increased prolactin secretion by sulpiride.	Sulpiride	46-55	prolactin	Rattus norvegicus	23-32
853259-1	1977	The effect of sulpiride, a neuroleptic agent, on the secretion of prolactin by the anterior pituitary gland of the rat was studied.	Sulpiride	14-23	prolactin	Rattus norvegicus	66-75
853259-5	1977	Injection of these rats with sulpiride restored prolactin biosynthesis and release of the hormone toward normal levels.	Sulpiride	29-38	prolactin	Rattus norvegicus	48-57
856708-3	1977	Sulpiride, a benzamide derivative with neuroleptic and thymoleptic properties, is known to act at the hypothalamic level and in particular, to inhibit releasing factors responsible for follicle-stimulating hormone and prolactin secretion.	Sulpiride	0-9	prolactin	Homo sapiens	218-227
977731-2	1976	A group of 6 normal men was treated for 4 consecutive days, on separate periods, with Sulpiride which is known to raise plasma prolactin (PRL) concentration.	Sulpiride	86-95	prolactin	Homo sapiens	127-136
977731-2	1976	A group of 6 normal men was treated for 4 consecutive days, on separate periods, with Sulpiride which is known to raise plasma prolactin (PRL) concentration.	Sulpiride	86-95	prolactin	Homo sapiens	138-141
1249187-0	1976	Effect of sulpiride on serum prolactin levels in humans.	Sulpiride	10-19	prolactin	Homo sapiens	29-38
989340-0	1976	Effect of sulpiride on serum gastrin in duodenal ulcer.	Sulpiride	10-19	gastrin	Homo sapiens	29-36
989340-1	1976	The effect of N-ethyl-2(2-methoxy-5-sulfamido-benzamidomethyl-pyrrolidine (sulpiride, Dobren) on serum gastrin in patients with duodenal ulcer was evaluated.	Sulpiride	75-84	gastrin	Homo sapiens	103-110
989340-4	1976	It is suggested that sulpiride by acting on the hypothalamus could possibly normalize the alterations of the mucosal barrier and restore the feed-back mechanism implicated in the autoregulation of antral gastrin secretion.	Sulpiride	21-30	gastrin	Homo sapiens	204-211
1036964-0	1976	A study of the EEG sleep patterns and the sleep and dream experience of a group of schizophrenic patients treated with sulpiride.	Sulpiride	119-128	potassium voltage-gated channel interacting protein 3	Homo sapiens	52-57
819939-1	1976	The behavioral effects (tremors, tail erection, increased motility) of intracerebrally injected TRF are enhanced by pretreatment with chlorpromazine, reserpine and sulpiride; haloperidol does not exert appreciable effects.	Sulpiride	164-173	thyrotropin releasing hormone	Homo sapiens	96-99
1249187-6	1976	Sulpiride induced in all subjects a quick and marked increment of serum prolactin levels with peak values at 30 minutes.	Sulpiride	0-9	prolactin	Homo sapiens	72-81
33264473-10	2021	Behaviorally induced defecation (caused by water avoidance stress) was reduced by the DRD2 antagonist, sulpiride.	Sulpiride	103-112	dopamine receptor D2	Homo sapiens	86-90
1251130-0	1976	Inhibition of sulpiride on the cephalic phase of gastric acid and gastrin secretion in duodenal ulcer patients.	Sulpiride	14-23	gastrin	Homo sapiens	66-73
813995-0	1975	Stimulation of human prolactin secretion by sulpiride.	Sulpiride	44-53	prolactin	Homo sapiens	21-30
813995-1	1975	Intramuscular injection of 100 mg of sulpiride significantly raised plasma human prolactin (hPRL) levels in all of 7 normal subjects examined.	Sulpiride	37-46	prolactin	Homo sapiens	81-90
813995-1	1975	Intramuscular injection of 100 mg of sulpiride significantly raised plasma human prolactin (hPRL) levels in all of 7 normal subjects examined.	Sulpiride	37-46	prolactin	Homo sapiens	92-96
813995-3	1975	Daily administration of sulpiride (50 mg tid po) raised plasma hPRL levels in all 7 patients with peptic ulcer, with peak values obtained within 2 weeks.	Sulpiride	24-33	prolactin	Homo sapiens	63-67
813995-5	1975	It is concluded that sulpiride stimulates hPRL secretion in man.	Sulpiride	21-30	prolactin	Homo sapiens	42-46
1121507-1	1975	The effect of the acute or chronic administration of sulpiride on serum prolactin and gonadotropin levels was studied in castrated male rats.	Sulpiride	53-62	prolactin	Rattus norvegicus	72-81
1121507-2	1975	Sulpiride administered in acute intravenous injections induced a quick increase in serum prolactin levels and no significant changes in serum gonadotropins.	Sulpiride	0-9	prolactin	Rattus norvegicus	89-98
1121507-3	1975	The peak in serum prolactin was observed 30 min after the injection of sulpiride, with a decrease of serum prolactin levels at 60 and 120 min.	Sulpiride	71-80	prolactin	Rattus norvegicus	18-27
1121507-3	1975	The peak in serum prolactin was observed 30 min after the injection of sulpiride, with a decrease of serum prolactin levels at 60 and 120 min.	Sulpiride	71-80	prolactin	Rattus norvegicus	107-116
1121507-4	1975	The subcutaneous administration of sulpiride for 13 days induced a significant increase in serum prolactin levels at the end of the treatment, and no significant changes in serum FSH and LH levels.	Sulpiride	35-44	prolactin	Rattus norvegicus	97-106
1211149-0	1975	[Changes in the ENG after administration of sulpiride].	Sulpiride	44-53	endoglin	Homo sapiens	16-19
33862125-10	2021	Intra-CA1 administration of sulpiride reversed the decreasing effects of cannabidiol on METH-induced CPP in both acquisition and expression phases but more prominent in the expression phase.	Sulpiride	28-37	carbonic anhydrase 1	Rattus norvegicus	6-9
1018732-0	1976	Effect of sulpiride on plasma prolactin in rats.	Sulpiride	10-19	prolactin	Rattus norvegicus	30-39
1018732-5	1976	significantly blunted plasma Prl response to S(1 mug/100 g b.w., i.v.).	Sulpiride	45-46	prolactin	Rattus norvegicus	29-32
1014111-2	1976	It is proposed that sulpiride effect may be mediated by the augment of prolactin level in serum.	Sulpiride	20-29	prolactin	Mus musculus	71-80
1243732-0	1975	[Effect of sulpiride and 2Br-alfa ergocryptine on the neuroendocrine control of hPRL incretion (author"s transl)].	Sulpiride	11-20	prolactin	Homo sapiens	80-84
1243732-2	1975	The incretion of hPRL after infusion of SULPIRIDE (100 mg) by e.v.	Sulpiride	40-49	prolactin	Homo sapiens	17-21
32976861-5	2021	Results indicated that the injection of the antagonists into the CA1 region dose-dependently attenuated the expression of the morphine-induced CPP and sulpiride revealed prominent behavioral results compared to SCH23390 in the expression phases.	Sulpiride	151-160	carbonic anhydrase 1	Rattus norvegicus	65-68
33667508-7	2021	Meanwhile, sulpiride offset the upregulated expression of th, th2 and fosab in the group of 1.5 muM NEP, which highlighted the significant role of D2R in NEP-induced locomotive effects.	Sulpiride	11-20	v-fos FBJ murine osteosarcoma viral oncogene homolog Ab	Danio rerio	70-75
33372063-9	2021	The D2R antagonist sulpiride restored decreased excitatory transmission and excitability of VTA dopamine neurons.	Sulpiride	19-28	dopamine receptor D2	Mus musculus	4-7
32350838-0	2020	The role of sulpiride in attenuating the cardiac, renal, and immune disruptions in rats receiving clozapine: mRNA expression pattern of the genes encoding Kim-1, TIMP-1, and CYP isoforms.	Sulpiride	12-21	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	174-177
32474048-7	2020	GNRH peptide content in mammary glands of females with sulpiride-induced hyperprolactinemia (HP) was significantly lower than that of control females (CT).	Sulpiride	55-64	gonadotropin releasing hormone 1	Homo sapiens	0-4
32656492-0	2020	A low dosage of the dopamine D2-receptor antagonist sulpiride affects effort allocation for reward regardless of trait extraversion.	Sulpiride	52-61	dopamine receptor D2	Homo sapiens	20-40
32390831-1	2020	Background: Sulpiride is a highly selective dopamine D2 receptor antagonist and is commonly used in psychiatric disorders, Tourette syndrome, peptic ulcer disease (PUD), and gastroesophageal reflux disease (GERD).	Sulpiride	12-21	dopamine receptor D2	Homo sapiens	44-64
32135149-8	2020	Results showed that intra-CA1 administration of SCH-23390 or sulpiride could prevent the intra-LH carbachol-induced antinociception.	Sulpiride	61-70	carbonic anhydrase 1	Rattus norvegicus	26-29
32306793-4	2021	Anxiety and depression-like behaviors were observed, but intra-ventricle injection of DR-D2 antagonist (Sulpiride) has shown to be efficient in reducing negative behavioral changes in offspring.	Sulpiride	104-113	dopamine receptor D2	Rattus norvegicus	86-91
32306793-5	2021	Furthermore, DR-D2 gene expression was increased in the amygdala and PFC of aggressive male rats" offspring, which the injection of Sulpiride decreased it significantly.	Sulpiride	132-141	dopamine receptor D2	Rattus norvegicus	13-18
32256734-2	2020	Sulpiride, a specific type 2 dopamine receptor antagonist, causes prostate toxicity by stimulating prolactin (PRL) production.	Sulpiride	0-9	prolactin	Rattus norvegicus	99-108
32256734-2	2020	Sulpiride, a specific type 2 dopamine receptor antagonist, causes prostate toxicity by stimulating prolactin (PRL) production.	Sulpiride	0-9	prolactin	Rattus norvegicus	110-113
32256734-8	2020	Sulpiride treatment increased serum PRL, follicle-stimulating hormone and testosterone levels, while serum luteinizing hormone levels were reduced.	Sulpiride	0-9	prolactin	Rattus norvegicus	36-39
32256734-9	2020	Immunohistochemical analysis revealed that proliferating cell nuclear antigen and B-cell lymphoma-2 were significantly increased in certain sulpiride treated groups.	Sulpiride	140-149	proliferating cell nuclear antigen	Rattus norvegicus	43-77
32256734-11	2020	The expression of stromal cell biomarkers, including vimentin, fibronectin and alpha-smooth muscle actin were significantly increased in LP following 40 mg/kg sulpiride administration.	Sulpiride	159-168	vimentin	Rattus norvegicus	53-61
32256734-11	2020	The expression of stromal cell biomarkers, including vimentin, fibronectin and alpha-smooth muscle actin were significantly increased in LP following 40 mg/kg sulpiride administration.	Sulpiride	159-168	fibronectin 1	Rattus norvegicus	63-74
32256734-11	2020	The expression of stromal cell biomarkers, including vimentin, fibronectin and alpha-smooth muscle actin were significantly increased in LP following 40 mg/kg sulpiride administration.	Sulpiride	159-168	actin gamma 2, smooth muscle	Rattus norvegicus	79-104
32256734-12	2020	These results suggest that sulpiride causes LP hyperplasia in BN rats by promoting proliferation and inhibiting prostate cell apoptosis via ERalpha and AR signaling.	Sulpiride	27-36	estrogen receptor 1	Rattus norvegicus	140-147
31610050-5	2020	We found that the blockade of D2 autoreceptors with sulpiride prevented the stimulatory effect of CB2 R activation; in fact, under this condition, CB2 R decreased dopamine release, indicating the role of the D2 autoreceptor in the paradoxical increase.	Sulpiride	52-61	cannabinoid receptor 2	Rattus norvegicus	98-101
32077679-6	2020	Photolysis of CyHQ-sulpiride rapidly blocked synaptic activity, enabling measurement of the unbinding rates of dopamine and quinpirole, a D2 receptor agonist.	Sulpiride	19-28	dopamine receptor D2	Mus musculus	138-149
31610050-9	2020	Finally, intra-striatal injection of CB2 R agonist induced contralateral turning in amphetamine-treated rats, which was prevented by sulpiride, indicating the role of the interaction in motor behavior.	Sulpiride	133-142	cannabinoid receptor 2	Rattus norvegicus	37-40
30919007-5	2019	METHODS: First, we determined the effects of MA alone versus MA in combination with the dopamine receptor D1 antagonist SCH-23390 or the dopamine receptor D2 antagonist sulpiride on cFos expression and monoamines at the age when rats in the cognitive experiment were to begin testing and monoamines in rats after cognitive testing.	Sulpiride	169-178	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	182-186
29767374-6	2019	Furthermore, pre-training intra-CA1 injection of sub-threshold doses of SKF38393 (0.0625 microg/mouse) or sulpiride (0.1 microg/mouse) increased pre-training harmane (4 and 8 mg/kg, i.p.	Sulpiride	106-115	carbonic anhydrase 1	Mus musculus	32-35
30919007-6	2019	RESULTS: SCH-23390 infused into the neostriatum prior to systemic administration of MA attenuated MA-induced cFos activation while sulpiride induced cFos activation.	Sulpiride	131-140	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	149-153
30767273-7	2019	The nAChR-induced enhancement of GABAergic synaptic transmission was decreased in the presence of SCH23390 irrespective of the presence of sulpiride, whereas that of glutamatergic synaptic transmission was not altered in the presence of SCH23390 and sulpiride.	Sulpiride	139-148	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	4-9
30767273-7	2019	The nAChR-induced enhancement of GABAergic synaptic transmission was decreased in the presence of SCH23390 irrespective of the presence of sulpiride, whereas that of glutamatergic synaptic transmission was not altered in the presence of SCH23390 and sulpiride.	Sulpiride	250-259	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	4-9
30922767-7	2019	Both dopamine D1 receptor antagonist SCH23390 and D2 receptor antagonist sulpiride protected from these neurotoxic consequences.	Sulpiride	73-82	dopamine receptor D2	Mus musculus	50-61